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ABSTRACT 
Diana R. Chirovsky: COMPARATIVE EFFECTIVENESS OF SURVEILLANCE AND CURRENT  
TREATMENT APPROACHES FOR THE DETECTION AND MANAGEMENT OF HEPATOCELLULAR CARCINOMA 
IN EAST ASIA 
 (Under the direction of Kristen Hassmiller Lich) 
Treatment approaches for hepatocellular carcinoma (HCC) in China are distinct in the use of 
resection with more advanced HCC, and continued research is needed to re-evaluate the 
appropriateness of guideline recommendations.  Surveillance is recommended among individuals with 
chronic hepatitis B virus (HBV) infection in East Asia to improve early disease detection; however, only 
limited evidence exists to quantify its survival impact, and the ideal screening interval is not known. The 
overall objectives of this dissertation were to (1) compare the effectiveness of HCC treatment 
approaches in China, (2) evaluate the impact of 6-month and 12-month screening intervals compared 
with no surveillance among individuals with chronic HBV in China, and (3) examine the survival Impact of 
surveillance among HCC patients in Taiwan.   
This dissertation used clinical data extracted from medical records for HCC patients in China and 
Taiwan, as part of the global BRIDGE to Better Outcomes in HCC (HCC BRIDGE) Study.  Multivariate Cox 
proportional hazard models compared survival with treatment in China, stratified by disease stage, and 
propensity score (PS) analysis was conducted to address selection bias.  An individual-based simulation 
model combined well-established data on chronic HBV progression and tumor growth in HCC with 
clinical data from the HCC BRIDGE study in China to project the survival impact of different surveillance 
strategies.  Using the HCC BRIDGE study in Taiwan, survival according to surveillance status was assessed 
using the Kaplan-Meier method, controlling for selection bias through PS analysis and lead time bias 
using a range of tumor volume doubling time (DT) estimated across tumor growth studies. 
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The results revealed that patients with intermediate to advanced disease tolerate resection, and 
have better outcomes than with other HCC therapies.  Surveillance improves survival with HCC, after 
applying lead time adjustments using a plausible range in DT.  Results of model simulation suggest that 
surveillance performed at 12-month versus 6-month intervals can be more easily implemented with 
little impact on survival with HCC.  These findings help inform efforts to ensure that individuals with 
chronic HBV are properly monitored for HCC given limited resources, and HCC patients receive 
appropriate treatment to improve survival outcomes in East Asia.   
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CHAPTER 1: INTRODUCTION 
Hepatocellular carcinoma (HCC) is highly prevalent and is the second leading cause of cancer-
related death in East Asia, where hepatitis B virus (HBV) infection is endemic and is the primary 
etiological risk-factor for HCC.
 1
  Current approaches for improving survival with HCC are primarily 
focused on the early detection and treatment of HCC.
 2,3
  Recommended treatment approaches for HCC 
in China are largely distinct from those in other settings, particularly in the use of surgical resection 
among more advanced stage patients.
 3-5
  With recent advancements in resection and localized therapies 
for HCC, continued research is needed to re-evaluate the appropriateness of current guideline 
recommendations.
 3
  
Resection and tumor ablation are the main curative treatment options for HCC, but eligibility to 
receive curative therapy diminishes with more advanced disease.
 2,3
   Both the CMH and Taiwanese 
Department of Health have strived to improve the early detection of HCC by providing government-
funded HCC surveillance in high-risk areas.
 3,6,7
 In both China and Taiwan, recommended screening tests 
include abdominal ultrasound (US) and measurement of serum alpha-fetoprotein (AFP), with a cut-point 
of ≥ 200 ng/mL.
 2,3
   
HCC surveillance is widely recommended; however, only limited evidence exists to quantify or 
even demonstrate its impact on survival with HCC.
 2-4,8
   An important limitation of prior studies 
assessing the impact of surveillance on the survival of patients with HCC is the potential for lead time 
bias.
 9
  This bias may occur if surveillance merely detects the tumor at an earlier stage without affecting 
the course of disease, leading in an overestimation of survival gains with surveillance.
 2 
  To address this 
limitation, observational studies have approximately adjusted for lead time by applying different 
assumptions surrounding estimated tumor volume doubling time (DT) to the well-established formula 
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for tumor growth. 
 10-13
  The results of these studies suggested that surveillance significantly improves 
survival, even after lead time adjustment. 
 10-13
 However, such methods were based solely on current 
knowledge surrounding HCC tumor growth, and did not comprehensively incorporate the full range in 
DT seen across prior tumor growth studies in HCC. 
 14-27
    
In addition, the ideal screening interval for HCC surveillance is not known.
 2,4,8,28
  Consensus 
guidelines suggest an interval of 6-12 months, based on average DT, 
 2,4,8
 although there are no 
randomized studies that have determined the optimal interval.   Guidelines acknowledge that the 
optimal interval for HCC surveillance should be assessed from the view of both resource use and survival 
outcomes, as it is clear that more frequent tests can detect HCC nodules of smaller size.
 2,3
  Thus, 
determining the optimal approach for HCC surveillance requires both an understanding of tumor 
development and progression over time, and an accurate assessment of treatment patterns and 
associated survival in clinical practice.   
Thus, there are several gaps in the literature surrounding the appropriate treatment of patients 
diagnosed at various stages of disease, particularly for patients with intermediate to advanced HCC.
 2-5
    
Surveillance among individuals at high-risk for HCC is recommended in East Asia, but further research is 
needed to understand its current impact on survival with HCC, and determine the optimal approach in 
light of the need to conserve resources.
 2-4,8
  Accordingly, this dissertation examined the comparative 
effectiveness of surveillance and current treatment approaches for the detection and management of 
HCC in East Asia.  Specific aims included: 
1. Compare the effectiveness of current treatment approaches for patients diagnosed with 
HCC in China 
a. Assess overall survival with primary treatment for patients diagnosed at various 
stages of HCC disease, controlling for selection bias 
b. Examine adherence to current treatment recommendations for HCC in China, 
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according to disease stage at diagnosis 
c. Explore disease characteristics and current treatment approaches for HCC across 
different regions in China   
2. Develop an Individual-based model to simulate a randomized trial of HCC surveillance 
among individuals with chronic HBV infection in China  
a. Provide a transparent overview of the model structure and input parameters 
b. Calibrate unknown parameters of HCC disease progression and incidental diagnosis  
c. Evaluate the impact of different screening intervals (i.e., 6 month vs. 12-month) for 
HCC surveillance based on current recommendations in China 
3. Examine the current Impact of surveillance on the survival of patients diagnosed with HCC in 
Taiwan 
a. Estimate the survival benefit of surveillance, adjusting for lead time and selection 
bias  
b. Compare tumor characteristics and primary treatment approaches, by surveillance 
status 
Clinical information for patients diagnosed with HCC were obtained from the global Bridge to 
Better Outcomes in HCC (HCC BRIDGE) study, a retrospective observational study of patients newly 
diagnosed with HCC from January 1, 2005 through June 30, 2011 across 14 countries in East Asia, 
Europe, and North America. 29,30  Data to assess Aims 1 and 2 were obtained from the HCC BRIDGE study 
in China, conducted across 10 tertiary hospital centers from 7 geographically diverse cities in mainland 
China.  For the simulation model in Aim 2, comprehensive literature reviews were additionally 
conducted to obtain parameters surrounding chronic HBV progression, HCC development, tumor 
growth, and surveillance accuracy.  Aim 3 analyses incorporated data from the HCC BRIDGE study in 
Taiwan, collected at the National Taiwan University Hospital, and the full range in tumor growth 
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parameters synthesized in Aim 2. 
With advancements in the management of HCC in China, continued research is needed to assess 
current treatment patterns and re-evaluate the appropriateness of current guideline recommendations.  
To assess current treatment approaches (Aim 1), patients with HCC included in the HCC BRIDGE study 
were first stratified according to disease stage at diagnosis, based on categories defined in the China 
Ministry of Health (CMH) guidelines. 3 For each disease stage, trends in the frequency of primary 
treatments were compared with current guideline recommendations (Aim 1b).  To compare survival 
with primary treatment, Kaplan-Meier curves were constructed for each disease stage; survival 
differences were assessed using the log-rank test (Aim 1a). 31  Multivariate Cox proportional hazard 
models further assessed the association between primary treatment and the hazard of death (aim 1a), 
controlling for underlying differences in patient characteristics across treatment groups. 31  Propensity 
score (PS) analysis, using the methods of propensity-based weighting and regression-based adjustment, 
were conducted to address residual selection bias. 32,33  PS for each treatment were estimated using 
multinomial logistic models. 32  Models for each disease stage controlled for patient demographics, co-
morbidities, etiology, liver function, disease characteristics, and hospital site where treatment was 
received.  Additional analyses explored disease stage at diagnosis and primary treatment across 
different regions in China; differences were assessed using the Chi
2
 test (Aim 1c). 34 
Although HCC surveillance is widely recommended, few studies have shown a survival benefit, 
and the ideal screening interval is not known.
 2,4,8,9,28
  An individual-based simulation model was 
developed to project the impact of HCC surveillance on survival following HCC development among 
individuals with chronic HBV infection in China (Aim 2).  The model incorporated well-established data 
on the natural disease course of chronic HBV infection and HCC development (Aim 2a).
 35-37
   A meta-
analysis using a random effects model was conducted to synthesize estimates of DT from prior tumor 
growth studies in HCC (Aim 2a).
 38,39
 Model calibration was conducted to obtain additional unknown 
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parameters of HCC disease progression and incidental diagnosis, based on the distribution of tumor 
characteristics seen among HCC patients who did not receive surveillance from the HCC BRIDGE study in 
China (Aim 2b).  The HCC BRIDGE study data was further used to assign HCC treatment probabilities and 
project survival with treatment using a series of parametric survival curves (2a). 31       
Based on the accuracy of diagnostic tests for HCC, the simulation model assessed three different 
strategies for HCC surveillance (Aim 2c):  1) no surveillance (for comparison), 2) 6-month US and AFP 
(with cutpoint ≥ 200 ng/mL), and 3) 12-month US and AFP.  As the primary outcome, overall survival 
following HCC development was compared across surveillance strategies using the Kaplan-Meier 
method; survival differences were assessed using the log-rank test . 31   Additional analyses compared 
disease stage and primary treatment at diagnosis, with statistical differences evaluated using the Chi
2
 
test. 34 Probabilistic sensitivity analyses were conducted to provide estimates of uncertainly in the 
model-projected outcomes.
 40
 
A major limitation of prior studies assessing the survival impact of HCC surveillance is the 
potential for lead time bias related to the earlier diagnosis of HCC.
 9
  Using data from the HCC BRIDGE 
study in Taiwan, analyses assessed the impact of surveillance on survival, controlling for lead time bias 
(Aim 3a).  Surveillance was defined as a binary variable, which indicated whether a patient received 
regular diagnostic imaging, with or without AFP, every 6-12 months.  Lead time was approximated using 
the well-established formula for tumor growth and subtracted from the survival of patients in the 
surveillance group. 10,11,13  Analyses explored different assumptions surrounding the estimated lead time, 
using a range in median DT estimated across prior tumor growth studies (synthesized in Aim 2).  14-27    
To address selection bias resulting from non-random allocation of HCC surveillance, PS analysis was 
conducted using the methods of propensity-based matching and propensity-based weighting. 33,41,42   
The PS for each surveillance group were estimated using a logistic model, controlling for patient 
demographics, co-morbidities, etiology, liver function, and year of diagnosis.  Kaplan-Meier curves 
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assessed survival according to surveillance status, controlling for both lead time and selection bias; 
survival differences were assessed using the log-rank test. 31 As secondary outcomes, the study also 
compared tumor characteristics and primary treatment approaches according to surveillance status; 
statistical differences were evaluated using the Chi
2
 test (Aim 3b). 34 
Together, these studies can help improve the detection and management of HCC in East Asia, 
where HCC is one of the leading causes of cancer-related mortality.
 43,44
   Continued research is needed 
to re-evaluate the appropriateness of current guideline recommendations in China, particularly with 
limited evidence on the comparative effectiveness of therapies for intermediate to advanced disease.
 3
  
Both China and Taiwan have implemented community-based surveillance to improve the early detection 
of HCC, but additional research is needed to examine the impact of HCC surveillance on survival 
outcomes.
 3,6,7
 Given the substantial clinical and economic burden of HCC in East Asia, this dissertation 
can help inform efforts to ensure that individuals at high-risk for developing HCC are properly monitored 
given limited resources, and patients with HCC receive appropriate treatment to improve survival. 
Sections of the dissertation are organized as follows: Chapter 2 details the current literature on 
the burden of HCC in East Asia, consensus guidelines for HCC management, comparative effectiveness of 
current treatment approaches, survival impact of HCC surveillance, and decision models of HCC 
surveillance.  Chapter 2 is intended to present background and justification for the dissertation study 
and to provide the reader with an understanding of the complexities and controversies involved when 
examining the impact of surveillance and treatment approaches on the survival of patients diagnosed 
with HCC.  Chapters 3 through 5 are individual manuscripts corresponding to Aims 1-3, respectively, and 
are intended for submission to peer-reviewed journals.  Chapter 6 summarizes the strengths and 
limitations of this work, policy relevance, and future research plans.  References are provided in a 
generalized bibliography at the end of the dissertation.  
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CHAPTER 2: LITERATURE REVIEW 
Overview 
HCC is highly prevalent in East Asia, with more than one-half of all global cases occurring in 
China alone.
 45
  Recognizing the clinical and economic burden of HCC, the CMH has declared HCC as one 
of 5 tumors of high national importance and has published its newest Diagnosis and Treatment 
Guidelines for Primary Liver Cancers (2011 edition).
 3
  The guidelines are largely distinct from those in 
other settings, mainly in their recommendations for patients diagnosed with intermediate and advanced 
HCC.
 3-5,8
  With recent advancements in the treatment of HCC, continued research is needed to re-
evaluate the appropriateness of current guideline recommendations.  To this end, this study explored 
current treatment approaches and compared the effectiveness of primary treatment on overall survival 
for patients diagnosed at various stages of disease in China.  
Both China and Taiwan have provided government-funded HCC surveillance in high-risk areas to 
improve the early detection of HCC.
 3,6,7
  Although HCC surveillance is widely recommended, few studies 
have provided direct evidence that surveillance improves survival.
 2,4,5,8
 Furthermore, the ideal screening 
interval for surveillance is not known.
 2,4,8,28
  Limitations of prior studies of HCC surveillance include: a 
relatively small number of patients diagnosed with HCC, data collected over a short follow-up, poor 
compliance to surveillance guidelines, suboptimal treatment following diagnosis, and potential lead time 
bias related to earlier diagnosis of HCC under surveillance. 
 9-12,46
 As such, the current study addresses 
this gap in the literature by assessing the current impact of surveillance on the survival of patients 
diagnosed with HCC, using data from a large cohort of patients diagnosed with HCC in Taiwan. To 
control for potential lead time bias, different assumptions surrounding the estimated lead time were 
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explored, using a range in median DT estimated across prior tumor growth studies.  14-27   Using an 
individual-based model to simulate a randomized trial of surveillance, the study further examined the 
impact of different screening intervals among individuals with chronic HBV infection, based on current 
recommendations in China.  
This dissertation collectively contributes to the existing literature in HCC by providing a more 
comprehensive outlook on the comparative effectiveness of current treatment approaches and 
surveillance for HCC, while addressing the limitations of prior studies.  In terms of policy relevance, the 
results can be used to (1) inform clinicians about the appropriate used of current treatments options for 
HCC in comparison with guideline recommendations in China, (2) provide additional evidence on the 
current impact of HCC surveillance in clinical practice to inform ongoing policy efforts to improve the 
early detection of HCC, and (3) determine the optimal screening interval for surveillance to improve 
survival with HCC in the setting of limited resources. 
Burden of Hepatocellular Carcinoma in East Asia 
HCC is the third leading cause of cancer-related death worldwide.
 47,48
  HCC is highly prevalent in 
East Asia, with more than one-half of all global cases occurring in China alone.
 45
 HCC is the third most 
frequent cancer and the second leading cause of cancer-related death in China; an estimated 402,000 
new cases were diagnosed and 372,000 HCC-related deaths occurred in 2008.
 47
  In Taiwan, HCC is the 
leading cause of cancer-related death among males and the second among females, with age-adjusted 
mortality rates of 40.8 and 14.1 per 100,000 persons, respectively.
 49
 
HCC is a highly complex and heterogeneous disease.  Major etiological risk factors for HCC vary 
among different regions and most commonly include chronic infection with hepatitis B or C virus (HBV, 
HCV), alcoholic liver disease (ALD), nonalcoholic fatty liver disease (NAFLD), primary biliary cirrhosis, 
hemochromatosis, and inherited metabolic disorder.
 2,3,5
  Whereas HCV, ALD and NAFLD are the most 
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common factors contributing to HCC in North America and Europe, HCC in East Asia is primarily linked to 
a high prevalence of HBV infection (9.75%) and to a lesser extent HCV infection (prevalence: 3.2%).
 45,50
  
Both chronic HBV or HCV infection can progress to liver cirrhosis, characterized by permanent scarring 
or fibrosis of liver tissue, which in turn can lead to the development of HCC.  In 2006, more than 80% of 
HCC cases in China were related to HBV infection, whereas 17% were related to HCV infection.
 45
 
Although both HBV and HCV infection are direct risk factors for HCC, the mechanisms through 
which infection is contracted can lead to a different disease course.   In East Asia, HBV is generally 
contracted through vertical transmission from mother to child, whereas HCV is generally contracted 
through needle contamination or injection drug use.
 51,52
  As a result, individuals with chronic HBV may 
develop HCC in late adulthood (≥40 years), whereas development of HCC in HCV generally occurs at a 
later age (mean age >60 years).
 52
  In addition, whereas HCC related to HCV almost always occurs with 
cirrhosis, HCC among individuals with chronic HBV can develop without the presence of underlying 
cirrhosis in approximately 10-20% of cases.
 52
   
During the past 3 decades, national campaigns to vaccinate infants in East Asia against HBV have 
diminished the incidence of new infection; however, effects on HCC incidence will not be seen until 20-
30 years from now when these individuals reach late adulthood.
 45,53
  In addition, antiviral therapies to 
slow the progression of chronic HBV to the development of cirrhosis and HCC have demonstrated only a 
modest impact.
 54
  Therefore, current approaches to HCC management are primarily focused on the 
early detection and treatment of HCC.   
Disease Staging for Hepatocellular Carcinoma  
According to global consensus guidelines for the management of HCC, the main determinants of 
treatment selection and prognosis for HCC include tumor characteristics, underlying liver function and 
performance status at diagnosis.
 2-5
  Relevant tumor characteristics include tumor size (diameter in cm), 
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number of tumor nodules, and tumor spread, defined by the presence of vascular invasion (i.e., 
macrovascular invasion or invasion of the main branch of the hepatic vein, any portal vein, or any 
vascular or bile duct) and tumor metastases (i.e., hepatic lymph node, extrahepatic or any 
regional/distant metastases).  An important consideration when evaluating therapeutic options for HCC 
is liver function.
 2
  A small percentage of patients (~10-20%) with chronic HBV may be diagnosed with 
HCC in the absence of cirrhosis.
 52
 The remaining patients are further staged based on degree of cirrhosis 
measured by the Child-Pugh (CP) scoring system, derived using laboratory values (i.e., international 
normalized ratio, bilirubin, albumin and prothrombin) and liver characteristics (i.e., presence of ascites 
and encephalopathy) at diagnosis.
 3,55
 Individuals with compensated cirrhosis with no or mild symptoms 
generally score in the range of CP A-B, whereas individuals with clinically significant decompensated 
cirrhosis generally score as CP C.  Performance status is commonly measured using the Eastern 
Cooperative Oncology Group (ECOG) scoring criteria, with scores ranging from 0-2 = fully active/partially 
disabled to 3-4 = substantially/completely disabled, and 5 = dead.
 3,56
   
According to the CMH guidelines, disease stage following HCC diagnosis is categorized in five 
stages: 1) Very Early/Early, 2) Intermediate - Solitary, 3) Intermediate - Multinodular, 4) Advanced, and 
5) Terminal (Figure 2.1).
 3
  Terminal stage includes patients with substantial performance status 
limitations (i.e., performance status = 3-4) or severely impaired liver function (i.e., CP C).  Patients with 
no/moderate performance status limitations and liver function impairment (i.e., performance status <3, 
no cirrhosis or CP A/B) are further categorized according to tumor size, number, and spread.  Advanced 
stage patients include those with tumor metastases or any vascular invasion.  Disease stage for solitary 
tumors without vascular invasion and tumor metastases is defined according to tumor size: Very Early: 
diameter ≤2 cm, Early: >2 cm but ≤5 cm, and Intermediate: >5 cm.  Multinodular tumors without 
vascular invasion and tumor metastases are categorized according to both tumor size and number: 
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Early: 2-3 tumors, with largest diameter ≤3 cm, and Intermediate: 2-3 tumors, with largest diameter >3 
cm, or ≥4 tumors (of any size). 
Guideline Recommended Treatment Approaches for Hepatocellular Carcinoma  
Recommended treatment approaches for HCC in China are largely distinct from those in the 
United States and Europe (Figure 2.1).
 3-5
 Worldwide consensus guidelines consistently recommend 
resection as the primary treatment for patients with early HCC and well-preserved liver function, and 
acknowledge that ablation may be used as a less invasive alternative.
 2-5  
Liver transplant is also 
commonly recommended for early HCC, as it can both remove the cancerous tumor and cure the 
underlying liver disease; however, a shortage of suitable donors has limited its availability in China.
 3
   
The majority of patients worldwide are diagnosed with intermediate to advanced HCC, for which 
the most appropriate treatments remain controversial.
  2-5
 According to guidelines published in the 
United States and Europe, the primary treatment option for intermediate HCC, characterized by 
multinodular tumors (i.e., 2-3 tumors, with largest ≥3 cm or ≥4 tumors), is trans-arterial (TA) therapy, 
and the only recommended therapeutic option for advanced HCC is sorafenib.
 4,5,8  
In contrast, the CMH 
guidelines have adopted a more aggressive approach.  Whereas the CMH guidelines agree that surgical 
resection may be recommended for large solitary HCC (i.e., > 5 cm), the guidelines further recommend 
resection for multinodular HCC, provided the tumors are in a suitable location and the patient has well-
preserved liver function.
 3
  Furthermore, patients with advanced disease may receive resection, provided 
the same conditions apply, although treatment is mainly for palliative intent.  TA therapy and systemic 
therapy are recommended for intermediate and advanced stage patients, respectively, who are not 
optimal surgical candidates or who elect to forgo surgical treatment.  
In part, the apparent disagreement in treatment recommendations can be explained by 
distinctions in the clinical context surrounding HCC across different regions.  In the United States and 
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Europe, where HCC is primarily linked to chronic HCV infection and ALD, nearly all patients present with 
cirrhosis.
 57
 In contrast, in China and other parts of East Asia, more than 80% of cases are related to 
chronic HBV infection; in this setting, HCC patients generally have well-preserved liver function, and 
approximately 10-20% of patients do not have evidence of cirrhosis.
 52
 Consensus guidelines agree that 
patients with significant liver function impairment, particularly portal hypertension, are poor candidates 
for surgical resection due to an increased risk of liver failure post resection.
 4-7  
 Thus, in western settings, 
resection is often not recommended based on underlying liver impairment alone and/or portal 
hypertension, regardless of tumor characteristics. 
Comparative Effectiveness of Treatments for Hepatocellular Carcinoma 
Studies conducted in East Asia have assessed the effectiveness of surgical resection for patients 
with intermediate and advanced disease, with varying results.  Prior research suggests that resection 
may be safely performed among patients with large solitary tumors with no evidence of vascular 
invasion, as the risk of recurrence is not significantly increased as compared to smaller tumors.
 58,59
 In 
contrast, earlier observational studies found that patients with multinodular HCC are poor candidates 
for resection, due to an increased risk of tumor recurrence.
 58,60
  With recent advancements in surgical 
techniques, however, a larger number of multinodular tumors are now considered resectable, with 3-
year survival reaching as high as 35-56%. 
 61-63
   Nevertheless, direct comparisons of survival with TA 
therapy have been limited.  A recent prospective study conducted by Luo et al. (2011) in China 
compared survival with resection (n=85) and TA therapy (n=83) among patients with large (≥5 cm) and 
multiple (≥2) tumors that were deemed resectable based on extensive clinical discussion.
 63
  Overall 3- 
and 5-year survival for patients who received resection (35% and 24%, respectively) were higher than 
those for patients initially allocated to TA therapy (26% and 19%, respectively), although survival 
differences were non-significant (p=0.26).  The authors noted, however, that 13 patients (16%) in the TA 
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therapy group subsequently received resection during follow-up. Although further evidence is needed, 
the authors suggested that TA therapy may be a better initial treatment for intermediate stage HCC, and 
resection should be recommended among patients who respond well to TA therapy. 
Studies conducted among advanced stage patients with portal vein tumor thrombosis have 
reported modest survival benefits associated with resection; however, post-operative recurrence and 
post-surgical complications are common.
 64,65
  Thus, the role of resection remains controversial, 
particularly in the absence of head-to-head clinical trials comparing survival with that of sorafenib.  A 
clinical trial of sorafenib conducted in East Asia demonstrated improved survival over placebo (p=0.014), 
with a reported median survival of 6.5 (5.6-7.6) months.
 66
  Other systemic treatments for HCC have 
been proven ineffective.
 67,68
 
Prior studies comparing long-term survival between resection and tumor ablation for early stage 
disease have largely reported conflicting results.
 69-71
  Clinical trials conducted in China noted higher 
survival rates with resection, but did not find a statistically significant difference in survival between the 
two groups.
 72,73
  In contrast, another trial found a substantial survival advantage with resection among 
early stage patients; 3-year survival rates for radiofrequency ablation versus resection were 69.6% and 
92.2%, respectively (p=0.001).
 74
  It should be noted, however, that the trials enrolled different 
proportions of patients with very early stage disease, which may in part explain the conflicting results, 
since ablation beyond this stage is less effective in achieving complete tumor necrosis.
 70
  Subgroup 
analyses among patients with solitary tumors 3-5 cm and 2-3 tumors <3 cm were generally limited by 
small sample size, but reported a survival benefit with resection.
 70,74
  Whereas resection may provide 
better long-term efficacy than ablation, it should also be noted that resection is associated with 
increased complications and longer hospital stays.
 69
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Surveillance to Detect Hepatocellular Carcinoma 
Resection and tumor ablation are the main curative treatment options for HCC, but eligibility to 
receive curative therapy diminishes with more advanced disease.
 2,3
   Whereas survival with HCC is 
generally poor (5-year survival 16.2%), 5-year survival for patients diagnosed at an earlier stage who 
receive curative therapy can exceed 50%.
 43,44
   Both the CMH and Taiwanese Department of Health have 
strived to improve the early detection of HCC by providing government-funded HCC surveillance in high-
risk areas.
 3,6,7
  In China, HCC surveillance is recommended every 6 months among men aged ≥40 years 
and women aged ≥50 years who are at high risk for HCC, including individuals with a history of chronic 
HBV or HCV infection, alcoholism and/or diabetes, or family history of HCC.
 3
  In Taiwan, HCC 
surveillance is also recommended every 6 months, but is primarily indicated among individuals with 
cirrhosis related to chronic HBV or HCV infection.
 2
     
In both China and Taiwan, recommended screening tests include abdominal US and 
measurement of serum AFP, with a cut-point of ≥200 ng/mL.
 2,3
  Additional screening modalities include 
computed tomography (CT) and magnetic resonance imaging (MRI) scan.  However, these tests are 
generally not recommended as primary screening tests given their high cost, and are mainly used to 
confirm diagnosis.  Guidelines acknowledge the use of additional biomarkers, such as des-c-
carboxyprothrombin and lens culinaris agglutinin-reactive fraction of AFP as potential screening tools; 
however, they do not provide any specific recommendations surrounding these tests.
 2
 
Impact of Hepatocellular Carcinoma Surveillance on Survival Outcomes  
HCC surveillance has been conducted in East Asia since the early 1970s.  However, few studies 
have provided direct evidence that HCC surveillance improves survival.  Early analyses evaluating the use 
of AFP alone among individuals at moderate risk for HCC found limited usefulness of this strategy 
provided the low incidence of disease among individuals at moderate risk and the low sensitivity and 
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specificity of the test.
 75
  Since the 1980s, the primary strategy for HCC surveillance evolved to the use of 
AFP in combination with US among individuals at high-risk for HCC.
 76
   
A randomized control trial among 18,816 participants with chronic HBV infection in China found 
that surveillance every 6 months with US and AFP was associated with a significant 37%-reduction in 5-
year mortality.
 9
 Despite demonstrating survival benefit, the trial had several limitations, including 
potential lead time bias related to the earlier diagnosis of HCC, a relatively low number of HCC cases 
(n=153) collected over a short follow-up (5 years), and suboptimal adherence to the surveillance 
protocol (less than 60%). Nevertheless, the trial provides the best evidence of a survival benefit 
associated with surveillance in HCC.   An earlier trial also conducted in China failed to show benefit with 
surveillance, largely because HCC patients did not undergo appropriate treatment.
 46
 
Controversies Surrounding Hepatocellular Carcinoma Surveillance 
An important limitation to the seminal trial of surveillance in China, as well as other studies 
assessing the impact of surveillance, is the potential for lead time bias.
 9
 This bias may occur if 
surveillance merely detects the tumor at an earlier stage without affecting the course of disease, leading 
in an overestimation of survival gains with surveillance.
 2 
  To address this limitation, observational 
studies have approximately adjusted for lead time by applying different assumptions surrounding 
estimated DT to the well established formula for tumor growth, first proposed by Schwartz (1961). 
 10-13
    
t = 
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where:   t   = time interval between measurements (days) 
 DT = tumor volume doubling time (days) 
 D0 = tumor diameter at first measurement 
 D1 = tumor diameter at last measurement 
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Using this formula, lead time represents the time interval (t, in days) for the primary tumor to 
grow from the median diameter among patients in the surveillance group (D0) to the median diameter 
among patients in the no surveillance group (D1).  The estimated lead times are then subtracted from 
the survival of patients in the surveillance group.  The results of observational studies suggest that 
surveillance significantly improves survival, even after lead time adjustment using a range in DT from 60 
to 120 days. 
 10-13
   However, such methods are based solely on current knowledge surrounding HCC 
tumor growth. Tumor growth in HCC is highly heterogeneous across individuals, and other aspects of 
HCC progression, including the development of multinodular HCC, vascular invasion and tumor 
metastases, are not fully understood.  14-27    
 Although HCC surveillance is recommended, the ideal screening interval for surveillance is not 
known.  Consensus guidelines suggest an interval of 6-12 months, based on average DT. 
 2,4,8
  Prior 
clinical studies have adopted an interval of 6 months between periodic diagnostic tests,
 9-11,28,30,77
 
although there are no randomized studies that have determined the optimal interval.  Evidence from a 
small retrospective study in Italy suggests that survival is similar among HCC patients who receive 
surveillance at a 6-month interval, as compared with a 12-month interval.
 28
  However, clinical guidelines 
have been hesitant to make definite recommendations using the results of this study alone.
 5
 Guidelines 
acknowledge that the optimal interval for HCC surveillance should be assessed from the view of both 
resource use and survival outcomes, as it is clear that more frequent tests can detect HCC nodules of 
smaller size.
 2,3
   
Prior Decision Models of Hepatocellular Carcinoma Surveillance 
Given the substantial clinical and economic burden of HCC in the Asia-Pacific region, clinical 
guidelines have explicitly considered evidence from prior cost-effectiveness studies when forming 
recommendations surrounding the use of different surveillance strategies.
 2
  Cost-effectiveness analyses 
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involve the systematic comparison of the costs and outcomes of two or more interventions, generally 
using decision modeling techniques.
 40
  In this case, each surveillance strategy is compared with the 
option of not providing surveillance.   
 In general, prior decision models of surveillance were developed using an aggregate state-
transition (Markov) model, simulating the impact of alternative intervention scenarios on outcomes 
among specific patient cohorts (Table 2.1).
 78-86
 In all cases, individuals were initially assumed to have no 
HCC disease at the start of simulation.  In turn, the progression of chronic liver disease was modeled, 
incorporating the risk of worsened liver function, HCC development and death.  Specific high-risk 
populations incorporated in the models included individuals with cirrhosis, whereas one study 
additionally modeled individuals with chronic HBV without cirrhosis.
84
  
 Among the alternative surveillance strategies modeled, all models incorporated screening with 
US ± AFP in 6- or 12-month intervals; 
 78-86
 additional strategies included the use of CT, MRI, and contrast 
enhanced US.
 79-81,85
  In evaluating the cost-effectiveness of these strategies, 5 studies assumed the 
perspective of the United States payer,
 80,81,85-87
  2 studies modeled the perspective of the National 
Health Service in the United Kingdom,
 82,83
  2 studies assumed the perspective of the national health 
insurance system in Japan,
 78,79
 and one study modeled the perspective of the National Health Insurance 
program in Taiwan.
 84
  
 Key model inputs included: 1) sensitivity/specificity of surveillance, 2) transition probabilities, 3) 
tumor growth rates, 4) costs of surveillance, diagnosis, and treatment, and 5) health utilities related to 
disease and treatment states.  
 78-86
  Model inputs for surveillance sensitivity/specificity inputs were 
largely similar, with one key difference.  All but one study assumed the same sensitivity of US across 
tumor size when, in reality, the sensitivity of US is only 21-35% for small tumors (<2 cm).
 88-90
  Transition 
probabilities generally included the progression of compensated cirrhosis to decompensated cirrhosis, 
HCC incidence, probabilities of incidental and symptomatic diagnosis, treatment probabilities and death.  
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 In modeling tumor progression, the majority of models incorporated evidence from prior tumor 
growth studies; however, the methods for incorporating this information varied considerably.  Most 
authors manually calibrated the transition probabilities from small to large HCC tumors to reflect the 
expected tumor size over time.
 81,85-87
  Unfortunately, the details of these methods were largely unclear.   
In contrast, Thompson Coon et al. and Chang et al. developed a more sophisticated approach using 
individual-based sampling methods.
 82-84
  This method involved a two-dimensional representation of 
tumor growth: The authors assumed a relationship between tumor growth and time (e.g., exponential 
growth) and provided a scale parameter (i.e., DT) to adjust the rate of tumor growth.  Although the 
methods employed by Chang et al. and Thompson Coon et al. were similar, the assumptions surrounding 
tumor growth and distribution of tumor doubling time were different (Table 2.1).
 82-84
  Using the tumor 
growth equation and a specified distribution of DT, the model would project tumor size for individuals 
with HCC.  The results for different values of DT then were pooled across a series of simulations to 
estimate ranges in the costs and outcomes associated with surveillance versus no surveillance.  
Whereas numerous studies have measured tumor growth in HCC, clinical data do not provide 
the necessary information to fully characterize the development of satellite tumors and tumor spread 
over time.  The estimation of these parameters would require information regarding when each 
individual developed an HCC tumor and when further complications occurred.  Such information is 
largely unavailable in clinical databases since most early stage patients are treated; even if patients elect 
to forgo treatment, large sample sizes would be needed to establish statistical power.  As a result, prior 
decision models made simplified assumptions surrounding tumor progression in HCC. 
 81,85-87
 For 
instance, both Chang et al. and Thompson Coon et al. observed that multinodular tumors and tumor 
metastases tended to occur with larger tumors.
 70-72 
 Based on these relationships, the authors assumed 
that a large primary tumor > 5 cm could serve as a surrogate for more advanced HCC.
 82-84
 These 
assumptions, however, are problematic for two reasons.  First, although there is a positive correlation 
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between tumor size and the presence of tumor-related complications in HCC, it is not uncommon for 
patients to present with multiple small tumors, with primary tumor size < 5 cm.
 11,12,28
  Secondly, 
treatment approaches and survival outcomes for patients with intermediate solitary HCC (> 5 cm) are 
vastly different than for individuals with other disease-related complications in addition to a large 
primary tumor.
 2,3
   
In addition, the rate at which HCC is detected outside of a surveillance program, either 
incidentally or based on clinical symptoms, cannot be directly measured.  Doing so would require 
knowing the proportion of all HCC cases (undiagnosed and diagnosed) that are detected in regular 
clinical practice.  A number of models excluded this parameter and assumed that all HCC patients in the 
no surveillance group were diagnosed with large HCC based on clinical symptoms.
 85,86
  In doing so, 
however, these models likely overestimated the impact of surveillance.  To approximate this parameter, 
Thompson Coon et al. manually calibrated the probability of incidental diagnosis, by tumor size, to 
reflect the overall distribution of tumor size from a study of patients diagnosed incidentally in clinical 
practice.
 82,83
 However, the details surrounding the calibration procedures were not fully documented.  
Another limitation of prior studies is that many did not appropriately account for the interaction 
between tumor characteristics and liver function in allocating treatments and projecting survival post 
treatment.  Certain studies acknowledged differences in probabilities of receiving curative treatment 
according to degree of cirrhosis.
 81,84,85
  However, given limited data availability, survival probabilities 
with treatment were based on mean unadjusted estimates.  As a result, survival with HCC treatment 
among patients with advanced cirrhosis and other risk factors, such as gender and age at diagnosis, was 
likely over-estimated, leading in an over-estimation of the survival impact of surveillance.  Therefore, 
determining the optimal approach for HCC surveillance requires both an understanding of tumor 
development and progression over time, and an accurate assessment of treatment patterns and 
associated survival in clinical practice. 
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Advantages of an Individual-Based Model for Hepatocellular Carcinoma Surveillance 
A major limitation of prior cohort-based models of HCC surveillance, which use Markov chains to 
model transitions through different health states, is that they cannot flexibly incorporate the impact of 
accumulating medical history in determining model transitions, and survival outcomes.
 40
  In HCC, 
treatment options and survival outcomes are highly dependent on tumor stage at diagnosis, liver 
function, gender, and age.
 2
  Prior Markov models have partially accounted for these interactions by 
stratifying HCC disease states according to degree of underlying cirrhosis when allocating treatment.
 
81,84,85
  On the other hand, in the absence of detailed data in regular clinical practice, these studies have 
not accounted for differences in treatment outcomes related to patient age, gender, and degree of 
cirrhosis.   
 In addition, prior decision models have made simplifying assumptions about the rate of tumor 
growth in HCC,
 85,86
 when, in reality, rates of tumor progression are highly heterogeneous across 
individuals.
 15,18,26
 Indeed, in a scenario analysis performed by Thompson Coon et al.,
 83
 in which tumor 
growth rates were varied across ten simulated cohorts, the optimal intervals for HCC surveillance varied 
substantially when it was assumed that the majority of individuals had very slow growing versus fast 
growing tumors.  Therefore, providing an accurate representation of tumor growth in HCC, as well as 
other aspects of tumor progression, is essential for understanding the optimal screening interval for HCC 
surveillance and the potential impact of non-compliance with surveillance protocols.   
 Individual-based models, sometimes described as agent-based or microsimulation models, 
provide an attractive alternative when the assumptions of Markov models prove to be limiting in this 
way.
 40,91
  As individuals move through the model one at a time, rather than as proportions of a cohort, 
the model can track individual-level characteristics (e.g., co-morbidities and medical history) and allow 
them to interact through a series of model  transition rules (or transition logic) to simulate the life-
course of disease.
 40
 Individual-based models generally consist of two components: a natural history 
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component and an intervention component.
 92,93
  The natural history model is developed first in the 
absence of an intervention.  The intervention is then incorporated into the natural history model to alter 
the course of disease.  Individual-based models are often complex, and the amount of complexity is 
largely governed by the disease process, specific questions to be addressed, and data available to inform 
model parameters.
 40,91,93
  As such, individual-based models are often used when large detailed datasets 
are available, as they can better incorporate the richness of the data to address a range of decision 
problems in the disease area as they emerge.    
Significance and Contribution 
With recent advancements in the treatment of HCC, continued research is needed to re-
evaluate the appropriateness of current guideline recommendations.  Studies conducted in East Asia 
have assessed the effectiveness of surgical resection for patients with intermediate and advanced 
disease, with varying results, and few studies have conducted direct survival comparisons with TA and 
sorafenib therapy.
 58,60-65
  Prior literature comparing long-term survival between resection and tumor 
ablation for early stage disease have also reported conflicting results.
 69-71
 The current study provides 
detailed comparative analyses of survival with HCC treatment for patients diagnosed at various stages of 
disease to clarify best treatment practices.  The results of this study can provide valuable insights into 
the impact of disease characteristics and current treatment approaches on the prognosis of HCC in 
China, to help prioritize areas for improvement. 
Both the CMH and Taiwanese Department of Health have sponsored government-funded HCC 
surveillance to reduce mortality associated with HCC.
 3,6,7
 Although surveillance is widely recommended, 
few studies have provided direct evidence that surveillance improves survival. 
 9-12
  Limitations of prior 
studies of HCC surveillance include a relatively small number of patients diagnosed with HCC collected 
over a short follow-up, poor compliance, and potential lead time bias related to the earlier diagnosis of 
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HCC.  The current study uses a large dataset of patients diagnosed with HCC in Taiwan to examine the 
survival impact of surveillance.  The analyses leverage previously established methods for lead time bias 
adjustment using the well-established formula for tumor growth in HCC,
 10-13
 and further extend this 
work by incorporating the full range in median DT estimated across prior tumor growth studies.
 14-27
  
Although HCC surveillance is recommended, the ideal screening interval for surveillance is not 
known. 
 2,4,8
 Determining the optimal approach for HCC surveillance requires both an understanding of 
tumor progression over time, and an accurate assessment of treatment patterns and associated survival 
in clinical practice.   In the absence of more detailed data, prior Markov models of HCC surveillance have 
made simplifying assumptions surrounding tumor progression and the impact of patient characteristics 
in determining HCC treatment and survival outcomes.
 83-86
 The individual-based model of HCC 
surveillance, developed in this study, flexibly integrates accumulating medical history for individuals 
with chronic HBV infection, individual-level heterogeneity in tumor progression, and survival with 
treatment to accurately project survival for individuals who develop HCC.  The simulation model then is 
used to simulate a randomized trial of HCC surveillance, controlling for lead time bias, to assess the 
impact of different screening intervals based on current recommendations in China.   This simulation 
model not only helps to identify the optimal approach for HCC surveillance, but also provides a basis for 
exploring other issues surrounding surveillance, such as poor compliance and specific high-risk groups 
that should be targeted, as policy efforts to improve early detection evolve in China. 
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Table 2.1: Summary of overall structure and key model inputs from prior decision models of HCC surveillance. † 
 
 
Thompson Coon, 
2007, 2008 
 82,83
 Chang, 2011 
 84
 Andersson, 2008 
 85
 Patel, 2005 
 86
 
Perspective 
United Kingdom National 
Health Service 
Taiwan National Health 
Insurance 
United States payer, 
Medicare costs 
United States payer, 
Medicare costs 
High-Risk Population(s) 
Cirrhosis (HBV & HCV), 
ALD 
Chronic HBV, cirrhosis 
(any etiology) Cirrhosis (any etiology) Cirrhosis & HCV 
Initial Age of Cohort(s) 
Mean Age at HCC 
diagnosis by etiology 
 
50 years 50 years 45 years 
Model Structure 
Markov Model, 
Individual- Based Tumor 
Growth Component for 
Scenario Analyses 
Markov Model, 
Individual-Based Tumor 
Growth Component Markov Model Markov Model 
Cycle Length 
1 month 3 months 6 months 6 months 
Model Horizon 
Lifetime 25 years 30 years 
Until age 80 
(i.e., 35 years) 
Surveillance Strategies 
6,12 month US, 
6,12 month US + AFP 
12 month US 
(3 months for individuals 
with chronic HBV who 
develop cirrhosis) 
6,12 month US, 
6 month US + AFP, 
12 month CT, 
12 month MRI 6 month US + AFP 
Sensitivity/Specificity US 
Sensitivity 
Small HCC: 0.18 
Med. HCC: 0.37 
Large HCC: 0.83 
Specificity: 0.96 
Sensitivity: 0.7 (.5-.9) 
Specificity: 0.8 
Sensitivity: 0.75(.4-.81) 
Specificity: 0.95(.8-1.0) 
Sensitivity: 0.79(.6-.9) 
Specificity: 0.87(.8-1.0) 
Sensitivity/Specificity AFP 
Based on distribution of 
AFP by tumor size, and 
among non-HCC cases 
from pooled tumor 
growth studies N/A 
Sensitivity: 0.6 (.4-.65) 
Specificity: 0.87(.63-.94) Modeled with US 
HCC Disease Stages Modeled 
Small HCC: <2 cm 
Med. HCC: 2-5 cm 
Large HCC: >5 cm 
Asymptomatic HCC 
Symptomatic HCC 
Small HCC 
Large HCC 
Small HCC: <2 cm 
Med. HCC: 2-5 cm 
Large HCC: >5 cm 
  
 
 
2
4
 
 
Thompson Coon, 
2007, 2008 
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 Chang, 2011 
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 Andersson, 2008 
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 Patel, 2005 
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Modeling Tumor Size 
Probability HCC growth 
manually calibrated to 
tumor growth studies 
Scenario Analyses: 
Exponential tumor 
growth rate, normal & 2 
beta distributions (fast, 
slow) of tumor doubling 
time  * 
Tumor growth rate 
piecewise linear & 
uniform distribution of 
tumor doubling time * 
Probability HCC growth 
manually calibrated to 
tumor growth studies 
(details unclear) 
Probability HCC growth 
manually calibrated to 
tumor growth studies 
(details unclear) 
Inc./Symp. Diagnoses 
Calibrated (manually) to 
reflect distribution of 
tumor size at diagnosis 
Inc./symp. diagnoses 
incorporated 
(details unclear) 
Symptomatic presentation 
only of large HCC tumors 
(details unclear) 
Symptomatic 
presentation only of large 
HCC tumors 
HCC Treatments 
Resection, ablation 
TA therapy, supportive 
care 
Resection, ablation, liver 
transplant, no treatment 
Resection, ablation, liver 
transplant, supportive 
care 
Resection, liver 
transplant, supportive 
care 
Excess Mortality 
**
 
Decompensated cirrhosis, 
large HCC, HCC treatment 
Compensated cirrhosis, 
decompensated 
cirrhosis, large HCC, HCC 
treatment 
Decompensated cirrhosis, 
large HCC, HCC treatment 
Decompensated cirrhosis, 
large HCC, HCC treatment 
ALD = alcoholic liver disease, AFP = alpha-fetoprotein, CT = computed tomography scan, HBV = hepatitis B virus, HCC = hepatocellular carcinoma, HCV = 
hepatitis C virus, Med. = medium, Inc. = incidental, MRI = magnetic resonance imaging, Symp. = symptomatic, TA = trans-arterial, US = ultrasound 
† A total of 10 decision models of HCC surveillance were identified; detailed comparisons were performed for the studies that provided the most appropriate 
model structure and transparent overview of the model methodology.
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* Tumor growth was varied at the individual level. 
** In addition to all-cause mortality – in most cases, assumed to encompass mortality associated with compensated cirrhosis.   
  
 
Figure 2.1: Summary of treatment recommendations for patients diagnosed with 
China Ministry of Health (CMH) 3 compared with the American Association for the Study of Liver 
Disease (AASLD) guidelines. 5,8 
 
 AASLD = American Association for the Study of Liver Disease, CMH = China Ministry of Health, CP = Child
score, HCC = hepatocellular carcinoma, TA = trans
* According to the AASLD guidelines, liver transplant is recomm
criteria. 5,94  The CMH guidelines primarily recommend liver transplant for patients with unresectable HCC or for 
those who cannot tolerate ablation or T
† 
Combination therapy with trans-arterial therapy followed by ablation among patients who respond to treatment.
** TA therapy is recommended for patients without evidence of tumor metastases.
‡ 
 Recommended systemic treatments include sorafenib, other molecular targeted therapies, chemotherapy and 
Traditional Chinese medicine. 3
25 
HCC based on the 
-arterial therapy, Tx = treatment 
ended for patients who fall within the Milan 
A therapy due to poor liver function. 3   
 3 
 
-Pugh 
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CHAPTER 3: COMPARATIVE EFFECTIVENESS OF CURRENT TREATMENT APPROACHES FOR 
HEPATOCELLULAR CARCINOMA: RESULTS FROM A LONGITUDINAL OBSERVATIONAL STUDY IN CHINA 
Introduction 
Hepatocellular carcinoma (HCC) is one of the most prevalent and deadly cancers worldwide.
 47,48
  
HCC is particularly common in Asian-Pacific countries, with more than one-half of all global cases 
occurring in China alone.
 45
 In China, HCC is the third most frequent cancer and the second leading cause 
of cancer-related death; an estimated 402,000 new cases were diagnosed and 372,000 HCC-related 
deaths occurred in 2008.
 47
   
In recent years, the China Ministry of Health (CMH) has declared HCC as one of 5 tumors of high 
national importance and has published its newest Diagnosis and Treatment Guidelines for Primary Liver 
Cancers (2011 edition).
 3
  Consistent with consensus guidelines published by other developed nations,
 
2,4,5
 recommended therapeutic options for HCC are administered based on tumor stage, liver function 
and performance status (Figure 3.1).
 3
  Worldwide, clinical guidelines consistently recommend resection 
as the primary treatment for patients with early HCC and well-preserved liver function, and 
acknowledge that ablation may be used as a less invasive alternative.
 4-7   
 
The majority of patients worldwide are diagnosed with intermediate to advanced HCC, for which 
the most appropriate treatments remain controversial.
 4-7 
 According to guidelines published in the 
United States and Europe, the primary treatment option for intermediate HCC, characterized by 
multinodular tumors (i.e., 2-3 tumors, with largest ≥3 cm or ≥4 tumors), is trans-arterial (TA) therapy, 
and the only recommended therapeutic option for advanced HCC is sorafenib.
 4,5,8 
In contrast, the CMH 
guidelines have adopted a more aggressive approach.  Whereas the CMH guidelines agree that surgical 
resection may be recommended for large solitary HCC (i.e., > 5 cm), the guidelines further recommend 
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resection for multinodular HCC, provided the tumors are in a suitable location and the patient has well-
preserved liver function.
 3
  Furthermore, patients with advanced disease may receive resection, provided 
the same conditions apply, although treatment is mainly for palliative intent.  TA therapy and systemic 
therapy are recommended for intermediate and advanced stage patients, respectively, who are not 
optimal surgical candidates or who elect to forgo surgical treatment.  
In part, the apparent disagreement in treatment recommendations can be explained by 
distinctions in the clinical context surrounding HCC across different regions.  In the United States and 
Europe, where HCC is primarily linked to chronic hepatitis C virus (HCV) infection and alcohol-related 
liver disease (ALD), nearly all patients present with cirrhosis.
 57
  In contrast, in China and other parts of 
East Asia, more than 80% of cases are related to chronic hepatitis B virus (HBV) infection; in this setting, 
HCC patients generally have well-preserved liver function, and approximately 10-20% of patients do not 
have evidence of cirrhosis.
 52
  Consensus guidelines agree that patients with significant liver function 
impairment, particularly portal hypertension, are poor candidates for surgical resection due to an 
increased risk of liver failure post resection.
 4-7  
 Thus, in western settings, resection is often not 
recommended based on underlying liver impairment alone and/or portal hypertension, regardless of 
tumor characteristics. 
Studies conducted in East Asia have assessed the effectiveness of surgical resection for patients 
with intermediate and advanced disease, with varying results. Earlier observational studies found that 
patients with multinodular HCC are poor candidates for resection, due to an increased risk of tumor 
recurrence.
 58,60
  With recent advancements in surgical techniques, however, a larger number of 
multinodular tumors are now considered resectable, with 3-year survival reaching as high as 35-56%. 
 61-
63
   Nevertheless, direct comparisons of survival with TA therapy have been limited.
 63
  Studies conducted 
among advanced stage patients with portal vein tumor thrombosis have reported modest survival 
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benefits associated with resection; however, post-operative recurrence and post-surgical complications 
are common.
 64,65
  Thus, the role of resection for advanced HCC remains controversial.  
With recent advancements in the treatment of HCC, continuing research is needed to re-
evaluate the appropriateness of current guideline recommendations.  Therefore, the objective of this 
study was to explore current treatment approaches and to compare the effectiveness of primary 
treatment on overall survival for patients diagnosed at various stages of disease in China.  
Methods 
Study Sample 
The study sample included data from the Bridge to Better Outcomes in Hepatocellular 
Carcinoma (HCC BRIDGE) study in China, a longitudinal cohort study of patients diagnosed with HCC 
across 12 tertiary hospital centers from 9 geographically diverse cities in mainland China.  Details of the 
study design and complete inclusion criteria for the HCC BRIDGE study have been previously described.  
29  Briefly, patients age ≥ 18 years who were newly diagnosed with HCC from January 1, 2005 through 
June 30, 2011 and received active treatment for HCC at one of the participating hospital sites were 
retrospectively enrolled in the study.    Patients with unknown date of HCC diagnosis and/or date of first 
visit to the participating site or whose first HCC treatment was received via participation in a randomized 
clinical trial were excluded.  All patients were followed until September 30, 2012 or date of death. 
 For the present study, additional inclusion criteria included complete clinical tumor 
characteristics, liver function and performance status information to appropriately classify disease stage 
at diagnosis, as well as available follow-up dates after date of diagnosis (Figure 3.2). Two hospital sites in 
Changsha and Nanjing, respectively, were ultimately excluded due to overall poor data quality, including 
>50% missing information for disease characteristics and follow-up information, thus restricting the 
analyses to 10 hospital sites in 7 cities. 
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Data Collection 
 Data for the HCC BRIDGE study were systematically collected for all enrolled patients through a 
retrospective review of patient medical records.  29  Study data were entered into an electronic data 
capture system developed by Outcome Sciences, Inc. (Cambridge, MA, USA) and were subject to 
rigorous monthly data monitoring and cleaning. The institutional review boards from each participating 
hospital site approved the data collection for the HCC BRIDGE study.  Data analyses for the present 
study were approved by The University of North Carolina Office of Human Research Ethics. 
 Available treatment approaches for HCC included: 1) surgical resection, 2) liver transplant, 3) 
ablation, 4) TA therapy, 5) systemic therapy, 6) supportive care, and 7) radiation/other locoregional 
therapy.  The full list of therapies for each treatment approach are listed in Appendix A.  The dates of all 
recorded treatments were compared to identify the primary and subsequent treatment approaches,.  
The primary treatment approach was generally defined as the first recorded treatment, with certain 
exceptions. Supportive care is often administered to reduce symptoms prior to or during primary 
therapy. 3  If patients received another therapy within one month (30 days) after supportive care, the 
other therapy was considered to be the primary treatment.  In practice, TA therapy can be used to 
shrink the tumor(s) in preparation for surgical treatment. 3  For such cases, the primary treatment 
approach was considered to be surgical treatment, rather than TA therapy.  Separate categories were 
created for patients who first received TA therapy then underwent resection, liver transplant or tumor 
ablation within 6 months (182 days) after the first administration of TA therapy.  After this period, any 
additional treatment following TA therapy was considered to be a second-line approach either to treat 
the primary or de novo HCC lesions.   
Clinical and laboratory assessments, including tumor characteristics, liver function, and 
performance status information, were obtained for all patients.  Tumor characteristics included tumor 
size (diameter in cm), number of nodules and tumor spread, defined as the presence of vascular 
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invasion and/or tumor metastases. To measure liver function among individuals with cirrhosis, Child-
Pugh (CP) scores were calculated, and presence of portal hypertension was documented at diagnosis. 3,55 
Performance status was measured using the Eastern Cooperative Oncology Group (ECOG) scoring 
criteria. 3,56  Patients with incomplete data were excluded from the analyses.  In cases where patients 
had multiple clinical assessments over time, only assessments obtained within 6 months (182 days) 
before and after date of diagnosis were considered, and the closest date to diagnosis was used.  
Laboratory values were taken within 1 month (30 days) before to 6 months (182 days) after date of 
diagnosis, and the earliest available laboratory values were selected. To maintain clinical validity, 
analyses and interpretation of clinical information at diagnosis were based on extensive discussions with 
an expert panel of gastroenterologists/hepatologists from China as well as other countries participating 
in the HCC BRIDGE study. 
Patients were categorized according to five disease stages based on the CMH guidelines: 1) Very 
Early/Early, 2) Intermediate - Solitary, 3) Intermediate - Multinodular, 4) Advanced, and 5) Terminal 
(Figure 3.1). 3 Terminal stage included patients with substantial performance status limitations (i.e., 
performance status =3-4) or severely impaired liver function (i.e., CP C).  Patients with no/moderate 
performance status limitations and liver function impairment (i.e., performance status <3, no cirrhosis 
or CP A/B) were further categorized according to tumor size, number, and spread.  Advanced stage 
patients included those with tumor metastases or any vascular invasion, as defined above.  Disease 
stage for solitary tumors without vascular invasion and tumor metastases was defined according to 
tumor size: Very Early: diameter ≤2 cm, Early: >2 cm but ≤5 cm, and Intermediate: >5 cm.  Multinodular 
tumors without vascular invasion and tumor metastases were categorized according to both tumor size 
and number: Early: 2-3 tumors, with largest diameter ≤3 cm, and Intermediate: 2-3 tumors, with largest 
diameter >3 cm, or ≥4 tumors (of any size). 
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 Additional patient demographic and clinical characteristics were collected at time of diagnosis or 
first visit to the hospital site, including patient age, gender, etiology, co-morbidities, and insurance 
status.  Etiology of HCC included chronic HBV infection, chronic HCV infection, ALD, non-alcoholic fatty 
liver disease (NAFLD), primary biliary cirrhosis, hemochromatosis, inherited metabolic disorder or 
idiopathic disease, based on documented evidence in the patient medical record. Relevant co-
morbidities included diagnosed diabetes mellitus, cardiovascular disease (CVD) and hypertension. 95,96   
Patients who paid out of pocket for their treatment were considered uninsured.  
Data Analyses 
Descriptive analyses compared patient demographics, clinical characteristics, disease stage and 
primary treatment approaches across different cities in China.  Statistical differences were assessed 
using analysis of variance (ANOVA) tests for continuous variables, and the χ2 or Fisher exact tests for 
categorical variables. 34  To assess compliance with the CMH guidelines for HCC treatment, additional 
analyses explored primary treatment approaches, according to disease stage, as well as additional 
treatment approaches following primary treatment. 
Survival analyses were conducted to assess differences in survival, according to disease stage 
and primary treatment.  Survival was estimated from the date of first treatment until death or 
censoring.  Patients who did not die during follow-up were considered censored at the last known 
follow-up or study end (September 30, 2012).  For each disease stage, unadjusted survival probabilities 
were estimated using the Kaplan-Meier method and compared by the log-rank test. 31 The life-table 
method was used to calculate yearly probabilities of survival; 95% confidence intervals (CI) were 
computed using the log-log transformation of the survivor function. 31  
For each disease stage, multivariate Cox proportional hazards models were constructed to 
assess the association between primary treatment and the hazard of death. 31   To maintain statistical 
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power, only analyses for treatments with an a priori minimum of n=50 patients were conducted; 
patients receiving other treatments were excluded. Models for all disease stages controlled for the 
following patient demographics and clinical characteristics: age, gender, co-morbidities, etiology, liver 
function (i.e., CP status and portal hypertension), and hospital site where treatment was received.  
Additional covariates for advanced stage disease included indicators for type of vascular invasion and/or 
tumor metastases.  For all other disease stages, models controlled for tumor size and number of tumor 
nodules, based on the aforementioned categories outlined in the CMH guidelines. 3   Model fit for 
different specifications was assessed using the Akaike information criterion (AIC). 31 Model-estimated 
standard errors were adjusted using robust sandwich standard errors to account for patient clustering 
by hospital sites. 97 Log cumulative hazard plots stratified by treatment were estimated to test the 
proportional hazard assumption. 31 
 In order to effectively control for selection bias arising from non-random allocation of primary 
treatment, two different methods for propensity score (PS) analysis were undertaken to adjust the 
survival analyses: 1) regression-based adjustment and 2) propensity-based weighting. 32,33  For each 
disease stage, PS for patients who received each primary treatment were estimated using multinomial 
logistic models, controlling for the variables included in the multivariate Cox proportional hazard 
models. 32 Histograms for the model-estimated PS were constructed to examine the overlap in the 
distribution of PS across treatment groups.  To increase overlap in the PS, fully saturated models were 
estimated by adding higher order terms for age and interaction terms between liver function (i.e., CP 
status and portal hypertension) and tumor characteristics (i.e., tumor stage, vascular invasion and tumor 
metastases).  Model fit for different model specifications was compared using the AIC, and likelihood 
ratio tests were performed to test the appropriateness of the interactions. 31  Once the models were 
correctly fitted, a series of Hausman tests were performed to test the Independence of Irrelevant 
Alternatives assumption. 98  
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 The model-estimated PS then were incorporated into the Cox proportional hazard models for 
each disease stage, in place of the model covariates specified above, to compare the hazard of death 
with treatment.  Using regression-based adjustment, the estimated PS were directly included in the 
regression as a linear model covariate. 32  For the method of propensity-based weighting, patients were 
weighted using stabilized inverse probability weights, defined as the ratio of the marginal predicted 
probability of treatment (m) divided by the PS (i.e., m/PS). 33 Stabilized weights were chosen over 
standard inverse probability of treatment weights (i.e., 1/PS) to provide better estimates of the variance 
in treatment effect.  To further remove selection bias from survival comparisons across treatments, 
patients were weighted by the stabilized inverse probability weights to form adjusted survival 
probabilities using the Kaplan Meier and life-table methods. 99   
All analyses were conducted using SAS version 9.2 (Cary, North Carolina, United States).   An a 
priori 5% significance level was used for all statistical tests, as well as tests for model specification.  
Results 
 A total of 6,194 patients from 10 hospital sites across 7 cities in China were included in the study 
(Figure 3.2).  Primary treatment approaches for the full HCC BRIDGE study (n=7,251) compared with the 
final sample (n=6,194, 85.4%) were similar (p=0.09), suggesting that unavailable disease characteristics 
and follow-up dates were primarily missing at random (data not shown).    
The majority of patients diagnosed with HCC were male (86.5%) with a mean age of 51.7 ± 11.9 
years (Table 3.1).  HCC etiology was primarily related to chronic HBV infection (88.7%).  Most patients 
had well-preserved liver function (CP A/no cirrhosis: 87.8%), and few patients had comorbidities, 
including diabetes (6.0%), CVD (1.8%) or hypertension (9.5%).  Patient characteristics appeared similar 
across different cities in China, although statistical differences were seen (all p<0.0001).  Notably, 
insurance status varied substantially across different cities; whereas most HCC patients were uninsured 
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(71.1%), only 22.2% of patients treated in Beijing were uninsured.  Additional differences included 
higher percentages of patients with underlying etiology related to chronic HCV infection in Harbin 
(11.9%), and moderate to severe liver impairment (i.e., CP B-C) in Xi’an (22.1%) and Nanning (24.6%).   
Disease Characteristics 
 Nearly 40% of patients were diagnosed in the intermediate stages, and more than one- third of 
patients (34.5%) were diagnosed with advanced stage HCC characterized by vascular invasion (16.7%) 
and tumor metastases (17.8%) (Table 3.2).  In contrast, less than one-quarter of patients (24.2%) were 
diagnosed in the early stages, when patients are prime candidates for curative surgical treatment.  
Disease stage at diagnosis varied significantly across the sampled cities (p<0.0001).  In Beijing, a larger 
percentage of patients were diagnosed in the early disease stages (38.5%), and only 12.3% were 
diagnosed with advanced HCC.  In Xi’an and Shanghai, on the other hand, nearly one-half of all patients 
were diagnosed with advanced HCC (Xi’an: 51.7%, Shanghai: 44.9%).  
Current Treatment Approaches 
 TA therapy was the most common primary treatment approach, administered to approximately 
one-half (50.6%) of all patients, followed by surgical resection, performed among nearly one- third 
(32.8%) of all HCC patients (Table 3.3).  Additional primary treatment approaches included tumor 
ablation (8.1%) and supportive care (4.7%); other primary treatments, including liver transplant (0.7%), 
systemic therapy (1.4%), and radiation/other (1.7%), were seldom used. Administration of TA therapy 
within 6 months prior to tumor ablation (39.8%) and liver transplant (32.6%) was common, but less 
common for resection (5.1%).  Primary treatment approaches significantly differed across cities 
(p<0.0001). 
 Trends in primary treatment approaches, according to HCC disease stage, were generally 
consistent with the CMH clinical guideline recommendations (Table 3.4).  Surgical resection and tumor 
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ablation were commonly performed for early and intermediate solitary HCC (<10 cm) and, to a lesser 
extent, among patients with 2-3 tumors.  Palliative resection was performed among a small minority of 
patients with a massive solitary tumor (i.e., ≥ 10 cm; 26.2%), multiple tumors (i.e., ≥ 4; 17.7%) and 
advanced HCC (14.4%-14.6%), whereas ablation was seldom performed for these patients (1.6-8.0%).  
Palliative treatments, such as TA therapy, systemic therapy and supportive care, were primarily used to 
treat intermediate to advanced disease.  Primary treatment for terminal stage patients with poor liver 
function (i.e., CP C) generally included supportive care (56.1%) or TA therapy (38.6%).  
 Approximately 29% of patients received at least one additional treatment after attempting 
primary therapy, of which 6% of patients received only supportive care.  Across all primary treatments, 
the most common additional treatment approach was TA therapy (Table 3.5). 
Survival with Primary Treatment 
 Median overall survival following primary treatment for the full study sample was 21.2 (95% 
confidence interval [CI]: 19.8-22.5) months, with 1- and 3-year survival of 62.9% (61.7-64.1%) and 40.9% 
(39.5-42.3%), respectively.   Overall survival with treatment differed significantly according to disease 
stage at diagnosis (unadjusted p<0.001; Figure 3.3).  As expected, patients diagnosed at an early stage 
experienced greater survival, with 1- and 3-year survival reaching 88.4% (86.6-90.0%) and 68.5% (65.6-
71.3%), respectively.  Among patients with intermediate stage disease, 1- and 3-year survival ranged 
from 67.8% (65.5-70.0%) and 42.6% (39.9-45.3%) for patients with a solitary tumor to 65.1% (61.6-
68.4%) and 37.7% (33.9-41.6) for patients with multinodular tumors.  Overall survival for patients with 
advanced and terminal stage HCC was generally poor; 1-year survival was only 42.6% (40.5-44.8%) and 
26.3% (18.3-35.0%) for advanced and terminal stage patients, respectively.    
 After PS adjustment, overall survival across all disease stages varied substantially according to 
primary treatment (Figure 3.4).   For early stage HCC, survival was markedly higher among patients who 
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underwent resection (3-year survival: 79.7%, 76.0-82.9%) compared with ablation (3-year survival: 
57.6%, 49.4-65.0%) or TA therapy (3-year survival: 44.9%, 38.6-51.0%; p<0.0001 across groups).  Similar 
trends were seen among intermediate stage patients with a solitary tumor, although differences in 
survival were less pronounced; 3-year survival was 58.6% (54.4-62.6%) for resection compared with 
48.1% (31.6-62.8%) and 30.0% (26.3-33.7%) for ablation and TA therapy, respectively (p<0.0001 across 
groups). For intermediate multinodular HCC, overall 3-year survival was similar for resection (56.3%, 
48.6-63.3%) and ablation (41.0%, 25.8-55.6%), but substantially lower for TA therapy (28.5%, 23.7-
33.4%; p<0.0001 across groups). Significant differences in survival according to primary treatment were 
also seen for advanced stage disease (p<0.0001 across groups), with overall 3-year survival for resection 
and ablation reaching only 38.3% (32.0-44.6%) and 19.7% (12.3-28.5%), respectively. 
 Consistent with the results of the PS-adjusted survival analyses, differences in the hazard of 
death associated with primary treatment were significant across all disease stages (Table 3.6; p-values 
<0.0001 across treatment groups).   Although results were slightly different across the multivariate and 
PS adjusted models, the 95% CIs surrounding the hazard ratios (HRs) generally overlapped, indicating 
consistent results for each disease stage.    
Discussion 
With advancements in the treatment of HCC, continuing research is needed to re-evaluate the 
appropriateness of current guideline recommendations.  This study provides detailed survival 
comparisons from the HCC BRIDGE study, the most comprehensive longitudinal study of patients 
undergoing therapy for HCC in China, to clarify best treatment practices. 29 Overall, the significant 
findings were that patients with intermediate to advanced disease tolerated hepatic resection and had 
better outcomes than those who underwent alternative modalities of HCC therapy.  Furthermore, 
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survival benefits associated with resection remained significant after PS adjustment, reducing concern 
that survival comparisons were biased by selection of better surgical candidates.    
Treatment recommendations for HCC in China are distinct from those in the United States and 
Europe, particularly in the use of resection for intermediate stage HCC. 3 Prior research suggests that 
resection may be safely performed among patients with large solitary tumors with no evidence of 
vascular invasion, as the risk of recurrence is not significantly increased as compared to smaller tumors. 
58,59  In the present study, resection was associated with a significant and substantial decrease in the 
hazard of death compared with TA therapy in this patient population, even after controlling for 
differences in patient characteristics at treatment selection.   
As prior trials have suggested, primary treatment using TA therapy provided little to no survival 
benefit over supportive care. 100 It should be noted, however, that trials of TA therapy have been 
heterogeneous in terms of patient characteristics, treatment schedule, and agent used, leading to very 
different conclusions. 67  A meta-analysis of randomized controlled trials indicated that patient survival is 
significantly improved with TA therapy, with an objective response rate of 35%. 67  Thus, additional 
information is needed on the specific treatment schedules that were used among the hospital sites 
enrolled in this study to better assess the appropriateness of primary treatment using TA therapy in this 
patient population.   
For patients with intermediate stage HCC, characterized by large multinodular tumors (i.e., 2-3 
tumors, size >3 cm, or ≥4 tumors), without vascular invasion, tumor metastases or liver function 
impairment, the choice of treatment remains largely controversial.  Based on previous evidence 
suggesting that the presence of multiple tumors is one of the most significant factors affecting survival, 
clinical guidelines in the United States and Europe consider patients with multinodular HCC to be poor 
candidates for resection, and TA therapy is recommended. 4,5  With recent advancements in surgical 
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techniques, however, a larger number of multinodular tumors are now considered resectable, with 3-
year survival reaching as high as 35-56%. 61-63   
In the present study, overall survival was higher for resection than for TA therapy; likewise, TA 
therapy was associated with a significant increased hazard of death compared with resection, following 
multivariate adjustment.  In interpreting these results, however, it is important to note that certain 
patients who received TA therapy in the present study may not have been candidates for surgical 
resection.  Specifically, multicentric tumors, particularly those affecting multiple liver segments, are 
generally associated with inferior survival outcomes and may, in certain cases, preclude treatment with 
resection. 3,61  Thus, if a substantial number of patients who received TA therapy had unresectable 
tumors, differences in survival between resection and TA therapy were likely over-estimated.   
A recent prospective study conducted by Luo et al. (2011) in China compared survival with 
resection (n=85) and TA therapy (n=83) among patients with large (≥5 cm) and multiple (≥2) tumors that 
were deemed resectable based on extensive clinical discussion. 63  Overall 3- and 5-year survival for 
patients who received resection (35% and 24%, respectively) were higher than those for patients initially 
allocated to TA therapy (26% and 19%, respectively), although survival differences were non-significant 
(p=0.26).  The authors noted, however, that 13 patients (16%) in the TA therapy group subsequently 
received resection during follow-up.  Although further evidence is needed, the authors suggested that 
TA therapy may be a better initial treatment for intermediate stage HCC, and resection should be 
recommended among patients who respond well to TA therapy. 
Among patients with advanced stage HCC, characterized by vascular invasion and tumor 
metastases, overall survival in the current study was poor regardless of treatment.  Patients who 
underwent resection achieved the largest survival benefit, with overall 3-year survival reaching 38%, 
whereas those who received TA or systemic therapy did not achieve a statistically significant survival 
benefit over supportive care.  For patients with advanced disease, consensus guidelines currently 
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recommend systemic therapy with the multikinase inhibitor sorafenib. 3,4,8  A clinical trial of sorafenib 
conducted in East Asia demonstrated improved survival over placebo (p=0.014), with a reported median 
survival of 6.5 (5.6-7.6) months. 66  In the present study, sorafenib was only used by 3.5% of patients 
following its introduction in 2009, either as a primary or second-line therapy (data not shown), 
suggesting patients had limited access to treatment.  Other systemic treatments have proven 
ineffective, 67,68 as was demonstrated in the current study.  
In contrast with other consensus guidelines, 4,5 the CMH guidelines additionally recommend 
palliative resection among patients with vascular invasion and in certain instances, in the setting of 
tumor metastasis. 3  Previous studies conducted among patients with portal vein tumor thrombosis have 
reported 3-year survival rates of approximately 13-23%. 64,65,101,102  However, post-operative recurrence 
is common, occurring in more than one-half of patients within 6 months, with more than one-third 
experiencing post-surgical complications. 64,65 Thus, the role of resection remains controversial, 
particularly in the absence of head-to-head clinical trials comparing survival with that of sorafenib.  In 
China, where access to sorafenib may be limited, the results of this study support the use of resection in 
this patient population, when clinically feasible.  
Another significant finding was that, for early stage disease, patients who received tumor 
ablation did not derive the same benefit as patients who underwent resection. Prior literature 
comparing long-term survival between resection and tumor ablation for early stage disease have largely 
reported conflicting results. 69-71  Clinical trials conducted in China noted higher survival rates with 
resection, but did not find a statistically significant difference in survival between the two groups. 72,73  In 
contrast, another trial found a substantial survival advantage with resection among early stage patients; 
3-year survival rates for radiofrequency ablation versus resection were 69.6% and 92.2%, respectively 
(p=0.001). 74  It should be noted, however, that the trials enrolled different proportions of patients with 
very early stage disease, which may in part explain the conflicting results, since ablation beyond this 
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stage is less effective in achieving complete tumor necrosis. 70  Subgroup analyses among patients with 
solitary tumors 3-5 cm and 2-3 tumors <3 cm were generally limited by small sample size, but reported a 
survival benefit with resection. 70,74  In the current study, the majority of early stage patients had solitary 
tumors 3-5 cm, which may explain the clear survival benefit seen with resection in this patient group.  
Whereas resection may provide better long-term efficacy than ablation, it should also be noted that 
resection is associated with increased complications and longer hospital stays. 69  Therefore, as currently 
recommended, ablation should be considered as a less-invasive alternative to resection, particularly 
among patients with very small tumors. 3 
 This study is the largest to date of survival with HCC treatment in China and provides useful 
insights into the role of hepatic resection for more advanced disease and the limitations of all therapies 
when cancer is discovered in the later stages.  The large number of HCC cases and meticulously collected 
data allowed for PS analysis to reduce elements of selection bias.  Nevertheless the study has several 
limitations.  First, as with any retrospective study of patient medical records, data on clinical 
characteristics were based solely on documented evidence in the patient medical record.  As a result, 
potential miscoding of clinical characteristics across different hospital sites may have been present, and 
approximately 15% of the study sample was excluded due to missing disease stage or follow-up 
information.  Likewise, only treatments provided to patients at the participating hospital site were 
generally documented; thus, the results may not reflect additional treatments if received from other 
sites.   
Whereas the observational study design allowed an accurate portrayal of HCC management in 
regular clinical practice, survival comparisons across treatments were complicated due to non-random 
treatment allocation.   In order to effectively control for underlying differences in patient characteristics 
across treatment groups, multivariate models were constructed, and PS analysis was further conducted 
to control for residual selection bias. 32 Nevertheless, residual confounding may still have been present, 
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leading to biased survival comparisons.  Unfortunately, the HCC BRIDGE database did not capture 
information on tumor location, which as previously noted, may have lead to biased estimates of the 
impact of resection on survival among patients with multinodular tumors.  More evidence is needed to 
better understand the comparative effectiveness of therapies for this patient population. Lastly, the 
study database exclusively captured treatment patterns and survival for patients treated across 10 large 
hospitals in China, and does not capture treatment patterns among patients treated in rural settings.  
Notably, over 70% of HCC patients included in the present study were uninsured, with wide differences 
in insurance status seen across the different cities that were sampled.  Patients in rural settings are 
largely uninsured and may not have access to comprehensive treatment centers, which would further 
lead to disparities in treatment.   
The results of this study can provide valuable insights into the impact of disease characteristics 
and current treatment approaches on the prognosis of HCC in China, to help prioritize areas for 
improvement.  Overall, the significant findings of this comparative effectiveness analysis of HCC 
treatment are that patients with intermediate to advanced disease tolerate hepatic resection and have 
better outcomes than those who undergo alternative modalities of HCC therapy.  Patients with early 
stage disease do not derive the same benefit from tumor ablation compared with patients who undergo 
resection.   Despite advancements in the clinical management of HCC, the majority of patients are 
diagnosed with intermediate to advanced HCC in China, and survival is generally poor.  Treatment 
patterns are generally consistent with current guideline recommendations in China.  However, 
additional research is needed to determine whether published guidelines appropriately assign the 
primary treatment for intermediate stage patients with multinodular tumors. 
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Table 3.1: Demographics and clinical characteristics for patients diagnosed with HCC, across different cities in China. 
 
Characteristic *  
All Patients  
(n=6,194)  
Guangzhou 
(n=1,523)  
Shanghai  
(n=1,266)  
Nanning  
(n=772)  
Xi’an  
(n=737)  
Chengdu  
(n=733)  
Harbin  
(n=649)  
Beijing  
(n=514)  p-value 
Age years  51.7 ± 11.9  50.0 ± 12.1  52.7 ± 11.0  48.5 ± 12.0  51.7 ± 11.5  52.5 ± 12.5  54.3 ± 10.8  55.1 ± 12.1  <0.0001 
Male Gender  5,360 (86.5)  1,393 (91.5)  1,070 (84.5)  695 (90.0)  633 (85.9)  628 (85.7)  527 (81.2)  414 (80.5)  <0.0001 
Co-morbidities      
Diabetes mellitus 370 (6.0)  91 (6.0)  95 (7.5)  16 (2.1)  58 (7.9)  34 (4.6)  34 (5.2)  42 (8.2)  <0.0001 
CVD 114 (1.8)  25 (1.6)  14 (1.1)  4 (0.5)  28 (3.8)  9 (1.2)  20 (3.1)  14 (2.7)  <0.0001 
Hypertension 588 (9.5)  148 (9.7)  157 (12.4)  34 (4.4)  62 (8.4)  74 (10.1)  45 (6.9)  68 (13.2)  <0.0001 
HCC Etiologies      
HBV 5,367 (88.7)  1,417 (93.0)  1,103 (87.1)  684 (88.6)  618 (83.9)  625 (85.3)  467 (72.0)  453 (88.1)  <0.0001 
HCV 209 (3.4)  21 (1.4)  26 (2.1)  3 (0.4)  38 (5.2)  11 (1.5)  77 (11.9)  33 (6.4)  <0.0001 
ALD  336 (5.4)  2 (0.1)  30 (2.4)  208 (27.0)  0 (0.0)  33 (4.5)  58 (8.9)  5 (1.0)  <0.0001 
NAFLD 47 (0.8)  4 (0.3)  11 (0.9)  1 (0.1)  22 (3.0)  4 (0.6)  1 (0.2)  4 (0.8)  <0.0001 
Other/Unknown  659 (10.6)  113 (7.4)  146 (11.5)  68 (8.8)  83 (11.3)  99 (13.5)  101(15.6)  49 (9.5)  <0.0001 
Liver Function      <0.0001 
CP A/No Cirrhosis  5,440 (87.8)  1,446 (94.9)  1,119 (88.4)  584 (75.6)  574 (77.9)  659 (89.9)  566 (87.2)  492 (95.7)  
CP B 693 (11.2)  77 (5.1)  141 (11.1)  156 (20.2)  153 (20.8)  68 (9.3)  76 (11.7)  22 (4.3)  
CP C 61 (1.0)  0 (0.0)  6 (0.5)  32 (4.2)  10 (1.3)  6 (0.8)  7 (1.1)  0 (0.0)  
Insurance Status     <0.0001 
Insured 1,218 (19.6)  37 (2.4)  247 (19.5)  93 (12.1)  91 (12.4)  181 (24.7)  173 (26.7)  396 (77.0)  
Uninsured 4,402 (71.1)  1,466 (96.3)  694 (54.8)  661 (85.6)  640 (86.8)  502 (68.5)  325 (50.1)  114 (22.2)  
Unknown 574 (9.3)  20 (1.3)  325 (25.7)  18 (2.3)  6 (0.8)  50 (6.8)  151 (23.3)  4 (0.8)  
ALD = alcohol liver disease, CP = Child-Pugh score, CVD = cardiovascular disease, HBV = hepatitis B virus, HCC = hepatocellular carcinoma, HCV = hepatitis C 
virus, NAFLD = non-alcoholic fatty liver disease 
* Values are expressed as mean ± standard deviation and n (%) for continuous and categorical variables, respectively.    
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Table 3.2: Disease characteristics for patients diagnosed with HCC, across different cities in China.  
 
Disease Stage,* n (%)  
All Patients  
(n=6,194)  
Guangzhou 
(n=1,523)  
Shanghai  
(n=1,266)  
Nanning  
(n=772)  
Xi’an  
(n=737)  
Chengdu  
(n=733)  
Harbin  
(n=649)  
Beijing  
(n=514)  p-value  
Very Early/Early †   1,492 (24.2)   411 (27.0)   335 (26.5)   95 (12.4)   104 (14.1)   212 (29.0)  137 (21.1)   198 (38.5)  <.0001 
1 Tumor, ≤2 cm 258 (4.2)   80  (5.3)  65 (5.1)   5  (0.7)  15 (2.0)  29 (4.0)  19 (2.9)  45 (8.8)  
1 Tumor, 3-5 cm 1,113 (18.0)   305 (20.0)  219 (17.3)   80 (10.4)   79 (10.7)   176 (24.0)  115 (17.7)  139 (27.0)  
2-3 Tumors, ≤ 3 cm 121 (2.0)   26 (1.7)   51 (4.0)  10 (1.3)   10 (1.4)   7 (1.0)   3 (0.5)   14 (2.7)  
Interm./Solitary † 1,675 (27.0) 445 (29.2) 221 (17.5) 282 (36.5) 138 (18.7) 165 (22.6) 201 (31.0) 223 (43.4) 
1 Tumor, 6-9 cm 1,042 (16.8)   286 (18.8)   143 (11.3)   130 (16.8)  90 (12.2)   117 (16.0)   131 (20.2)   145 (28.2)  
1 Tumor, ≥ 10 cm 633 (10.2)   159 (10.4)   78 (6.2)   152 (19.7)  48 (6.5)   48 (6.6)   70 (10.8)   78 (15.2)   
Interm./Multinodular †  787 (12.7) 154 (10.1) 125 (9.9) 217 (28.1) 94 (12.7) 58 (7.9) 110 (16.9) 29 (5.6) 
2-3 Tumors, > 3 cm 376 (6.1)   75 (4.9)  87 (6.9)  106 (13.7)   32 (4.3)   33 (4.5)   15 (2.3)   28 (5.4)  
≥ 4 Tumors 411 (6.6)   79 (5.2)   38 (3.0)   111 (14.4)  62 (8.4)  25 (3.4)   95 (14.6)   1 (0.2)  
Advanced ‡   2,134 (34.5)   513 (33.7)   568 (44.9)   143  (18.5)  381 (51.7)   275 (37.5)   191 (29.4)   63 (12.3)  
Vascular Invasion  1,034 (16.7)   222 (14.6)   259 (20.5)   115 (14.9)  199 (27.0)   113 (15.4)   108 (16.6)    18 (3.5)  
Tumor Metastases  1,100 (17.8)   291 (19.1)   309 (24.4)   28 (3.6)   182 (24.7)   162 (22.1)   83 (12.8)   45 (8.8)  
Terminal 106 (1.7)  0 (0.0)   17 (1.3)  35 (4.6)   20 (2.7)   23 (3.1)   10 (1.6)   1 (0.2)  
CP C  57 (0.9)  0 (0.00)   5 (0.4)   32 (4.2)   9 (1.2)   6 (0.8)   5 (0.8)  0 (0.0)  
Perf. Stat. 3-4 49 (0.8)  0 (0.00)   12 (1.0)   3 (0.4)   11 (1.5)   17 (2.3)   5 (0.8)   1 (0.2)  
CP = Child-Pugh score, HCC = hepatocellular carcinoma, Interm. = intermediate, Perf. Stat. = performance status 
* Disease stages are based on the China Ministry of Health Diagnosis and Treatment Guidelines for Primary Liver Cancers (2011 edition).
 3
   
† Patients in these categories have compensated cirrhosis (CP A/B), performance status 0-2, no venous invasion and no tumor metastases. 
‡ Patients in these categories have compensated cirrhosis (CP A/B) and performance status 0-2.  
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Table 3.3: Primary treatment approaches for patients diagnosed with HCC across different regions in China. 
 
Primary Treatment,  
n (%)  
All Patients  
(n=6,194)  
Guangzhou 
(n=1,523)  
Shanghai  
(n=1,266)  
Nanning  
(n=772)  
Xi’an  
(n=737)  
Chengdu  
(n=733)  
Harbin  
(n=649)  
Beijing  
(n=514)  p-value 
Resection 2,029 (32.8)  675 (44.3)   244 (19.3)   283 (36.6)  145 (19.7)   364 (49.6)   144 (22.2)  174 (33.9)  <0.0001 
TA Therapy*  103 (5.1)   54 (8.0)   7 (2.9)   13 (4.6)   13 (9.0)   1 (0.3)   7 (4.9)  8 (4.6)  
Transplant 46 (0.7)   3 (0.2)   4 (0.3)   2 (0.3)  2 (0.3)   35 (4.8)  0 (0.0) 0 (0.0)  
TA Therapy*  15 (32.6)  0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)  9 (25.7)  0 (0.0) 0 (0.0) 
Ablation 503 (8.1)  232 (15.2)   100 (7.9)   19 (2.4)   60 (8.1)   64 (8.7)   15 (2.3)   13 (2.5)  
TA Therapy*  200 (39.8)   111 (47.8)   43 (43.0)   6 (31.6)   30 (50.0)   2 (3.1)   5 (33.3)   3 (23.1)  
TA Therapy  3,135 (50.6)   538 (35.3)   856 (67.6)   325 (42.1)  482 (65.4)   230 (31.4)   401 (61.8)   303 (58.9)  
Systemic Therapy 88 (1.4)   16 (1.1)   7 (0.6)   9  (1.2)   39 (5.3)   0 (0.0)   7 (1.1)   10 (2.0)  
Supportive Care 289 (4.7)   49 (3.2)   28 (2.2)   131 (17.0)  7 (0.9)   8 (1.1)   66 (10.1)   0 (0.0)  
Radiation/Other  104 (1.7)   10 (0.7)   27 (2.1)   3  (0.4)  2 (0.3)   32 (4.4)   16 (2.5)   14 (2.7)  
HCC = hepatocellular carcinoma, TA = trans-arterial 
* Proportion of patients who receive trans-arterial therapy within 6 months prior to resection, liver transplant or tumor ablation. 
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Table 3.4: Primary treatment approaches, according to disease stage,* for patients diagnosed with HCC in China. 
 
Very Early / Early†  Intermediate / Solitary†  Intermediate / Multinodular†  
Treatments,  
n (%)  
1 Tumor,  
≤2 cm 
(n= 258)  
1 Tumor, 3-5 
cm 
(n=1,113) 
2-3 Tumors,  
≤ 3 cm 
(n=121) 
1 Tumor,  
6-9 cm 
(n=1,042)  
1 Tumor,  
≥ 10 cm 
(n=633) 
2-3 Tumors,  
> 3 cm  
(n=376)  
≥ 4 Tumors 
(n=411) 
Resection  118 (45.7)  628 (56.4)   35 (28.9)   544 (52.2)   166 (26.2)  143 (38.0)   73 (17.7)  
TA Therapy**   2 (1.7)   13 (2.1)   1 (2.9)   29 (5.3)   8 (4.8)   9 (6.3)   8 (11.0)  
Transplant  1 (0.4)   7 (0.6)  0 (0.0)  6 (0.6)   6 (0.9)   1 (0.3)   2 (0.5)  
TA Therapy** 0 (0.0)  1 (14.3)  0 (0.0)  2 (33.3)   2 (33.3)   2 (50.0)   1 (20.0)  
Ablation  74 (28.7)   168 (15.1)   27 (22.3)   49 (4.7)   10 (1.6)   25 (6.7)   33 (8.0)  
TA Therapy**  15 (20.3)   35 (20.8)   8 (29.6)   30 (61.2)   9 (90.0)   12 (48.0)   19 (57.6)  
TA Therapy  56 (21.7)   269 (24.2)   53 (43.8)   397 (38.1)   401 (63.4)   191 (50.8)  256 (62.3)  
Systemic Therapy  0 (0.0)  2 (0.2)  1 (0.8)  5 (0.5)   7 (1.1)   4 (1.0)   8 (2.0)  
Supportive Care  3 (1.2)   20 (1.8)   4 (3.3)   25 (2.4)   40 (6.3)   11 (2.9)   31 (7.5)  
Radiation/Other   6 (2.3)   19 (1.7)   1 (0.8)   16 (1.5)   3 (0.5)   1 (0.3)   8 (2.0)  
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Table 3.4: (Continued). 
 
Advanced
‡
 Terminal  
VI 
(n=1,034) 
TM 
(n=1,100) 
CP C  
(n=57) 
Perf. Stat. 3-4 
(n=49)  
149 (14.4)   160 (14.6)   1 (1.8)  12 (24.5)  
17 (11.4)  16 (10.0)  0 (0.0) 0 (0.0) 
 13 (1.3)   7 (0.6)   2 (3.5)   1 (2.0)  
 6 (46.2)  3 (42.9)  1 (50.0)  0 (0.0) 
 52 (5.0)   65 (5.9)   0 (0.0)   0 (0.0)  
 37 (71.2)  35 (53.9)  0 (0.0) 0 (0.0) 
730 (70.6)   739 (67.2)   22 (38.6)   21 (42.9)  
 22 (2.1)   39 (3.6)  0 (0.0) 0 (0.0) 
  53 (5.1)   58 (5.3)   32 (56.1)   12 (24.5)  
 15 (1.5)   32 (2.9)  0 (0.0)  3 (6.1)  
 
CP = Child-Pugh score, HCC = hepatocellular carcinoma, Perf. Stat. = performance status, TA = trans-arterial, TM = tumor metastases, VI = vascular invasion 
* Disease stages are based on the China Ministry of Health Diagnosis and Treatment Guidelines for Primary Liver Cancers (2011 edition).
 3
   
** Proportion of patients who receive trans-arterial therapy within 6 months prior to resection, liver transplant or tumor ablation. 
† Patients in these categories have compensated cirrhosis (CP A/B), performance status 0-2, no venous invasion and no tumor metastases. 
‡ Patients in these categories have compensated cirrhosis (CP A/B) and performance status 0-2.
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Table 3.5: Additional treatment approaches following primary treatment for patients diagnosed with HCC in China. 
Primary Treatment Approach  
Additional Treatment, n (%)  
Resection  
(n=2,029)  
Transplant 
(n=46)  
Ablation 
(n=503)  
TA Therapy 
(n=3,135)  
Systemic  
Therapy  
(n=88)  
Supportive 
Care  
(n=289)  
Radiation/ 
Other  
(n=104)  
Any Treatment   833 (41.1)   13 (28.3)   233 (46.3)   618 (19.7)   62 (70.5)   7 (2.4)   44 (42.3)  
Resection  47 (2.3)* 0 (0.0)   15 (3.0)  18 (0.6)**   4 (4.6)  0 (0.0)  4 (3.9)  
Transplant  8  (0.4)   1 (2.2)*  3 (0.6)  2 (0.06)**  0 (0.0) 0 (0.0) 0 (0.0) 
Ablation 116 (5.7)   1 (2.2)  −−−− 37 (1.2)**  1 (1.1)   1 (0.4)   5 (4.8)  
TA Therapy   602 (29.7)  6 (13.0)   180 (35.8)  −−−−  51 (58.0)   5 (1.7)  32 (30.8)  
Systemic Therapy  86 (4.2)   3 (6.5)   28 (5.6)  144  (4.6)  −−−−  1 (0.4)   3 (2.9)  
Supportive Care  153 (7.5)   4 (8.7)   32 (6.4)   325 (10.4)   9 (10.2)  −−−−  10 (9.6)  
Radiation/Other   104 (5.1)   4 (8.7)   41 (8.2)   184 (5.9)   5 (5.7)   1 (0.4)  −−−− 
HCC = hepatocellular carcinoma, TA = trans-arterial 
*Indicates that patient underwent a repeated resection or transplant, following primary resection or transplant. 
** Indicates that patient underwent resection, ablation or transplant more than 6 months after the first administration of trans-arterial therapy.   
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Table 3.6: Cox proportional hazard models of the association between primary treatment and overall 
survival, according to disease stage, among patients diagnosed with HCC in China. 
CI = confidence interval, HCC=hepatocellular carcinoma, HR = hazard ratio, Interm. = intermediate, TA = trans-
arterial, Ref = referent category 
*Disease stages are based on the China Ministry of Health Diagnosis and Treatment Guidelines for Primary Liver 
Cancers (2011 edition).
 3
   
**For all disease stage regressions, p-values were <0.0001 for comparisons across treatment groups.  
Unadjusted** 
Multivariate 
Adjusted** 
Regression-Based 
Adjustment**  
Propensity-Based 
Weighting** 
Disease Stage,* Treatment  HR (95% CI)  HR (95% CI)  HR (95% CI)  HR (95% CI)  
Very Early/Early, n = 1,428   
Resection (Ref)   
Ablation   2.00 (1.60-2.50)   2.16 (1.71-2.73)   1.68 (1.33-2.14)   2.06 (1.72-2.48)  
TA Therapy  3.16 (2.46-4.06)   3.21 (2.39-4.31)   2.87 (2.15-3.82)  3.55 (2.49-5.07)  
Ablation (Ref)   
TA Therapy  1.58 (1.16-2.15)  1.49 (1.16-1.90)   1.70 (1.34-2.17)   1.72 (1.24-2.39)  
Interm./Solitary, n = 1,632   
Resection (Ref)      
Ablation  1.40 (1.14-1.73)   1.52 (1.16-1.99)   1.20 (0.93-1.55)   1.31 (0.88-1.94)  
TA Therapy  2.43 (1.88-3.13)   2.42 (2.06-2.85)   2.46 (2.01-3.02)   2.21 (2.06-2.36)  
Supportive Care 3.79 (2.82-5.09) 2.30 (1.68-3.16)  3.27 (2.35-4.55) 2.57 (1.35-4.86) 
Ablation (Ref)   
TA Therapy  1.73 (1.23-2.43)  1.59 (1.16-2.19)   2.05 (1.47- 2.87)  1.69 (1.15-2.47)  
Supportive Care 2.70 (1.80-4.04) 1.51 (1.06-2.14)  2.72 (1.76-4.23) 1.96 (0.80-4.80) 
TA Therapy (Ref)  
Supportive Care 1.56 (0.98-2.49) 0.95 (0.60-1.51) 1.33 (0.87-2.03) 1.16 (0.59-2.29) 
Interm./Multinodular, n = 721   
Resection (Ref)      
Ablation  1.25 (0.91-1.71)   1.20 (0.79-1.82)  1.21 (0.89-1.65)  1.46 (1.06-2.02) 
TA Therapy   2.31 (1.91-2.79)  2.16 (1.77-2.64)   2.36 (2.08-2.68)  2.13 (1.57-2.92) 
Ablation (Ref)   
TA Therapy  1.85 (1.23-2.78)  1.81 (1.16-2.82)  1.95 (1.38-2.78)   1.47 (0.98-2.20)  
Advanced, n = 2,067   
Resection (Ref)   
Ablation   1.38 (1.07-1.78)   1.38 (1.11-1.70)  1.45 (1.09-1.93)   1.55 (1.30-1.86)  
TA Therapy   2.11 (1.65-2.72)   2.03 (1.71-2.42)   1.66 (1.27- 2.18)   1.84 (1.44-2.36)  
Systemic Therapy  2.52 (1.88-3.37)   1.90 (1.46-2.47)  2.73 (1.95- 3.81)   2.05 (1.27-3.32)  
Supportive Care   3.23 (2.24-4.64)   2.50 (1.91-3.27)   3.35 (2.32-4.83)   2.78 (1.86-4.15)  
Ablation (Ref)   
TA Therapy   1.53 (1.05-2.24)   1.48 (1.07-2.04)   1.15 (0.69-1.92)   1.19 (0.84-1.68)  
Systemic Therapy  1.82 (1.58-2.11)   1.38 (1.13-1.69)  1.88 (1.60-2.22)   1.32 (0.83-2.11)  
Supportive Care   2.34 (1.57-3.48)   1.82 (1.36-2.44)   2.31 (1.51-3.53)   1.79 (1.29-2.48)  
TA Therapy (Ref)   
Systemic Therapy   1.19 (0.84-1.68)   0.94 (0.69-1.28)   1.64  (0.97-2.77)  1.12 (0.71-1.75)  
Supportive Care   1.53 (0.97-2.40)   1.23 (0.87-1.74)   2.01 (1.24-3.27)   1.51 (0.98-2.31)  
Systemic Therapy (Ref)   
Supportive Care  1.28 (0.88-1.86)   1.32 (1.03-1.68)   1.23 (0.82-1.85)   1.35 (0.87-2.10)  
  
Figure 3.1: Summary of treatment recommendations for patients diagnosed with HCC based on the 
China Ministry of Health (CMH)
 3
 compared with the American Association for the Study of Liver 
Disease (AASLD) guidelines.
 5,8
 
 
  
AASLD = American Association for the Study of Liver Disease, CMH = China Ministry of Health, CP = Child
score, HCC = hepatocellular carcinoma, TA = trans
* According to the AASLD guidelines, liver transplant is recommended for patients who fall within the Milan 
criteria.
 5,94
  The CMH guidelines primarily recommend liver transplant for patients with 
those who cannot tolerate ablation or TA therapy due to poor liver function.
† 
Combination therapy with trans-arterial therapy followed by ablation among patients who respond to treatment.
** TA therapy is recommended for patients without evidence of tumor metastases.
‡ 
 Recommended systemic treatments include sorafenib, other molecular targeted therapies, chemotherapy and 
Traditional Chinese medicine.
3
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Figure 3.2: Sample selection from the HCC BRIDGE study in China. 
 
 
 
HCC = hepatocellular carcinoma, HCC BRIDGE = The Bridge to Better Outcomes in Hepatocellular Carcinoma Study  
  
HCC BRIDGE Study in China 
(n=8,683)  
Complete Treatment Information 
(n=7,251)  
Complete Tumor Characteristics, 
Liver Function & Performance 
Status Information 
(n=6,282)  
2 Hospital Sites 
Excluded  
(Poor Data Quality) 
(n=1,432)  
Available Follow-up Information 
(n=6,194)  
  
Figure 3.3: Unadjusted Kaplan-Meier survival curves for patients diagnosed with HCC in China, 
according to disease stage.* 
 
 
 
HCC = hepatocellular carcinoma, Interm. = intermediate, No. = number
 
* Disease stages are based on the China Ministry of Health Diagnosis and Treatment Guidelines for Primary Liver 
Cancers (2011 edition).
 3
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Figure 3.4: Propensity Score Adjusted† Kaplan
according to disease stage and primary treatment: A) Very Early/Early Stage, B) Intermediate Stage
Solitary Tumor > 5cm, C) Intermediate Stage 
52 
-Meier survival curves for patients diagnosed with HCC, 
– Multinodular Tumors, D) Advanced Stage.
 -
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HCC = hepatocellular carcinoma, No. = 
* Disease stages are based on the China Ministry of Health Diagnosis and Treatment Guidelines for Primary Liver 
Cancers (2011 edition).
 3
   
† The Kaplan-Meier survival curves were adjusted using stabilized inve
55 
number 
rse probability weights.
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CHAPTER 4: INDIVIDUAL-BASED MODEL OF SURVEILLANCE TO DETECT HEPATOCELLULAR CARCINOMA 
AMONG INDIVIDUALS WITH CHRONIC HEPATITIS B VIRUS INFECTION IN CHINA 
Introduction 
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide.
 103
 
In China, where hepatitis B virus (HBV) infection is endemic and is the leading etiological risk-factor for 
HCC, HCC is the second most common malignancy.
 45
  China alone contributes more than 55% of 
diagnosed cases of HCC worldwide.
 103
  Resection and tumor ablation are the main curative treatment 
options for HCC, but eligibility to receive curative therapy diminishes with more advanced disease.
 3
 
Whereas current survival with HCC in China is generally poor (5-year survival 16.2%), 5-year survival for 
patients diagnosed at an earlier stage who receive curative therapy can exceed 50% (Chapter 3).
 43,104
  
The China Ministry of Health (CMH) has strived to improve the early detection of HCC by 
providing government-funded HCC surveillance in high-risk areas and publishing its newest Diagnosis 
and Treatment Guidelines for Primary Liver Cancers (2011 edition).
 3
 According to the CMH guidelines, 
HCC surveillance is recommended every 6 months among men aged ≥40 years with a history of chronic 
HBV infection and women aged ≥50 years with a history of chronic HBV infection.  Recommended 
screening tests include abdominal ultrasound (US) and measurement of serum alpha-fetoprotein (AFP), 
with a cut-point of ≥200 ng/mL.   
HCC surveillance has been conducted in China since the early 1970s, though only limited 
evidence exists to quantify or even demonstrate its impact on survival.  A randomized control trial 
conducted among 18,816 participants with chronic HBV infection in China found that surveillance every 
6 months with US and AFP was associated with a significant 37% reduction in 5-year mortality.
 9
 Despite 
demonstrating survival benefit, the trial had several limitations, including potential lead time bias 
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related to the earlier diagnosis of HCC, a relatively low number of HCC cases (n=153) collected over a 
short follow-up (5 years), and suboptimal adherence to the surveillance protocol (less than 60%).  On 
one hand, the results likely underestimate the survival benefit from surveillance, because of poor 
compliance; on the other hand, potential lead time bias could have resulted in an overestimation of 
survival with surveillance.  An earlier trial also conducted in China failed to show benefit with 
surveillance, largely because HCC patients did not undergo appropriate treatment.
 46
 
Although HCC surveillance is recommended, the ideal screening interval for surveillance is not 
known.  Consensus guidelines suggest an interval of 6-12 months, based on average tumor volume 
doubling time (DT). 
 2,4,8
 However, evidence from a small retrospective study suggests that survival is 
similar among HCC patients who receive surveillance at a 6-month interval, as compared with a 12-
month interval.
 28
 More research is needed to inform the optimal interval.  DT in HCC can vary 
considerably across individuals, and clinical data do not provide the necessary information to fully 
characterize other components of HCC disease progression, such as the development of multinodular 
tumors, vascular invasion (VI), and tumor metastases (TM).
  14-27
 
Determining the optimal approach for HCC surveillance requires both an understanding of 
tumor development and progression over time, and an accurate assessment of treatment patterns and 
associated survival in clinical practice. The objective of this study was to develop and calibrate an 
individual-based simulation model of surveillance to detect HCC among individuals with chronic HBV 
infection in China.   The model then was used to simulate a randomized trial of HCC surveillance, 
controlling for lead time bias, to assess the impact of different screening intervals based on current 
recommendations in China, using no surveillance as a basis for comparison.  
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Methods 
Model Overview 
In the absence of more detailed data, prior Markov models of HCC surveillance have made 
simplifying assumptions surrounding the rate of tumor growth in HCC and the impact of patient 
characteristics, such as liver function, age and gender, in determining HCC treatment and survival 
outcomes.
 83-86
 Individual-based models provide an attractive alternative when the assumptions of 
Markov models prove to be limiting.
 40,91
  As individuals move through the model one at a time, rather 
than as part of a cohort, the model can track individual-level characteristics and allow them to change 
over time through a series of transition rules to simulate the life-course of disease.
 40
  The individual-
based model of HCC surveillance, further described below, flexibly integrates accumulating medical 
history with individual-level heterogeneity in tumor growth to accurately project the impact of 
surveillance on disease stage at diagnosis, treatment selection, and survival for individuals who develop 
HCC.  
The model incorporates well-established data on the natural disease course of chronic HBV 
infection, HCC development, and tumor growth in HCC.
 14-27,35-37
   Model calibration was conducted to 
provide estimates of unknown parameters surrounding the progression and detection of HCC disease 
outside of a surveillance program, based on the distribution of tumor characteristics among a cohort of 
patients diagnosed in clinical practice in China (Chapter 3).
 29
 The clinical data were further used to 
accurately portray treatment selection and associated survival with HCC in China. The model then was 
used to simulate a randomized trial of HCC surveillance, using different screening intervals. 
Model Structure    
The individual-based model of HCC surveillance in China was developed and calibrated using 
AnyLogic simulation software version 6.8.1 (© XJ Technologies Co., www.anylogic.com, St. Petersburg, 
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Russia).  The structure of the individual-based model includes three parallel components designed to 
simulate: 1) the natural progression of chronic HBV infection, cirrhosis, and death; 2) the development, 
progression, and diagnosis of HCC; and 3) treatment and survival following HCC diagnosis. Three 
different surveillance strategies then were incorporated into the model, based on the CMH 
recommendations: 1) no surveillance (for comparison), 2) 6-month US and AFP (with cutpoint ≥ 200 
ng/mL), and 3) 12-month US and AFP.
 3
  HCC tumors detected based on a positive US and/or AFP test 
were assumed to undergo confirmatory imaging with a computed tomography (CT) and/or magnetic 
resonance imaging (MRI) scan. 
The model simulated a hypothetical cohort of 10,000 individuals, representative of the general 
population with chronic HBV infection in China, from time of chronic HBV diagnosis (based on a positive 
HBV surface antigen test) until death. At the start of the simulation, all individuals were in the chronic 
HBV state, without evidence of cirrhosis or HCC.  With time, individuals could develop cirrhosis with no 
or mild symptoms (i.e., Child-Pugh [CP] A/B status), progress to clinically significant decompensated 
cirrhosis (i.e., CP C), or die (Figure 4.1).  At any stage of progressive liver disease, individuals could 
simultaneously develop HCC.  At the time of HCC development, individuals were assumed to have a 
solitary, very early stage tumor, which would grow continuously over time.  Individuals with HCC could 
further develop satellite tumors (i.e., multinodular HCC), VI and/or TM, and with more advanced 
disease, die due to liver disease complications.  At any stage of HCC progression, individuals could be 
diagnosed incidentally or through surveillance with US and AFP; individuals without HCC or whose HCC 
tumors were not detected would remain in their current health state.  Treatment options for patients 
diagnosed with HCC were allocated according to disease stage, as defined by the current CMH 
guidelines, based on liver function and tumor characteristics at diagnosis (Figure 4.2).
 3
 Once allocated to 
treatment, HCC patients would remain in the post-treatment state until death.    
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Input Parameters 
Input parameters for the simulation model were obtained from observational data and 
literature reviews, and were further verified by expert opinion from gastroenterologists and 
hepatologists. The following sections provide an overview of the methodologies for obtaining the model 
parameters for each model component. 
Chronic HBV Progression 
Literature searches of the Medline (PUBMED) and EMBASE databases were conducted to 
identify peer-reviewed articles that assessed the natural history of chronic HBV disease [Appendix B]. In 
order to maximize study relevance to the clinical context in China, specific emphasis was placed on 
prospective cohort studies conducted in East Asia. The natural disease course of chronic HBV infection 
has been extensively studied (Table 4.1).  Model parameters for the incidence rate of HCC and cirrhosis 
among individuals with chronic HBV infection were obtained from the REVEAL-HBV (Risk Evaluation of 
Viral Load Elevation and Associated Liver Disease/ Cancer-Hepatitis B Virus) study, a prospective cohort 
study (n=3,683) conducted across seven counties in Taiwan over 11 years of follow-up.
 36,37
  A larger 
prospective cohort study (n=11,506) also assessed HCC development in chronic HBV in China; however, 
the study was ultimately excluded as the primary outcome was HCC mortality, and there was no 
evidence of screening in the baseline period to detect prevalent cases of HCC.
 105
 
Consistent with population-based studies of HCC prevalence,
 1
 the risk of both HCC and cirrhosis 
development in chronic HBV were substantially higher for males compared with females.
  36   
To adjust 
for gender, risk ratios (RR) reported in the REVEAL-HBV study were incorporated in the model.
 36,37
  The 
REVEAL-HBV study additionally provided gender-stratified annual rates for HCC incidence, but not for 
cirrhosis incidence.  As a result, the annual rate of cirrhosis among males was obtained from an earlier 
prospective study conducted in Taiwan (n=1,506)
 106
, which provided a similar rate (0.70 per 100 
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person/years) to the pooled estimate from the REVEAL-HBV study (0.91 per 100 person/years).
 37
 After 
the development of cirrhosis, the incidence rate of HCC was considerably higher than among individuals 
with chronic HBV, but did not differ significantly according to gender (males vs. females: RR = 1.8, 0.4-
8.6).
 35
  Likewise, gender differences in the rate of marked clinical decompensation (CP C) were also non-
significant (RR = 0.7, 0.1-3.7).
 35
  As a result, these rates were not adjusted by gender. 
All individuals who were not treated for HCC were subject to an annual rate of death due to all 
causes, adjusted by age and gender, based on China-specific estimates reported by the World Health 
Organization.
 107
 Studies have cited complications related to cirrhosis decompensation and advanced 
HCC disease as the main causes of death among individuals with chronic HBV; in contrast, mortality 
among individuals without cirrhosis, compensated cirrhosis or early stage HCC is generally similar to that 
of the general population.
 108,109
  Accordingly, an excess mortality rate, based on survival probabilities 
reported in retrospective studies of patient medical records, were applied to individuals with 
significantly decompensated cirrhosis (CP C) and advanced HCC.  
 110-112
 Separate mortality rates were 
applied during the first and subsequent years following decomposition to account for the increased 
hazard of death within the first year following decomposition.
 111,112
 The hazard of death among 
individuals with undiagnosed advanced HCC was assumed to be the same as for patients diagnosed with 
advanced HCC who received supportive care, and was projected using parametric survival curves as 
further described below. 
 Initial Population 
Baseline characteristics of the study population at the start of simulation were based on the 
distribution of age (67% ≥ 40 years) and gender (62% male) from the REVEAL-HBV study (Table 4.1).
 36
   
Consistent with the CMH recommendations, HCC surveillance was provided among men and women 
with chronic HBV aged ≥ 40 and ≥ 50 years, respectively.
 3
 Therefore, the distribution of baseline 
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characteristics incorporated in the simulation model captured the broad population of individuals with 
chronic HBV who would undergo HCC surveillance in China. 
HCC Disease Progression 
 Model parameters for the progression of HCC disease included tumor growth rates to project 
the size of the primary tumor, rates for the development of satellite tumors, VI, and TM, as well as 
incidental/symptomatic diagnosis rates.  The following section describes the methodology for projecting 
tumor growth over time.  Methods for obtaining the additional HCC-related parameters are later 
described in the calibration procedures.  
Based on the seminal work by Schwartz (1961), HCC tumors are generally assumed to grow 
exponentially with time, at a rate governed by the tumor volume doubling time (DT), such that, at any 
time t (in days), tumor diameter (Dt) can be predicted as follows: 
 13
 
  Dt = D0*2 
t/(3*DT)
      
 where: Dt = tumor diameter at time t 
  D0 = tumor diameter at initial measurement 
  DT = tumor volume doubling time (days) 
  t    = time (days) 
 Literature searches were conducted to identify peer-reviewed articles that assessed tumor 
growth in HCC using multiple measurements of tumor diameter (or volume) over time and calculated DT 
using the tumor growth formula (or equivalent, using tumor volume 
 13
) (Appendix C).  The search 
identified 26 studies that met these criteria, of which 9 were excluded, as they were not conducted 
among the general population of HCC tumors,
 113-117
 or focused on the growth of macroregenerative 
nodules of which only a minority were later diagnosed as HCC.
 118-121
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The results of the 17 remaining studies are summarized in Appendix D.
 14-27,122-124
 DT was highly 
variable across study samples, with mean/median DT ranging from 71 to 272 days, as well as across 
individuals, evidenced by a wide range of DT.  Several studies noted that DT varied within individuals 
over follow-up;
 14,15,18,19,21
 however, the studies did not identify any definite trends.  The majority of 
studies were conducted in East Asia, and 6 studies were from the United States or Europe.
 18,25,26,122-124
 
Although HCC patients in China display different disease characteristics than patients in western settings 
due to differences in HCC etiology,
 52,57
 studies assessing the predictors of DT did not find an association 
between HCC etiology/degree of cirrhosis and DT.
 18,21,122,124
 Therefore, regional differences in HCC 
etiology were assumed to have no impact on HCC tumor growth, and all 17 studies were considered for 
a pooled meta-analysis.  
The pooled meta-analysis was conducted using Microsoft Excel for Mac 2011 (version 14.3.9) 
(Figure 4.3).
 38
 Differences in the initial tumor size and characteristics across study samples suggested 
that a random effects model was more appropriate than a fixed effects model.
 39
  Most studies noted 
that the distribution of DT in HCC was highly skewed, suggestive of a log-normal distribution.
 14,15,17-20,22-
24,26
 Thus, to satisfy the normality assumption for the random effects model, the meta-analysis was 
conducted using the geometric mean
 
± SD for DT to achieve normality at the log-scale.
 39,125
 Studies were 
included if they directly estimated the geometric mean,
 24,26
 or provided raw data to allow estimation of 
the geometric mean.
 14,15,17,19-23
 For studies that provided only the arithmetic mean ± SD,
 16,18,25,27
 the 
geometric mean
 
and 95% CI were approximated using previously validated methods.
 125
 Three studies 
that provided only the median and range for DT were ultimately excluded.
 122-124
   
Using the mean and standard error (SE) estimates from the pooled meta-analysis (Figure 4.3), 
DT was incorporated into the formula for tumor growth to project primary tumor size over time for all 
individuals who developed HCC.  Consistent with prior evidence, DT was randomly assigned using a log-
normal distribution.
 14,15,17-20,22-24,26
  Initial tumor size (D0) was assigned using a uniform distribution, 
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based on the range in the minimum detected tumor size across all tumor growth studies (0.3-1.5 cm; 
Appendix D).  
Diagnostic Accuracy of HCC Surveillance 
 As diagnostic imaging techniques for the detection of HCC are rapidly evolving, literature 
searches to identify the diagnostic accuracy of HCC surveillance were restricted to studies published 
since the year 2000 (Appendix E).  To project the impact of surveillance, it was critical to capture the 
sensitivity of abdominal US in detecting tumors of various sizes. Six studies assessing US accuracy met 
these criteria, of which 3 studies included an insufficient sample of HCC cases (n<30) to reliably estimate 
differences across tumor size.
 126-128
 The remaining three studies provided different sensitivity estimates 
for very early tumors ranging from 21% to 35%.
 88-90
   The lower sensitivity estimate was conservatively 
chosen, and sensitivity analyses incorporated the full range in sensitivity across studies (Table 4.1). For 
AFP ≥ 200 ng/mL, sensitivity analyses also assessed the full range in sensitivity (20%-36%), with the 
lowest estimate assumed in the base-case analysis.
 90,129-132
  Earlier studies, using different AFP cut-
points, have suggested variations in AFP sensitivity according to HCC etiology; however, these 
associations have not been consistent.
 132-134
  Therefore, HCC etiology originating from chronic HBV 
infection was not considered a relevant inclusion criteria.  Although both CT and MRI scan can exhibit a 
significant false-negative rate when used in first-line assessments, when used as confirmatory imaging, 
the sensitivity of both CT and MRI is as high as 91-100%.
 89
 
HCC Treatment  
Treatment probabilities and survival with treatment incorporated in the simulation model were 
based on a prior analysis of the BRIDGE to Better Outcomes in HCC (HCC BRIDGE) study in China, a 
retrospective cohort study of patients diagnosed with HCC at 10 hospital centers across 7 cities in 
mainland China (see Chapter 3). Details of the study design and complete inclusion criteria for the HCC 
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BRIDGE study have been previously described (see Chapter 3). 
 29
  For the present analyses, the cohort 
was further restricted to HCC patients with documented evidence of chronic HBV infection and 
complete tumor characteristics, liver function, and follow-up information (n=4,797; 80%) (Appendix F).  
Analyses were conducted using SAS version 9.2 (Cary, North Carolina, United States).   An a priori 5% 
significance level was used for all statistical and model specification tests.  
For each disease stage at diagnosis, probabilities of HCC treatment were incorporated in the 
simulation model based on the frequency of primary treatment approaches found in the HCC BRIDGE 
study (Table 4.2).  Primary treatment was generally defined as the first recorded treatment, with certain 
exceptions, as previously described (see Chapter 3). Prior analyses of the HCC BRIDGE study found that 
HCC treatment patterns are generally consistent with the CMH guideline recommendations (see 
Chapter 3).
 3
 Common primary treatment approaches include resection, ablation, trans-arterial therapy 
and supportive care.  Although recommended, liver transplant (n=38, 0.8%), systemic therapy (n=59, 
1.2%) and radiotherapy/other loco-regional therapy (n=74, 1.5%) are rarely provided and, therefore, did 
not warrant inclusion in the simulation model.  
Additional analyses explored treatment delays from diagnosis to first treatment.  Treatment 
delays were minimal across all primary treatments (mean (95% CI): 10.2, 9.6-10.9 days) with the vast 
majority (95.4%) of patients receiving treatment within one month following diagnosis.  Therefore, 
treatment delays were not incorporated in the model, and patients were assumed to receive treatment 
immediately following diagnosis. 
To assess differences in survival across disease stage and primary treatment, initial survival 
curves were fitted to individual-level data from the HCC BRIDGE study. Kaplan-Meier survival curves 
were estimated for each primary treatment, and pair-wise log-rank tests were conducted to identify 
significant differences in survival across disease stages.
 31
 Using the same procedure, additional Kaplan-
Meier curves compared survival with treatment for each disease stage.  Survival differences were 
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generally significant across the disease stage and treatment strata, with some exceptions.  For resection, 
ablation and trans-arterial therapy, survival for patients with intermediate-solitary and intermediate-
multinodular tumors was similar (all p>0.05).   In addition, survival did not significantly differ across all 
disease stages for patients allocated to supportive care, and survival was poor regardless of treatment 
for terminal stage patients.   Where survival differences were non-significant, patients were pooled 
together, resulting in a total of 11 treatment/disease stage groups (Figure 4.4).  
 In order to project survival beyond the 3-5 year follow-up of the HCC BRIDGE Study, parametric 
survival curves were fitted separately for each treatment/disease stage group.  Candidate model 
distributions included the exponential, Weibull, log-normal, log-logistic and generalized gamma models.
 
135 
Comparisons between fitted distributions were quantitatively judged using the Akaike Information 
Criteria (AIC).
 31,135
 In cases where models (Weibull, exponential, and log-normal) were nested within a 
parent model (generalized gamma), likelihood ratio tests were performed to further compare model fit.
 
31,135
  To qualitatively assess model fit, the unadjusted parametric survival curves were graphed against 
the corresponding non-parametric survival curves, estimated using the life-table method (Figure 4.4).   
Based on the quantitative test results, the log-normal model generally provided the best fit to 
the HCC BRIDGE data. 
 31,135
   As exceptions, gamma models provided the best fit for terminal stage 
patients and for intermediate stage patients receiving trans-arterial therapy.  Despite these results, the 
unadjusted gamma survival curves were qualitatively similar to the log-normal models.  To maintain 
consistency in the assumptions surrounding the hazard of death across models, log-normal models were 
ultimately chosen across all treatment and disease stage categories.  The hazard of death for individuals 
with undiagnosed advanced HCC was additionally assumed to be the same as for patients diagnosed 
with advanced HCC who receive supportive care, and was therefore, projected from time of VI/TM 
development using the log-normal model for supportive care. 
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All of the final parametric survival curves were adjusted for age and gender.  The terminal stage 
model additionally controlled for primary treatment (i.e., TA therapy or supportive care).  All other 
models controlled for tumor size, number of nodules, and tumor spread (i.e., VI and TM), based on the 
tumor stage categories outlined in the CMH guidelines (Figure 4.2, Table 4.2).
 3
 Probability plots, using a 
modified Kaplan-Meier method that adjusts for covariates, were used to graphically assess model fit for 
each parametric curve at different values of the model covariates.
 31
 Quantitative comparisons of model 
fit for each fitted distribution were re-conducted, as described above.  Model fit results were 
qualitatively similar with those of the unadjusted models.     
Calibration Procedures 
 Whereas numerous studies have measured tumor growth in HCC, clinical data do not provide 
the necessary information to fully characterize the development of satellite tumors and VI/TM over 
time.  The estimation of these parameters would require information regarding when each individual 
developed an HCC tumor and when further complications occurred.  Such information is largely 
unavailable in clinical databases since most early stage patients are treated; even if patients elect to 
forgo treatment, large sample sizes would be needed to establish statistical power.  In addition, the rate 
at which HCC is detected outside of a surveillance program, either incidentally or based on clinical 
symptoms, cannot be directly measured.  Doing so would require knowing the proportion of all HCC 
cases (undiagnosed and diagnosed) that are detected in regular clinical practice.   
Unknown parameters surrounding HCC disease progression were estimated through model 
calibration, a process that involves the systematic adjustment of model parameters to maximize 
consistency between simulated and observed data.
 136
 The following parameters were estimated by 
calibrating the simulation model: 1) the annual growth rate of an additional tumor if 1, 2 and ≥ 3 tumors 
are present; 2) the annual rates of VI and TM development; and 3) annual incidental/symptomatic 
  68 
diagnosis rates. All parameters were adjusted by primary tumor size (≤5 cm, >5 and ≤ 10cm, >10 cm).  
Given that these unknown parameters cannot be measured in clinical practice, there were no prior data 
to inform plausible ranges.  Thus, ranges for all 18 unknown parameters initially explored every possible 
value (rate per person: 0-1 per year) using continuous step sizes; base case values and plausible ranges 
were iteratively adjusted based on initial calibration results.   
Through model calibration, the unknown parameters were chosen to produce model outputs 
optimized to reflect the distribution of tumor characteristics found in the HCC BRIDGE study data.   The 
HCC BRIDGE data were first restricted to HCC patients who were not enrolled in a HCC surveillance 
program prior to HCC diagnosis (n=3,288; Appendix F).  The data were then stratified into 27 mutually 
exclusive categories by tumor size, number of tumor nodules, and tumor spread (Table 4.3). Trends in 
tumor characteristics revealed that the majority of patients were diagnosed with a solitary tumor, and 
the frequency of VI and TM generally increased with tumor size.  The frequency of multinodular tumors 
tended to increase with primary tumor size, presumably with the increased likelihood of VI/TM 
development; however, the development of satellite tumors in early HCC was also common.  
  Based on these trends, the following assumptions were made to reduce the complexity of the 
calibration process: 1) All individuals with HCC were initially assumed to have a solitary (primary) tumor, 
the size of which was projected using the tumor growth formula and the randomly assigned DT.
 13
  With 
time, individuals could develop satellite tumors, VI and/or TM.  2) As most patients present with a 
solitary tumor, individuals with a solitary tumor had a lower rate of developing an additional tumor than 
those who already had multiple nodules, 3) Satellite tumors were assumed to be the same size or 
smaller than the primary tumor, and were assumed to vary according to the primary tumor size. 4) The 
rates of VI and TM development were assumed to vary with primary tumor size.  5) The growth rate of 
the primary tumor was assumed to be independent of any satellite tumors and VI/TM. 6) The rates of 
incidental/symptomatic diagnosis increased with primary tumor size to reflect differences in the 
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sensitivity of diagnostic imaging with tumor size, as well as an increase in disease-related complications 
leading in symptomatic disease.
 3,89
  
 The model calibration was conducted using the Optquest Optimization Engine (© OptTek 
Systems, Inc., www.opttek.com, Boulder, CO, United States) incorporated in the AnyLogic simulation 
software. The parameter search strategy is proprietary to Optquest, and uses a modified Newton 
method for optimization (www.opttek.com). Goodness of fit for the model outputs compared with the 
observed data was measured using the method of least squares.
 136
 To obtain the optimal parameter set, 
multiple iterations were run, each with different combinations of the calibrated parameters, for a total 
of 10,000 iterations.  To account for underlying model stochasticity, multiple replications were run per 
iteration until the 95% CI of the least squares value had been reached with 0.5% error, with a minimum 
of 10 replications. The mean least squares value across all replications was used to search for the 
minimum value across model iterations.   
Parameter sets that produced local minimum least square values that fell within a 0.001 relative 
change from the global minimum least squares value were compared.
 136
  As the acceptance criteria, the 
parameter set that produced the lowest percentage point differences in the distribution of tumor 
characteristics compared with the HCC BRIDGE data, within a maximum 5 percentage-point radius for 
each of the 27 strata, was ultimately retained.  The resultant optimal set of parameters was used to 
conduct the model analyses.    
Model Verification  
Throughout development, the simulation model was run with enhanced animation to identify 
errors, oversights, or bugs in the model logic. Extreme value testing was performed to ensure the model 
behaved as expected as input parameters changed, both one at a time and in combination.  
Gastroenterologists/hepatologists were additionally consulted to ensure the model provided a clinically 
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valid representation of the natural disease course for chronic HBV infection and outcomes for HCC 
patients.  
Model Analyses 
Model Outcomes 
All model outcomes were exported from AnyLogic into text files and read into SAS. Model 
outcomes included the 18 unknown parameters of HCC disease progression, and the model projected 
distribution of tumor characteristics following HCC diagnosis.  Following model calibration, the model 
was used to project the impact of 3 different surveillance strategies from time of chronic HBV diagnosis 
until death: 1) no surveillance (for comparison), 2) 6-month US and AFP (with cutpoint ≥ 200 ng/mL), 
and 3) 12-month US and AFP.  The primary model outcome was the survival time for individuals who 
developed HCC from time of HCC development until death.  Survival was measured from time of HCC 
development, as opposed to time of diagnosis (as in clinical trial settings), to eliminate lead-time bias 
and incorporate cases of undiagnosed HCC that died prior to diagnosis.  To account for underlying model 
stochasticity, multiple replications were run per iteration until the 95% CI of the mean survival estimate 
had been reached with 0.5% error, with a minimum of 10 replications.  The maximum number of 
replications needed across all HCC surveillance strategies was then used to compare survival across 
strategies.  For each strategy, the resultant individual-level survival estimates were pooled across 
replications and analyzed using the Kaplan-Meier method; differences in survival across HCC surveillance 
strategies were compared using the log-rank test.
 31
  Overall survival probabilities (1-, 3-, 5-, 10-, and 20-
year) were calculated using the Life-Table method.
 31
  
Additional model outcomes for each surveillance strategy included disease stage at diagnosis, 
primary treatment following diagnosis, and the total number of screening tests needed to detect one 
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case of HCC.  Statistical differences across surveillance strategies were assessed using the Chi
2
 test.  An a 
priori 5% significance level was used for all statistical tests. 
Probabilistic Sensitivity Analyses 
 Probabilistic sensitivity analyses, using Monte-Carlo simulation, were conducted to provide 
estimates of uncertainty in the model-projected outcomes.  The simulation model was run for 100 
iterations with model parameters drawn from fitted parameter distributions reported in Table 4.1.  
Probabilities of HCC treatment, according to disease stage at diagnosis, were drawn from Dirichlet 
distributions, using frequencies reported in Table 4.2.  To incorporate probabilistic uncertainty in the 
hazard of death following HCC treatment, the covariance matrices of the estimated log-normal survival 
curves were estimated.
 40
 Cholesky decomposition was then applied to the covariance matrices to 
account for correlation between the model parameters, when sampled using a normal distribution.
 40
  
The same procedures, described above, were used to analyze survival for individuals who develop HCC 
across iterations to form ranges surrounding the base-case model outcomes. 
Results 
Model Calibration 
After a total of 10,000 iterations, the model calibration resulted in 12 best fitting solutions (local 
minima), of which 5 iterations produced calibrated output with minimum least square values within a 
0.001 relative change of the global minimum value (sum of square errors [SSE] = 0.005).  The optimal 
calibrated distribution of tumor characteristics, compared with results from the HCC BRIDGE data, are 
presented in Table 4.4.  The model-estimated distribution of tumor characteristics for the best fitting 
solution (sum of square errors = 0.006) fell well within the maximum 5 percentage point tolerance 
radius for each of the 27 strata, suggesting an acceptable model fit to the data.  The resultant model-
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estimated optimal parameter set is listed in Table 4.5.  As expected, the rates of HCC disease 
progression and incidental/symptomatic diagnosis generally increased with tumor size.  The rates of 
satellite tumor development were initially low for patients with a solitary tumor, and then increased 
among individuals with multinodular tumors. 
Model-Projected Outcomes 
 Using the base-case model parameters, the results of the simulation model suggest that HCC 
surveillance with US and AFP, compared with no surveillance, provides a clear survival benefit among 
individuals who develop HCC (Figure 4.5a; log-rank: p < 0.0001).  Overall survival following HCC 
development was also significantly higher among patients who received surveillance with US and AFP 
every 6 months, as compared with 12 months (p < 0.0001); however, the magnitude of the survival 
difference was small (median survival for 6- vs. 12-month interval: 4.60 vs. 4.11 years).  Short-term 
differences in survival for individuals with HCC who did not receive surveillance compared with 
individuals who received surveillance every 6 or 12 months were minimal, but increased substantially 
over follow-up.  Overall survival 5 and 10 years following HCC development was only 28.9% and 13.5% in 
the no surveillance group, compared with 48.1% and 30.1% for surveillance conducted using a 6-month 
interval, and 44.2% and 27.0% using a 12-month interval, respectively (Table 4.6). 
 Consistent with these results, a markedly higher proportion of HCC patients who underwent 
surveillance were diagnosed with early stage HCC (6- and 12-month interval: 84.6% and 73.8%), 
compared with patients who did not undergo surveillance (29.7%), and fewer patients were diagnosed 
with advanced HCC (Table 4.6; overall p < 0.0001 for all comparisons).  Surveillance was also associated 
with increased use of curative resection and ablation as the primary treatment (overall p < 0.0001 for all 
comparisons).  Despite these benefits, approximately 399 screening tests would be needed to detect 
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one case of HCC for surveillance using a 6-month interval; using a 12-month interval, the ratio in the 
number of screening tests is reduced to 218 per HCC case detected.  
Probabilistic Sensitivity Analyses 
 Survival results from the probabilistic sensitivity analyses, conducted across a series of 100 
iterations, were consistent with results from the base case analyses.  Both surveillance conducted using 
a 6-month and 12-month interval, compared with no surveillance, consistently improved survival with 
HCC (Figure 4.5b-c).   On the other hand, survival following HCC development for individuals who 
received 6-month as compared with 12-month surveillance was similar (Figure 5d). Overall survival 5 
and 10 years following HCC development ranged from 26.9-29.3% and 12.2-14.4% in the no surveillance 
group, respectively, compared with 45.4-51.8% and 40.9-47.5% for surveillance conducted using a 6-
month interval, and 40.9-47.5% and 24.2-30.7% using a 12-month interval, respectively. 
Discussion 
This individual-based simulation model of HCC surveillance combines well established data on 
the natural progression of chronic HBV infection and HCC disease, along with detailed clinical data from 
patients diagnosed with HCC in China, to provide an accurate portrayal of the impact of surveillance on 
survival outcomes for individuals who develop HCC.   The results of this model suggest that surveillance 
with ultrasound and AFP is associated with both earlier disease detection and an increased rate of 
curative surgical treatment.  As a result, surveillance markedly improves the survival of patients who 
develop HCC.   Despite the clear survival benefit, however, a large number of screening tests are needed 
to detect one case of HCC, suggesting that resource use is an important consideration.  In the setting of 
limited resources, the results of this model suggest that surveillance performed at 12-month as opposed 
to 6-month intervals, as currently recommended in China, can be more easily implemented with little 
impact on the survival of patients who develop HCC.  
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Although HCC surveillance is widely recommended, few studies have demonstrated that 
surveillance improves survival. 
 2-5,8
  The seminal clinical trial of surveillance in China, conducted by 
Zhang et al. (2004), found a 37% reduction in HCC mortality associated with surveillance every 6 months 
with US and AFP.
 9
   Among patients diagnosed with HCC, surveillance was associated with a significant 
survival benefit (p<0.01); 5-year survival among patients who received surveillance was 46.4% compared 
with 0% in the no surveillance group.  In comparison with these results, 5-year survival following HCC 
development in the current study was similar among individuals who received surveillance using a 6-
month interval (45.4-51.8%), but was substantially higher in the no surveillance group (26.9-29.3%).  In 
interpreting these survival differences, it is important to note that HCC treatment approaches have 
evolved substantially since Zhang et al. conducted the trial in 1993-1998.  In particular, local ablation has 
emerged as a less invasive alternative to resection for individuals with early stage tumors.
 2,71
 With 
advancements in surgical techniques, a larger number of multinodular tumors are now considered 
resectable, with 3-year survival reaching as high as 56%.
 61-63
 Further advancements in curative 
treatment options for HCC will likely increase the survival advantages associated with HCC surveillance. 
An important limitation to the trial conducted by Zhang et al., as well as other studies assessing 
the impact of surveillance, is the potential for lead time bias.
 9
 This bias may occur if surveillance merely 
detects the tumor at an earlier stage without affecting the course of disease, leading in an 
overestimation of survival gains with surveillance.
 2 
  To address this limitation, observational studies 
have approximately adjusted for lead time by applying different assumptions surrounding estimated DT 
to the well-established formula for tumor growth (see Chapter 5). 
 10-13
   The results of these studies 
suggest that surveillance significantly improves survival, even after lead time adjustment using a range 
in DT from 60 to 120 days. However, such methods are based solely on current knowledge surrounding 
HCC tumor growth. Tumor growth in HCC is highly heterogeneous across individuals, and other aspects 
of HCC progression, including the development of multinodular HCC, vascular invasion and tumor 
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metastases, are not fully understood. 
 14-27
   In the current model, survival with HCC was defined from 
the time of HCC development, as opposed to diagnosis, to effectively remove lead time bias and also 
account for cases of HCC-related mortality prior to HCC diagnosis.  Thus, the results of this model not 
only overcome controversies surrounding potential lead time bias, but also provide a more accurate 
portrayal of the true benefit of surveillance among the full population of HCC tumors. 
Further advantages of this simulation model include the detailed representation of tumor 
growth in HCC, based on evidence synthesized across published tumor growth studies. 
 14-27
 Whereas 
prior decision models of HCC surveillance have made simplifying assumptions surrounding tumor growth 
in HCC, 
 83-86
 the current model sought to expand the representation of disease progression in HCC by 
incorporating individual-level heterogeneity in tumor growth and disease-related complications through 
model calibration.  The model-based projections were generally concordant with trends in the 
distribution of tumor characteristics seen in clinical practice in China (see Chapter 3);
 45
 nevertheless, 
several assumptions were incorporated to simplify the calibration process.  Thus, further research on 
the biological mechanisms surrounding HCC progression, if feasible, would help test and inform the 
model-based assumptions. Likewise, additional large-scale datasets of patients diagnosed with HCC are 
needed to cross-validate the model-based outcomes.   
In interpreting the results of this study, it is important to note that survival outcomes  
incorporated in the model were based on data from HCC patients diagnosed and treated at large tertiary 
hospitals in China. Thus, the results may represent a more ideal scenario in which patients were 
routinely provided appropriate care. Physician’s level of experience in staging and treating HCC patients 
can have a profound impact on survival outcomes. 46,137 An earlier trial conducted in China noted that 
screening with AFP led to earlier diagnosis, but did not result in an overall reduction in mortality largely 
due to ineffective treatment. 46  Community-based screening projects conducted in Taiwan have 
suggested that two-stage screening programs consisting of AFP followed by US among suspected cases 
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of HCC is economically feasible with a large proportion of HCC cases detected in the early disease stage. 
7,138-140 On the other hand, the lack of a suitable comparator group has limited survival comparisons to 
establish the survival impact of surveillance in this setting.  7  
Lastly, the current model was designed to assess survival among individuals who develop HCC as 
a result of chronic HBV infection, the most common etiology of HCC disease in China, representing over 
80% of all HCC cases (see Chapter 3).
 45
 Further research is needed to understand the impact of 
surveillance among the population of HCC patients with other underlying risk factors, including chronic 
HCV infection and alcohol liver disease, which generally present with more advanced liver disease (CP 
B/C: 30-49%).
 10,28,30,77
   Advanced liver disease has been found to reduce the survival benefit associated 
with surveillance, as these patients are generally not optimal candidates for surgical resection and 
experience higher mortality from liver-disease related complications.
 11
 
In conclusion, the results of this simulation model of HCC development among individuals with 
chronic HBV in China reveal that surveillance using abdominal US and AFP is associated with earlier 
disease detection, increased use of curative treatment, and improved survival.   Based on current 
knowledge surrounding HCC tumor progression, HCC surveillance conducted using a 12-month interval 
is associated with similar survival benefits, as compared with surveillance conducted every 6 months.  
Therefore, surveillance using a 12-month interval among individuals with chronic HBV infection can be 
more easily implemented with little impact on the survival of patients who develop HCC.  Additional 
large-scale studies are needed to establish whether survival gains associated with surveillance withstand 
differences in the underlying etiology of HCC disease and access to effective HCC treatments in China
  
7
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Table 4.1: Model parameters incorporated in the simulation model to project the natural history of chronic HBV disease and sensitivity of 
diagnostic imaging for surveillance.  
 
  Probabilistic Sensitivity Analyses  
Model Inputs  Base Case Distribution Parameters Sources 
Demographics     
Gender Distribution (% Male) 61.9 Beta α = 2,260, β = 1,393 Chen et al., 2006 
 36
 
Age Distribution (years) * 
30-39 33.3 
Dirichlet 
α List =  
(1,216, 1,014, 1,058, 365) 
Chen et al., 2006
 36
 
40-49 27.7 
50-59 29.0 
60-79 10.0 
Cirrhosis Incidence **     
Annual Rate – Comp. Cirrhosis      
Male 0.70 Beta α = 89, β = 12,625  Yu et al., 1997;
 106
 Iloeje et al., 2006
 37
 
RR Male vs. Female 2.5 Log-Normal Normal Mean = 0.9, SD = 0.1 † Iloeje et al., 2006 
 37
 
Annual Rate – Decomp. Cirrhosis 1.5 Beta α = 12, β = 788 Chen et al., 2007
 35
 
HCC Incidence **     
Annual Rate in Chronic HBV      
Male 0.53 Beta α = 135, β = 25,337 Chen et al., 2006
 36
 
RR Male vs. Female 3.0 Log-Normal Normal Mean = 1.1, SD = 0.2 † Chen et al., 2006
 36
 
Annual Rate in Cirrhosis 2.7 Beta α = 21, β = 757 Chen et al., 2007 
 35
 
Mortality Rates 
Annual Mortality – Decomp. Cirrhosis      
≤ 1 year After First 
Decompensation 0.60 ‡ Beta α = 75, β = 91 ‡ 
Jiang et al., 2008;
 110
  Fattovich et al., 2002;
 111
 
Tsai et al., 1988 
 112
 
> 1 year After First 
Decompensation 0.25 ‡ Beta α = 7, β = 26 ‡ 
Fattovich et al., 2002;
 111
  
Tsai et al., 1988 
 112
 
Mortality UnDxed Advanced HCC Survival Curves Adjusted for Gender, Age & Tumor Stage  HCC BRIDGE Study 
¶
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Annual All-Cause Mortality in China Gender & Age Adjusted World Health Organization, 2011 
 107
 
Sensitivity of Diagnostic Imaging    
Abdominal US     
<2 cm 0.21 Beta α = 33, β = 86 
§
 
Di Martino et al., 2013;
 88
 Yu et al., 2011;
 89
 
Snowberger et al., 2007 
 90
 
2-4 cm 0.62 Beta α = 44, β = 27 Yu et al., 2011
 89
 
>4 cm 0.85 Beta α = 28, β = 5 Yu et al., 2011
 89
 
AFP ≥ 200 ng/mL 0.20 Beta α = 30, β = 85 
§
 
Sterling et al., 2009;
 129
 Arrieta et al., 2007;
 130
 
Nguyen et al., 2002; 
 131
 Trevisani et al., 2001;
 132
 
Cedrone et al., 2000 
 133
 
CT/MRI  0.91 Beta α = 85, β = 4 
§
 Yu et al., 2011
 89
 
AFP = alpha-fetoprotein, Comp. = compensated, Decomp. = decompensated, HBV = hepatitis B virus, HCC = hepatocellular carcinoma, HCC BRIDGE = BRIDGE to 
Better Outcomes in Hepatocellular Carcinoma Study, RR = risk ratio, SD = standard deviation, UnDxed = undiagnosed, US = ultrasound 
* Within each age category, age was randomly assigned using a uniform distribution.  
** Annual rates are per 100 person/years.  
† Parameters were estimated using the 95% confidence intervals for the RR estimates: Annual Rate Compensated Cirrhosis, RR = 2.5 (1.9-3.3); Annual Rate HCC 
in Chronic HBV, RR = 3.0 (2.0-4.5). 
‡ Annual mortality rates were estimated using the reported 1-year (0.55)
 110
 and 5-year (0.28)
 111
 survival probabilities, assuming a standard constant hazard of 
death within each time interval.
 40
  
 
¶
 The hazard of death among individuals with undiagnosed advanced HCC was assumed to be the same as for patients diagnosed with advanced HCC who 
received supportive care, and was projected using parametric survival curves fitted to the HCC BRIDGE Study data.     
§
 The distribution surrounding the sensitivity of diagnostic imaging was derived using the method of moments fitting for the beta distribution with parameters 
approximated using the mean and range across studies: US for size < 2cm = 21%-35%; AFP ≥ 200 ng/mL = 20-36%; CT/MRI = 91-100%. 
40
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Table 4.2: Frequency of primary treatment approaches for patients diagnosed with HCC, according to tumor characteristics and liver function, 
incorporated in the simulation model: results from the HCC BRIDGE study in China, (n=4,797). 
 
Very Early/Early†  
Intermediate/ 
Solitary†  
Intermediate/ 
Multinodular†  Advanced‡ Terminal 
Treatments, n (%)* 
1 tumor,  
≤2 cm 
(n=226)  
1 tumor, 
3-5 cm 
(n=931) 
2-3 
tumors,  
≤ 3 cm 
(n=111) 
1 tumor,  
6-9 cm 
(n=871) 
1 tumor,  
≥ 10 cm 
(n=525) 
2-3 
tumors,  
> 3 cm 
(n=319)  
≥ 4 
tumors 
(n=292) 
VI 
(n=724) 
TM 
(n=755) 
CP C 
(n=43) 
Resection **  112 (49)  571 (61)  33 (30)  476 (55)  140 (27)  119 (37)  64 (22)  128 (18)  133 (18) − 
Ablation **  63 (28)  142 (15)  26 (23)  43 (5)  9 (2)  22 (7)  26 (9)  48 (6)  43 (6) − 
TA Therapy  51 (23)  218 (23)  52 (47)  334 (38) 343 (65)  168 (53)  180 (62)  514 (71)  538 (71) 15 (35) 
Supportive Care − − − 18 (2)  33 (6)  10 (3)  22 (7)  34 (5)  41 (5)  28 (65) 
 
CP = Child-Pugh, HCC = hepatocellular carcinoma, HCC BRIDGE = BRIDGE to Better Outcomes in Hepatocellular Carcinoma Study TA = trans-arterial therapy, TM 
= tumor metastases, VI = vascular invasion 
 
* The frequency of other primary treatments, including liver transplant (n=38, 0.8%), systemic therapy (n=59, 1.2%),and radiotherapy/other loco-regional 
therapy (n=74, 1.5%), were not incorporated in the decision model, as these treatments were rarely provided.  
** Includes patients who received trans-arterial therapy within 6 months prior to resection or ablation.  
 − Frequency of primary treatment was insufficient to warrant inclusion (all <2%).  
 † Patients in these categories have compensated cirrhosis (CP A/B), no venous invasion and no tumor metastases. 
 ‡ Patients in these categories have compensated cirrhosis (CP A/B). 
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Table 4.3: Distribution of tumor characteristics among HCC patients who did not undergo surveillance 
incorporated in the model calibration: results from the HCC BRIDGE study in China (n=3,288). 
Number of Tumor Nodules, n (%) 
Tumor Size & Spread 
1 tumor 
(n = 2,340) 
2 - 3 tumors 
(n = 439) 
≥ 4 tumors 
(n = 419) 
≤ 5 cm (n = 1,239) 
No VI/TM 837 (25.46) 156 (4.74) 78 (2.37) 
VI* 54 (1.64) 11 (0.33) 9 (0.27) 
TM 28 (0.85) 33 (1.00)  33 (1.00) 
> 5 & < 10 cm (n = 1,177) 
No VI/TM  581 (17.67) 88 (2.68) 70 (2.13) 
VI*  147 (4.47) 30 (0.91) 34 (1.03) 
TM  112 (3.41) 49 (1.49) 66 (2.01) 
≥ 10 cm (n = 872) 
No VI/TM  341 (10.37) 28 (0.85)  49 (1.49) 
VI* 205 (6.23) 20 (0.61)  39 (1.19) 
TM 125 (3.80) 24 (0.73) 41 (1.25) 
 
 
HCC = hepatocellular carcinoma, HCC BRIDGE = BRIDGE to Better Outcomes in Hepatocellular Carcinoma Study, TM 
= tumor metastases, VI = vascular invasion 
* Includes patients with vascular invasion, but without tumor metastases. 
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Table 4.4: Distribution of tumor characteristics among HCC patients who did not undergo surveillance: 
results from the HCC BRIDGE study in China compared with model output after calibration.† 
Number of Tumor Nodules 
Tumor Size  
& Spread 1 tumor 
% Point 
Difference 2-3 tumors 
% Point 
Difference ≥ 4 tumors 
% Point 
Difference 
≤ 5 cm     
No VI/TM 25.46 (29.28) 3.82 4.74 (3.24) -1.5 2.37 (0.45) -1.92 
VI* 1.64 (2.26) 0.62 0.33 (0.46) 0.13 0.27 (0.07) -0.2 
TM 0.85 (1.07) 0.22 1.00 (0.14) -0.86 1.00 (0.01) -0.99 
> 5 & < 10 cm     
No VI/TM 17.67 (17.02) -0.65 2.68 (4.63) 1.95 2.13 (1.1) -1.03 
VI* 4.47 (5.66) 1.19 0.91 (1.47) 0.56 1.03 (0.43) -0.6 
TM 3.41 (3.65) 0.24 1.49 (1.25) -0.24 2.01 (0.23) -1.78 
≥ 10 cm    
No VI/TM 10.37 (6.4) -3.97 0.85 (2.32) 1.47 1.49 (0.88) -0.61 
VI* 6.23 (4.48) -1.75 0.61 (1.76) 1.15 1.19 (0.92) -0.27 
TM 3.80 (6.12) 2.32 0.73 (2.42) 1.69 1.25 (2.26) 1.01 
 
HCC = hepatocellular carcinoma, HCC BRIDGE = BRIDGE to Better Outcomes in Hepatocellular Carcinoma Study, TM 
= tumor metastases, VI = vascular invasion 
* Includes patients with vascular invasion, but without tumor metastases. 
† Note: Data represent the percentages of patients with each tumor characteristic: % HCC BRIDGE Data (% Model 
Output).  Model output was pooled across a series of 10 replications, based on the minimum number of 
replications needed per iteration for the 95% CI of the least squares value to be reached with 0.5% error.  
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Table 4.5: Model estimated rates of HCC disease progression and incidental/symptomatic diagnosis: 
results of model calibration. 
Model Parameter Calibrated Results 
HCC Disease Progression Rates (annual) * 
Rate Additional Tumor  
For Primary tumor:  ≤ 5 cm  
1 tumor present 0.12 
2 tumors present 0.37 
≥ 3 tumors present 0.66 
For Primary tumor:  > 5 cm, ≤ 10 cm  
1 tumor present 0.027 
2 tumors present 0.33 
≥ 3 tumors present 0.45 
For Primary tumor:  > 10 cm  
1 tumor present 0.14 
2 tumors present 0.56 
≥ 3 tumors present 0.63 
Rate of VI development  
Primary tumor:  ≤ 5 cm 0.17 
Primary tumor:  > 5 cm, ≤ 10 cm 0.43 
Primary tumor:  > 10 cm 0.38 
Rate of TM development  
Primary tumor:  ≤ 5 cm 0.058 
Primary tumor:  > 5 cm, ≤ 10 cm 0.34 
Primary tumor:  > 10 cm 0.38 
Incidental/Symptomatic Diagnosis Rate (annual) * 
Primary tumor:  ≤ 5 cm 0.091 
Primary tumor:  > 5 cm, ≤ 10 cm 0.48 
Primary tumor:  > 10 cm 0.44 
HCC = hepatocellular carcinoma, TM = tumor metastases, VI = vascular invasion   
* Rates were calibrated to produce model outputs optimized to reflect the distribution of tumor characteristics 
among individuals who did not participate in surveillance found in the HCC BRIDGE study.  
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Table 4.6: Comparison of model outcomes across surveillance strategies for the detection of 
hepatocellular carcinoma among individuals with chronic HBV infection. 
 Surveillance Strategy p-value ** 
Model Outcome 
No  
Surveillance 
6 mo.  
US + AFP 
12 mo.  
US + AFP 
No 
Surv.  
vs.  
6 mo.  
No 
Surv.  
vs.  
12 mo.  
6 mo.  
vs.  
12 mo.  
Median Survival, years 
†
 3.26 4.60 4.11 <.0001 <.0001 <.0001 
1-year, % 86.55 87.31 87.19    
3-year, % 54.94 62.87 60.36    
5-year, % 28.92 48.13 44.24    
10-year, % 13.45 30.12 27.04    
20-year, % 6.46 13.79 12.62    
Disease Stage at Dx, %    <.0001 <.0001 <.0001 
Very Early/Early  29.7 84.6 73.8    
Intermediate - Solitary 24.4 1.8 6.0    
Intermediate - Multinodular 10.6 2.2 5.2    
Advanced 34.2 10.3 13.9    
Terminal 1.1 1.1 1.1    
Primary Treatment, %    <.0001 <.0001 <.0001 
Resection 36.4 47.5 46.2    
Ablation 10.9 21.1 18.5    
Trans-arterial Therapy 49.1 29.9 33.6    
Supportive Care 3.6 1.5 1.7    
No. Surv. Tests per HCC Case − 399 218 − − − 
alpha-fetoprotein = AFP, Dx = diagnosis, HCC = hepatocellular carcinoma, HR = hazard ratio, mo. = month, No. = 
number, Surv. = surveillance, US = ultrasound 
* Represents the base case model outcomes pooled across a series of 30 replications, based on the maximum 
number of replications needed for the 95% CI of the mean survival estimate across all surveillance strategies to be 
reached with 0.5% error.  
** Statistical differences were assessed using the Chi
2
 test for categorical model outcomes, and differences in 
overall survival were assessed using the log-rank test. 
† For individuals who develop HCC, survival was measured from time of HCC development until death.
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Figure 4.1: Model health states for the chronic HBV and HCC disease progression components of the 
 
 
CP = Child-Pugh status, Dxed = diagnosed, TM = tumor metastases, HBV = hepatitis B virus, HCC = hepatocellular carcinoma, No. = number, 
undiagnosed, VI = vascular invasion
simulation model. 
UnDxed = 
  
Figure 4.2: Model health states and transition logic for the HCC treatment component of the 
simulation model. 
 
 
HBV = hepatitis B virus, HCC = hepatocellular carcinoma
Note: Solid rectangles represent health states, whereas dotted 
85 
 
rectangles indicate model transition logic.
  
Figure 4.3: Results of the pooled random effects meta
conducted among studies that assessed tumor growth in HCC.  
 
DT = tumor volume doubling time, HCC = hepatocellu
95% UL = 95% confidence interval upper limit 
Random Effects Model Statistics: Q = 124.48, p = <0.0001, Tau
* Represents the geometric mean and 95% confidence interval for tumor volume doubling time. 
† Geometric mean and standard deviation were approximated using the arithmetic mean and standard deviation, 
using previously validated methods.
 125
86 
-analysis for tumor volume doubling time (DT) 
 
lar carcinoma, 95% LL = 95% confidence interval lower limit, 
 
2
 = 0.17 
 
 
  
Figure 4.4: Graphical assessment of model fit for the unadjusted parametric survival curves
comparison with the life-table survival curve estimates for each primary HCC treatment and disease 
stage: results from the HCC BRIDGE study in China (n=4,797). A) Resection, B) Ablation, C) Trans
arterial Therapy, D) Supportive Care and Terminal Disease Stage.
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GG = generalized gamma model, HCC = hepatocellular carcinoma, 
Hepatocellular Carcinoma Study, LTM = 
 
NOTE: Grey areas represent the 95% confidence intervals
estimated using the life-table method.
 
 
* Intermediate stage HCC with solitary (> 5cm) or multi
 
† Based on results of the Akaike Information Criteria (AIC)
generally provided the best fit to the HCC BRIDGE data.
for terminal stage patients as well as for intermediate stage patients receiving trans
these results, the unadjusted gamma survival curves were qualitatively similar to the log
normal models were ultimately chosen across all treatment and di
the assumptions surrounding the hazard of death across models.
90 
HCC BRIDGE = BRIDGE to Better Outcomes in 
life-table method, LN = log-normal model  
 using the log-log transformation of the
31
  
-nodular tumors (2-3 tumors, > 3 cm or ≥ 4 
 and likelihood ratio tests, the Log-normal model 
 
 31,135
   As exceptions, gamma models provided the best fit 
-arterial therapy.  Despite 
-normal model.  Log
sease stage models to maintain consistency in 
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Figure 4.5: Comparison of model-projected overall survival across surveillance strategies among 
individuals who developed HCC, analyzed usi
Probabilistic Sensitivity Analyses: B) No Surveillance vs. 6
Month US + AFP, and D) 6-Month US + AFP vs. 12
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alpha-fetoprotein = AFP, HCC = hepatocellular carcinoma, US = ultrasound
* Note: Shaded areas represent the range in survival 
sensitivity analyses. For each iteration, survival outcomes
the maximum number of replications needed per iteration for the 95% CI of the 
surveillance strategies, to be reached with 0.5% error
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estimates across the 100 iterations used in probabilistic 
 were pooled across a series of 30 replications, based on 
mean survival estimate, across all 
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CHAPTER 5: IMPACT OF SURVEILLANCE ON THE SURVIVAL OF PATIENTS WITH HEPATOCELLULAR 
CARCINOMA: RESULTS FROM A LONGITUDINAL STUDY IN TAIWAN 
Introduction 
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide.
 103
 
HCC is highly prevalent in East Asia, where hepatitis B virus (HBV) infection is endemic and is the primary 
etiological risk-factor for HCC.
 1
 In Taiwan, HCC is the leading cause of cancer-related death among males 
and the second among females, with age-adjusted mortality rates of 40.8 and 14.1 per 100,000 persons, 
respectively.
 49
 Resection and tumor ablation are the main curative treatment options for HCC, but 
eligibility to receive curative therapy diminishes with more advanced disease.
 2
 Whereas survival with 
HCC in Taiwan is generally poor (5-year survival 16.2%), 5-year survival for patients diagnosed at an 
earlier stage who receive curative therapy can exceed 50%.
 43,44
   
To improve the early detection of HCC, the Taiwanese Department of Health has funded 
community-based surveillance since 1991 to identify and monitor individuals at high-risk for HCC, as part 
of the Taiwan Community-Based Cancer Screening project.
 6,7
 HCC surveillance currently is 
recommended every 6 months among individuals with cirrhosis related to chronic HBV or hepatitis C 
virus (HCV) infection.
 2
 Recommended screening tests include abdominal ultrasound (US) and 
measurement of serum alpha-fetoprotein (AFP), with a cut-point of ≥200 ng/mL.   
Although HCC surveillance is widely recommended, few studies have provided direct evidence 
that surveillance improves survival.
 2,4,5,8
  A randomized control trial conducted among 18,816 
participants with chronic HBV infection in China found that surveillance every 6 months with US and AFP 
was associated with a 37% - reduction in 5-year mortality.
 9
 Despite demonstrating survival benefit, the 
trial had several limitations, including potential lead time bias related to the earlier diagnosis of HCC, a 
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relatively low number of HCC cases (n=153), and suboptimal adherence to the surveillance protocol (less 
than 60%).  On one hand, the results likely underestimate the survival benefit from surveillance because 
of poor compliance; on the other hand, potential lead time bias could have resulted in an 
overestimation of survival with surveillance.  
The objective of this study was to evaluate the impact of HCC surveillance in current clinical 
practice in Taiwan on the survival of patients diagnosed with HCC.  To control for potential lead time 
bias, we explored different assumptions surrounding the estimated lead time, using a range in median 
tumor volume doubling time (DT) estimated across prior tumor growth studies (synthesized in Chapter 
4).
 14-27
 Propensity score (PS) analysis was also conducted to address selection bias resulting from non-
random allocation of HCC surveillance.  As secondary outcomes, the study compared tumor 
characteristics and primary treatment approaches according to surveillance status. 
Methods 
Study Sample 
The study sample was collected at the National Taiwan University Hospital in Taipei, Taiwan, as 
part of the Bridge to Better Outcomes in Hepatocellular Carcinoma (HCC BRIDGE) study, a retrospective 
cohort study of patients diagnosed with HCC across 14 countries in East Asia, Europe, and North 
America. 29,30  Inclusion criteria for the HCC BRIDGE study included patients age ≥ 18 years who were 
newly diagnosed with HCC from January 1, 2005 through June 30, 2011 and received active treatment 
for HCC.  Patients with unknown date of HCC diagnosis and/or date of first visit or whose first HCC 
treatment was received via participation in a randomized clinical trial were excluded.  For the present 
study, additional inclusion criteria included documented surveillance status prior to HCC diagnosis, 
complete patient characteristics and liver function information at diagnosis, and available follow-up 
information (Figure 5.1).  All patients were followed until September 30, 2012 or date of death.   
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Data Collection 
Data for the HCC BRIDGE study were systematically collected for all enrolled patients through a 
retrospective review of patient medical records.  29,30   Study data were entered into an electronic data 
capture system developed by Outcome Sciences, Inc. (Cambridge, MA, USA) and were subject to 
rigorous monthly data monitoring and cleaning. The institutional review boards from each participating 
hospital site approved the data collection for the HCC BRIDGE study.  Data analyses for the present 
study were approved by The University of North Carolina Office of Human Research Ethics Institutional 
Review Board.  
Surveillance status was collected prior to HCC diagnosis.  The general surveillance protocol 
within the Department of Hepatology and Gastroenterology at the National Taiwan University Hospital 
included abdominal ultrasound and AFP examination every 6-12 months.  Patients were considered to 
be diagnosed under HCC surveillance if imaging by abdominal ultrasound computed tomography and/or 
magnetic resonance imaging, with or without AFP, was repeated at regular intervals of 6-12 months and 
the most recent imaging study was documented within 12 months prior to HCC diagnosis.  Patients with 
unknown surveillance status, due to unavailable clinical information prior to HCC diagnosis, were 
excluded from the study (Figure 5.1). 
Clinical and laboratory assessments, including tumor characteristics and liver function 
information, were obtained for all patients.  Tumor characteristics included tumor size (diameter in cm), 
number of nodules and tumor spread, defined as the presence of vascular invasion and/or tumor 
metastases.  To measure liver function among individuals with cirrhosis, Child-Pugh (CP) scores were 
calculated. 2,55  In cases where patients had multiple clinical assessments over time, only assessments 
obtained within 6 months (182 days) before and after date of diagnosis were considered, and the closest 
date to diagnosis was used.  Laboratory values were taken within 1 month (30 days) before to 6 months 
(182 days) after date of diagnosis, and the earliest available laboratory values were selected.  
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 Available treatment approaches for HCC included: 1) surgical resection, 2) liver transplant, 3) 
ablation, 4) trans-arterial (TA) therapy, 5) systemic therapy, 6) supportive care, and 7) radiation/other 
locoregional therapy. The full list of therapies for each treatment approach are listed in Appendix A.  
The primary treatment approach was generally defined as the first recorded treatment, with certain 
exceptions. Supportive care is often administered to reduce symptoms immediately prior to and 
following primary therapy. 2,5  If patients received another therapy within one month (30 days) after 
supportive care, the other therapy was considered to be the primary treatment.  In practice, TA therapy 
can be used to shrink the tumor(s) in preparation for surgical treatment. 2  The primary treatment 
approach was considered to be surgical treatment, rather than TA therapy, if patients underwent 
resection, liver transplant or tumor ablation within 6 months (182 days) after the first administration of 
TA therapy.  
 Additional patient demographic and clinical characteristics, including patient age, gender, 
etiology, and co-morbidities, were collected at time of diagnosis or first visit to the hospital site.  
Etiology of HCC included chronic HBV infection, chronic HCV infection, alcohol-related liver disease 
(ALD), non-alcoholic fatty liver disease (NAFLD), primary biliary cirrhosis, hemochromatosis, inherited 
metabolic disorder or idiopathic disease, based on documented evidence in the patient medical record. 
Relevant co-morbidities included diagnosed diabetes mellitus, cardiovascular disease (CVD), and 
hypertension. 95,96  
Data Analyses 
Descriptive analyses compared patient demographics, clinical characteristics, tumor 
characteristics, and primary treatment approaches according to surveillance status.  Statistical 
differences were assessed using analysis of variance (ANOVA) tests for continuous variables, and the χ
2
 
or Fisher exact tests for categorical variables. 34 All analyses were conducted using SAS version 9.2 (Cary, 
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North Carolina, United States).   An a priori 5% significance level was used for all statistical tests, as well 
as tests for model specification.  
Survival analyses were conducted to assess differences in survival, according to surveillance 
status.  Survival was estimated from the date of diagnosis until death or censoring.  Patients who did not 
die during follow-up were considered censored at the last known follow-up or study end (September 30, 
2012).  Unadjusted survival probabilities were estimated using the Kaplan-Meier method and compared 
by the log-rank test. 31 The life-table method was used to calculate yearly probabilities of survival; 95% 
confidence intervals (CI) were computed using the log-log transformation of the survivor function. 31  
Cox proportional hazards models were constructed to assess the association between 
surveillance status and the hazard of death, controlling for the following patient demographics and 
clinical characteristics: age, gender, co-morbidities, etiology, liver function (i.e., CP status), and year of 
diagnosis.  31 Model fit for different specifications was assessed using the Akaike information criterion 
(AIC). 31 To test the proportional hazard assumption, log cumulative hazard plots stratified by 
surveillance status were estimated. 31 
Propensity Score Analysis to Address Selection Bias 
Two different methods for PS analysis were undertaken to control for selection bias arising from 
non-random allocation of surveillance: 1) propensity-based weighting (PBW), and 2) propensity-based 
matching (PBM). 33,41,42 In the absence of unmeasured confounding, both methods control for selection 
bias; however, the methods produce distinct estimates of the treatment effect.   Applied to surveillance, 
the PBW method estimates the average effect of surveillance among the population of HCC patients 
with the same distribution of risk factors found in the full study sample (i.e., average treatment effect). 
33,41 In contrast, the PBM method estimates the effect of surveillance for patients with the same 
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distribution of risk factors found in the surveillance group (i.e., average effect of treatment among the 
treated). 42 
The PS for patients who underwent surveillance and no surveillance were estimated using a 
logistic model, controlling for the variables included in the multivariate Cox proportional hazard model. 
32 Histograms for the model-estimated PS were constructed to examine the overlap in the distribution of 
PS across surveillance groups. For the PBW method, patients were weighted using stabilized inverse 
probability weights, defined as the ratio of the marginal predicted probability of treatment (m) divided 
by the PS (i.e., m/PS). 33 Stabilized weights were chosen over standard inverse probability of treatment 
weights (i.e., 1/PS) to provide better estimates of the variance in the effect of surveillance. 34 
PBM was conducted using the nearest available neighbor approach: Patients in the no 
surveillance group were matched with patients in the surveillance group using a 1:1 ratio with sample 
replacement.  42,141  To avoid bad matches, patients were matched within a ± 0.05 range (i.e., caliper) of 
the PS. This commonly used range (± 0.05) was chosen because it produced a reasonable balance of 
baseline characteristics across surveillance groups, while maximizing the number of successful matches. 
32  Additional analyses explored a smaller caliper (± 0.01), with and without sample replacement, which 
did not produce meaningfully different results from those reported below (data not shown). 
  Following both PS analysis methods, ANOVA and χ
2
 tests were conducted to examine differences 
in baseline characteristics according to surveillance status. 32,42  Using the survival analysis methods 
described previously, patients were weighted by the stabilized inverse probability weights to form 
adjusted hazard ratios and survival probabilities. 99 For the PBM method, survival analyses were 
restricted to patients who were matched based on the PS. 
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Lead Time Bias Adjustments 
An important consideration when estimating the impact of surveillance on survival is the potential 
for lead time bias. This bias may occur if surveillance merely detects the tumor at an earlier stage 
without affecting the course of disease, leading in an overestimation of survival gains associated with 
surveillance. 2 Using a similar approach described by Trevisani et al. (2004, 2007), “lead time” was 
approximated using the well-established formula for tumor growth, first proposed by Schwartz (1961): 
10,11,13 
  t = 
   	





	
       
where:   t   = time interval between measurements (days) 
 DT = tumor volume doubling time (days) 
 D0 = tumor diameter at first measurement 
 D1 = tumor diameter at last measurement 
 
Using the formula, lead time represents the time interval (t, in days) for the primary tumor to grow from 
the median diameter among patients in the surveillance group (D0) to the median diameter among 
patients in the no surveillance group (D1).  Sensitivity analyses assessed different assumptions about the 
DT, based on the range of median DT (i.e., 60, 130, 200 days) estimated across published tumor growth 
studies conducted among the general population of HCC tumors (synthesized in Chapter 4).
 14-27
 The 
estimated lead times were subtracted from the survival of patients in the surveillance group.  For cases 
in which survival became negative, time of death/censoring was reassigned to 1 day.   Survival curves 
were re-estimated using the lead time adjusted survival estimates, as described above. 
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Results 
 A total of 1,533 patients from the HCC BRIDGE study in Taiwan met the study inclusion criteria 
(Figure 5.1).  Primary treatment approaches for the full HCC BRIDGE study (n=1,587) compared with the 
final sample (96.6% of full sample) were not statistically different (p=0.8), suggesting that unavailable 
patient characteristics and follow-up information were primarily missing at random (data not shown).    
The majority of patients diagnosed with HCC were male (72.0%) with a mean age of 61.0 ± 12.4 
years (Table 5.1).  HCC etiology was primarily related to chronic HBV (64.0%) and HCV (31.5%) infection.  
Most patients had well-preserved liver function (CP A/no cirrhosis: 92.2%), and a moderate percentage 
of patients had co-morbidities, such as diabetes (20.3%), CVD (10.6%), and hypertension (35.0%), with 
16.4% of patients presenting with more than one comorbidity.   
A total of 829 patients (54.1%) underwent HCC surveillance prior to HCC diagnosis (Table 5.1).  
Patients who received surveillance were slightly older (mean age: 62.1 years vs. 59.7; p=0.0002), with a 
lower percentage of males (66.8% vs. 78.1%; p<0.0001) compared with patients who did not receive 
surveillance.  HCC etiology also significantly differed according to surveillance status; chronic HCV 
infection was more frequent (38.6% vs. 23.2%; p<0.0001), and ALD (3.3% vs. 5.5%; p=0.03) was slightly 
less frequent in the surveillance group than in the no surveillance group.  In addition, the frequency of 
advanced liver cirrhosis (CP B-C) was significantly lower among patients who received surveillance 
versus no surveillance (4.5% vs. 11.6%; p<0.0001).  
Following PS adjustment, baseline characteristics were generally balanced across the 
surveillance groups (Appendix G).  As expected, baseline characteristics for the PS weighted sample 
were similar to the original study sample, whereas characteristics of patients who were matched based 
on the PS were similar to those of the surveillance group.  
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Tumor Characteristics and Primary Treatment 
 A higher percentage of patients who underwent surveillance were diagnosed with early HCC, 
defined as a solitary tumor ≤ 5 cm (66.1% vs. 28.8%), and fewer patients had advanced HCC (5.9% vs. 
25.5%), compared with patients who did not undergo surveillance (Table 5.2; overall p<0.0001).  
Likewise, primary tumor size was significantly smaller in the surveillance group (median, interquartile 
range:  2.6, 2.0-3.8 cm) compared with the no surveillance group (5.8, 3.3-10.0 cm).  Surveillance 
resulted in a higher percentage of patients receiving tumor ablation as the primary treatment (25.1% vs. 
7.1%).  On the other hand, the frequency of surgical resection was similar across the surveillance groups 
(surveillance: 52.1% vs. no surveillance: 53.3%), and few patients received liver transplant (1.2% vs. 
0.4%, respectively).  
Survival Benefit of Surveillance 
Overall 1- and 3-year survival following HCC diagnosis for the full study cohort was 86.6% (95% 
confidence interval [CI]: 84.7-88.2%) and 75.0% (72.4-77.4%), respectively.   Unadjusted survival was 
significantly higher among patients who received surveillance (3-year survival: 85.5%, 82.3-88.2%) than 
among patients who did not undergo surveillance (62.0%, 57.7-65.9%, p<0.0001; Figure 5.2a).  After 
multivariate adjustment, surveillance was associated with a significant 67% - reduction in the hazard of 
death (hazard ratio [HR], 95% CI: 0.33, 0.25-0.42; p<0.0001), compared with no surveillance  (Table 5.3).  
Additional significant factors affecting survival included etiology related to NAFLD (HR, 95% CI: 0.42, 
0.33-0.53), and poor liver function (CP B vs. No Cirrhosis/CP A: 3.93, 2.92-5.28; CP C: 6.73, 1.93-23.45).  
Survival differences according to surveillance status were less pronounced but remained highly 
significant after PS adjustment, using both the PBW (HR, 95% CI: 0.40, 0.32-0.50; p<0.0001) and PBM 
methods (HR, 95% CI: 0.42, 0.33-0.53; p<0.0001).   
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Lead Time Bias Adjustment  
The survival benefit associated with surveillance remained significant after lead time bias 
adjustment using a range in DT of 60-200 days, corresponding to an estimated lead time of 6.8-22.7 
months (all p<0.0001; Figure 5.2b).  Overall 3-year survival in the surveillance group was 83.3% (79.7-
86.3%), 82.0% (78.2-85.3%) and 81.0% (76.5-84.7%) using a DT of 60, 130, and 200 days, respectively, 
compared with 62.0% (57.7-65.9%) in the no surveillance group.   
After PS adjustment, however, survival differences according to surveillance status were 
sensitive to assumptions surrounding the estimated lead time (Figure 5.2c-d).  Using a DT of 130 days, 3-
year survival after PBW and PBM adjustments was 79.0% (75.0-82.5%) and 82.0% (78.2-85.3%) in the 
surveillance group compared with 66.3% (62.1-70.3%) and 71.7% (67.8-75.2%) in the no surveillance 
group, respectively (log-rank p<0.0001 and p<0.001).  When using a DT of 200 days, however, survival 
differences were significant using the PBW method (p=0.02), but were not significant using the PBM 
method for adjustment (p=0.19).  Despite statistical differences in the estimated impact of surveillance, 
survival estimates were consistent across the two PS analysis methods, evidenced by overlap in the CIs 
surrounding the survival probabilities. Using the PBW method, 1- and 3-year survival for a DT of 200 
days were 83.7% (80.6-86.4%) and 75.8% (70.8-80.0%) in the surveillance group compared with 80.1% 
(76.8-82.9%) and 66.3% (62.1-70.3%) in the no surveillance group, respectively. Corresponding 1- and 3-
year survival for surveillance, using the PBM method and a DT of 200 days, were 85.7% (82.7-88.2%) and 
81.0% (76.5-84.7%) versus 84.7% (81.9-87.1%) and 71.7% (67.8-75.2%) for no surveillance, respectively.  
Differences in survival using the two PS analysis methods can be explained by slightly different baseline 
characteristics in the underlying sample of HCC patients (Appendix G).   
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Discussion 
 In this cohort of patients diagnosed with HCC in Taiwan, HCC surveillance was associated with 
earlier disease detection, increased rate of curative treatment, and improved survival. To the best of our 
knowledge, this is the first study to assess the current impact of surveillance on the survival of HCC 
patients in clinical practice in Taiwan, controlling for both selection bias through PS analysis and lead 
time bias using DT adjustments. The results suggest that the survival benefit associated with surveillance 
is consistent when using different methods of lead time and PS adjustment, with one exception. Using a 
DT of 60 or 130 days to correct for lead time, survival differences across surveillance groups remained 
statistically significant, regardless of PS analysis method used. On the other hand, when assuming a DT 
of 200 days, differences in survival across surveillance groups were marginal and even non-significant, 
depending on the method of PS adjustment.  
 In interpreting these results, it is important to note that the lead time adjustments used in this 
study were approximated based on current knowledge surrounding HCC tumor growth. The range in DT 
(60-200 days) to estimate lead time was chosen based on the full range of median DT estimated across 
tumor growth studies (see Chapter 4).
 14-27
  Using the well established formula for tumor growth and 
differences in median tumor size across surveillance groups, this range in DT translated to a broad range 
in estimated lead time from approximately 7 to 23 months.
 13
 Thus, the expected lead time resulting 
from earlier HCC diagnosis remains uncertain.  Tumor growth in HCC is highly heterogeneous across 
individuals, and other aspects of HCC progression, including the development of multinodular HCC, 
vascular invasion and tumor metastases, are not fully understood.
 14-27
   
Prior observational studies of surveillance, using similar methods for lead time bias adjustment, 
have used a smaller range in DT from 60 to 120 days.
 10-12
 A smaller study conducted in Hong Kong found 
that surveillance among HCC patients with chronic HBV (n=492) was associated with a significant 
increase in survival when using a DT up to 90 days (estimated lead time = 8 months; p<0.0001).
 12
  On 
  106 
the other hand, when assuming a DT of 120 days (lead time = 10 months), survival differences across 
surveillance groups were no longer significant (p=0.18). To some extent, the lower survival benefits 
associated with surveillance may be explained by differences in the surveillance protocol employed.  In 
the current study, surveillance was generally conducted every 6 months using US with or without AFP, 
whereas in the prior study, surveillance was conducted with AFP every 6 months and US every 1-2 years.  
As a result, the prior study noted a larger median tumor diameter in the surveillance group (4.2 cm vs. 
2.6 cm in the current study), and much lower use of surgical resection (20% vs. 52%).  Additional large-
scale studies conducted in regular clinical practice are needed to establish whether survival gains 
associated with surveillance withstand assumptions surrounding estimated lead time. 
  After PS adjustment to address nonrandom allocation of surveillance, the survival benefit 
associated with surveillance in this study was also slightly higher compared with results reported in the 
seminal trial of HCC surveillance in China, conducted by Zhang et al.
 9
   In the current study, surveillance 
was associated with a 58% - reduction in the hazard of death prior to lead time bias adjustment (HR, 
95% CI: 0.42, 0.33-0.53, using PBM method).  In contrast, Zhang et al. found a 37% - reduction in HCC 
mortality associated with surveillance (relative risk [RR], 95% CI: 0.63, 0.41–0.98).
 9
  There are several 
possible explanations for the larger survival benefit associated with surveillance in the current study.  
Although Zhang et al. initially recruited a large sample of high-risk patients, a relatively small number of 
HCC cases were detected (n=153); thus, the trial may have been underpowered to detect survival 
differences. In addition, compliance with the trial protocol for surveillance was poor (less than 60%), 
which may have lead to the lower frequency of early HCC (tumor < 5 cm) among individuals who 
received surveillance (45.3% in prior trial vs. 66.1% in the current study).  Lastly, HCC treatment 
approaches have evolved substantially since Zhang et al. conducted the trial in 1993-1998.  In particular, 
local ablation has emerged as a less invasive alternative to resection for individuals with early stage 
tumors.
 2,71
 In addition, with advancements in surgical techniques, a larger number of multinodular 
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tumors are now considered resectable, with 3-year survival reaching as high as 56%.
 61-63
 Further 
advancements in curative treatment options for HCC will likely increase the survival advantages 
associated with HCC surveillance. 
In interpreting the results of this study, it is important to note that HCC patients were treated at 
a large tertiary hospital with an established liver care center. Thus, the results may represent a more 
ideal scenario in which patients were routinely screened and provided appropriate care.  Whereas more 
than half of all patients included in this study received surveillance prior to HCC diagnosis, prior research 
suggests that patient compliance with surveillance is often poor.
 9
 Furthermore, physician’s level of 
experience in staging and treating HCC patients can have a profound impact on survival outcomes.
 46,137
 
An earlier trial conducted in China noted that screening with AFP led to earlier diagnosis, but did not 
result in an overall reduction in mortality largely due to ineffective treatment.
 46
  Community-based 
screening projects conducted in Taiwan have suggested that two-stage screening programs consisting of 
AFP followed by US among suspected cases of HCC is economically feasible with a large proportion of 
HCC cases detected in the early disease stage.
 7,138-140
 On the other hand, the lack of a suitable 
comparator group has limited survival comparisons to establish the survival impact of surveillance in this 
setting. 
 7
  Therefore, additional research is needed to understand the current impact of non-compliance 
and geographical variations in access to effective HCC treatments on the survival benefits associated 
with surveillance in Taiwan.  
This study provides valuable insights into the current impact of surveillance on the survival of 
patients diagnosed with HCC, using a broad range of assumptions surrounding tumor growth in HCC to 
address lead time bias. In addition, the large number of HCC cases and detailed clinical data allowed for 
PS adjustment to reduce elements of selection bias.  Nevertheless the study has several limitations.  
First, as with any retrospective study of patient medical records, data on clinical characteristics were 
based solely on documented evidence in the patient medical record.  As a result, potential miscoding of 
  108 
clinical characteristics may have been present, and approximately 3% of the study sample was excluded 
due to missing surveillance status, disease stage, or follow-up information.  
Another limitation is the incomplete definition of HCC surveillance, which indicates whether the 
patient underwent surveillance prior to diagnosis, but does not account for the duration and frequency 
of surveillance. For patients treated at the University hospital, surveillance was provided using a 
standard protocol (i.e., US and AFP every 6 months); however, surveillance provided to patients 
diagnosed at another hospital/clinic prior to referral may have differed and was not consistently 
recorded.  As a result, there is some possibility that certain patients in the no surveillance group had 
some monitoring of liver disease.  Thus, the true benefit of HCC surveillance may be slightly greater than 
the observed benefit found in this study. Lastly, this study identifies the impact of HCC surveillance on 
survival, based on current practice, but does not distinguish differences in the impact of surveillance 
among different risk groups and factors that affect their implementation.  A better understanding of 
these associations can help target and increase participation in surveillance programs among the broad 
population of individuals at high-risk for HCC in Taiwan. 
In conclusion, currently recommended surveillance strategies in Taiwan, using abdominal US 
and AFP, are associated with earlier disease detection, increased use of curative treatment, and 
improved survival.  The results of this study suggest that the survival benefit associated with surveillance 
remains significant following adjustment using a plausible range in estimated lead time and methods to 
control for selection bias. However, when assuming the upper range in median DT estimated across 
prior tumor growth studies, the survival gains associated with surveillance are only marginal or even 
non-significant, depending on the method of PS adjustment. Additional large-scale studies, using similar 
methods for lead time and selection bias adjustment, are needed to establish whether survival gains 
associated with surveillance withstand differences in compliance with surveillance and access to 
effective HCC treatments in Taiwan.  
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Table 5.1: Demographics and clinical characteristics for patients diagnosed with HCC in Taiwan, 
according to surveillance status. 
 
Characteristic *  
All Patients  
(n=1,533)  
Surveillance  
(n=829)  
No Surveillance  
(n=704)  p-value 
Age (years)  61.0 ± 12.4  62.1 ± 11.7  59.7 ± 13.1  0.0002 
Male Gender 1,104 (72.0) 554 (66.8)   550 (78.1) <0.0001 
Co-morbidities  
Diabetes mellitus 311 (20.3) 165 (19.9) 146 (20.7) 0.7 
CVD 162 (10.6)   80 (9.7) 82 (11.7) 0.2 
Hypertension 536 (35.0) 282 (34.0)   254 (36.1) 0.4 
HCC Etiologies  
HBV 981 (64.0) 532 (64.2) 449 (63.8) 0.9 
HCV 483 (31.5) 320 (38.6) 163 (23.2) <0.0001 
ALD  66 (4.3)   27 (3.3) 39 (5.5) 0.03 
NAFLD 126 (8.2) 62 (7.5) 64 (9.1) 0.3 
Other/Idiopathic 114 (7.4) 20 (2.4) 94 (13.4) <0.0001 
Liver Function  
CP A/No Cirrhosis  1,414 (92.2) 792 (95.5) 622 (88.4) 
CP B 114 (7.4) 37 (4.5) 77 (10.9) <0.0001 
CP C   5 (0.3) 0 (0.0)   5 (0.7) 
 
ALD = alcohol liver disease, CP = Child-Pugh score, CVD = cardiovascular disease, HBV = hepatitis B virus, HCC = 
hepatocellular carcinoma, HCV = hepatitis C virus, NAFLD = non-alcoholic fatty liver disease 
 
* Values are expressed as mean ± standard deviation and n (%) for continuous and categorical variables, 
respectively.    
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Table 5.2: Tumor characteristics and primary treatment approaches for patients diagnosed with HCC 
in Taiwan, according to surveillance status.  
 
Characteristic *  
All Patients  
(n=1,533)  
Surveillance  
(n=829)  
No Surveillance  
(n=704)  p-value  
Tumor Characteristics, n = 1,502**  
Tumor Size  3.4 (2.2-6.5) 2.6 (2.0-3.8) 5.8 (3.3-10.0) <0.0001 
Solitary HCC † 993 (66.1) 609 (75.0) 384 (55.6) <0.0001 
≤ 5 cm 736 (49.0) 537 (66.1) 199 (28.8)  
> 5 cm 257 (17.1) 72 (8.9) 185 (26.8) 
Multinodular HCC † 285 (19.0) 155 (19.1) 130 (18.8) 
2-3 Tumors, size ≤ 3 cm 101 (6.7) 77 (9.5) 24 (3.5) 
2-3 Tumors, size > 3 cm 101 (6.7) 46 (5.7) 55 (8.0) 
≥ 4 Tumors 83 (5.5) 32 (3.9) 51 (7.4) 
Advanced HCC   224 (14.9) 48 (5.9) 176 (25.5) 
Vascular Invasion 129 (8.6) 35 (4.3) 94 (13.6) 
Tumor Metastases 95 (6.3) 13 (1.6) 82 (11.9) 
Primary Treatment    <0.0001 
Resection 807 (52.6) 432 (52.1) 375 (53.3)  
Transplant   13 (0.8) 10 (1.2)   3 (0.4)  
Ablation 258 (16.8) 208 (25.1) 50 (7.1)  
TA Therapy  357 (23.3) 169 (20.4)   188 (26.7)  
Systemic Therapy 73 (4.8) 10 (1.2) 63 (8.9)  
Supportive Care 21 (1.4) 0 (0.0) 21 (3.0)  
Radiation/Other    4 (0.3) 0 (0.0) 4 (0.6)  
 
HCC = hepatocellular carcinoma, TA = trans-arterial 
 
* Values are expressed as median (interquartile range) and n (%) for continuous and categorical variables, 
respectively.    
 
** Represents the sample size with complete tumor characteristics information at diagnosis.  
 
† Patients in these categories have no venous invasion or tumor metastases. 
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Table 5.3: Cox proportional hazards model of the association between surveillance status and overall 
survival for patients diagnosed with HCC in Taiwan, controlling for other patient characteristics. 
 
All Patients 
(n = 1,533) 
Characteristics *  HR (95% CI) ** p-value 
Surveillance  
Surveillance (vs. No Surveillance)  0.33 (0.25-0.42) <0.0001 
Characteristics  
Age (per 1 year)  1.00 (0.99-1.01) 0.67 
Male gender  1.20 (0.92-1.59) 0.19 
Co-morbidities  
Diabetes mellitus  1.24 (0.94-1.64) 0.13 
CVD  1.26 (0.88-1.80) 0.21 
Hypertension  0.98 (0.76-1.27) 0.89 
 HCC Etiology  
HBV  0.74 (0.47-1.16) 0.19 
HCV  0.85 (0.54-1.31) 0.46 
ALD  0.96 (0.57-1.61) 0.87 
NAFLD  0.23 (0.12-0.42) <0.0001 
Other/Idiopathic 0.66 (0.36-1.20) 0.18 
Liver Function  
CP B (vs. CP A/No Cirrhosis) 3.93 (2.92-5.28) <0.0001 
CP C  6.73 (1.93-23.45) 0.0028 
 
ALD = alcohol liver disease, CI = confidence interval, CP = Child-Pugh score, CVD = cardiovascular disease, HBV = 
hepatitis B virus, HCC = hepatocellular carcinoma, HCV = hepatitis C virus, HR = hazard ratio, NAFLD = non-alcoholic 
fatty liver disease 
 
* Analyses additionally controlled for year of HCC diagnosis. 
 
** To test the proportional hazard assumption, log cumulative hazard plots stratified by surveillance status were 
estimated; the plots were approximately parallel, suggesting little evidence of departure from the proportional 
hazard assumption.
 31
 
  
  
Figure 5.1: Sample selection from the HCC BRIDGE study in Taiwan.
 
 
 
HCC = hepatocellular carcinoma, HCC BRIDGE = The Bridge to Better Outcomes in Hepatocellular Carcinoma Study 
 
* Note: According to the inclusion criteria for the HCC BRIDGE study, the study sample included complete 
information on primary treatments follow
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ing HCC diagnosis. 
 
 
 
  
Figure 5.2: Kaplan-Meier survival curves for patients diagnosed with HCC, according to surveillance 
status: A) Unadjusted for Lead Time Bias and Selection Bias, B) Lead Time Bias Adjustment, using DT = 
60-200 days,* C) Propensity-Based Weighting and Lead Time Bias Adjustment, using DT = 60
days,* D) Propensity-Based Matching ** and Lead Time Bias Adjustment, using DT = 60
 
 
 
log-rank test:
†
  p<0.0001 
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log-rank test:† DT=60 days, p<0.0001; DT=130 days, p<0.0001; DT=200 days, p<0.0001 
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log-rank test:
†
 DT=60 days, p<0.0001; DT=130 days, p<0.0001; DT=200 days, p=0.02
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log-rank test:
†
 DT=60 days, p<0.0001; DT=130 days, p<0.001; DT=200 days, p=0.19
DT = tumor volume doubling time, HCC = hepatocellular carcinoma, No. = number
* The range in median tumor volume doubling time (DT) from HCC tumor growth studies (60, 130 and 200 days) 
was applied to the tumor growth formula
surveillance groups (5.8 cm), respectively. The resultant estimated lead times (6.8, 14.7
respectively) were then subtracted from the survival of patients
survival became negative, occurring among n= 48, 136, and 310 patients for DT= 60, 130
respectively, time of death/censoring was reassigned to 1 day. 
** Patients in the no surveillance group were matched with 
of the PS;
 42,141
  a total of 526 patients from the no surveillance group (74.7%) were identified as matches.  To reta
the full sample of patients in the surveillance group, patients in the no surveillance group were sampled 
replacement to achieve a 1:1 ratio of patients in the two groups
† 
Pair-wise statistical comparisons between each estimated survival curve fo
were conducted using the log-rank test.
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, and 22.7 months, 
 who underwent surveillance.  For cases in which 
, and 200 days, 
 
patients in the surveillance group within a 
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CHAPTER 6: POLICY IMPLICATIONS, LIMITATIONS, AND CONCLUSIONS 
Summary of Findings, Policy Implications and Limitations 
 This study used data from the HCC BRIDGE study, the largest longitudinal study of patients 
diagnosed with HCC in China and Taiwan, to examine the impact of HCC surveillance and clarify best 
treatment practices. 29  The analyses conducted in this study represent one of the most comprehensive 
attempts to compare the impact of current treatment approaches on the survival of patients diagnosed 
at various stages of HCC disease.  Furthermore, this study is the first to examine the survival impact of 
different surveillance strategies using multiple approaches to correct for lead time bias, based on 
current knowledge of HCC tumor growth.    
 In Chapter 3, we conducted detailed survival comparisons across current treatment approaches, 
for patients diagnosed at various stages of HCC disease, to re-evaluate the appropriateness of current 
guideline recommendations.  Overall, the significant findings were that patients with intermediate to 
advanced disease tolerated surgical resection and had better outcomes than those who underwent 
alternative modalities of HCC therapy. Furthermore, survival benefits associated with resection 
remained significant after PS adjustment, reducing concern that survival comparisons were biased by 
selection of better surgical candidates.   For intermediate solitary and multinodular HCC, trans-arterial 
therapy significantly increased the hazard of death over resection (hazard ratio [HR] = 2.13, 95% 
confidence interval: 1.57 - 2.92; HR = 2.21,2.06-2.36), following PS adjustment using the method of 
propensity-based weighting.  Another significant finding was that, for early stage disease, patients who 
received tumor ablation did not derive the same benefit as patients who underwent resection (HR=3.55, 
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2.49-5.07).  Despite advancements in the clinical management of HCC, however, the majority of patients 
are diagnosed with intermediate to advanced HCC in China, and survival is generally poor.  
 In Chapter 4, we developed and calibrated an individual-based simulation model of HCC 
surveillance, which combined well-established data on the natural progression of chronic HBV infection 
and HCC disease, along with detailed clinical data from patients diagnosed with HCC in China, to provide 
an accurate portrayal of the impact of surveillance on survival outcomes for individuals who develop 
HCC.   The results of this model suggested that surveillance with US and AFP was associated with earlier 
disease detection, increased use of curative treatment, and improved survival.  Whereas overall 5- and 
10-year survival following HCC development for individuals who did not receive surveillance was only 
28.9% (26.9-29.3%) and 13.5% (12.2-14.4%), 5- and 10-year survival for 6-month US+AFP was as high as 
48.1% (45.4-51.8%) and 30.1% (40.9-47.5%), respectively (log-rank test: p<0.0001). In comparison, 
survival for 12-month US+AFP was similar to using a 6-month interval, with 5- and 10-year survival 
reaching 44.2% (40.9-47.5%) and 27.0% (24.2-30.7%), respectively.  Thus, in the setting of limited 
resources, surveillance performed at 12-month as opposed to 6-month intervals as currently 
recommended in China, can be more easily implemented with little impact on the survival of patients 
who develop HCC. 
 In Chapter 5, we assessed the current impact of surveillance on the survival of HCC patients in 
clinical practice in Taiwan, controlling for both selection bias through PS analysis and lead time bias 
using current knowledge surrounding HCC tumor growth. The results of this study suggest that the 
survival benefit associated with surveillance remains significant following adjustment using a plausible 
range in estimated lead time and methods to control for selection bias. Using a DT of 130 days to adjust 
for lead time bias, 3-year survival after PS adjustment using propensity-based matching was 79.0% 
(75.0-82.5%) in the surveillance group compared with 66.3% (62.1-70.3%) in the no surveillance group, 
respectively (log-rank p<0.0001). 
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This dissertation makes several important contributions to the literature.  The HCC BRIDGE study 
is currently the largest and most comprehensive longitudinal study of patients diagnosed and treated for 
HCC in current clinical practice in China.
 29
  The large number of HCC cases and meticulously collected 
data allowed for detailed survival comparisons according to disease stage at diagnosis, as well as PS 
analysis to reduce elements of selection bias.  The database included data for HCC patients diagnosed 
across 10 tertiary hospitals from 7 geographically diverse cities in mainland China, increasing the 
generalizability of the study outcomes, while also facilitating geographic comparisons in disease stage 
and primary treatment following diagnosis.   Thus, the results of this study can help guide current clinical 
and policy efforts to improve the management of HCC disease and reduce disparities across different 
regions in China. 
To the best of our knowledge, this is the first study to assess the current impact of surveillance 
on the survival of HCC patients in clinical practice in Taiwan, controlling for both selection bias through 
PS analysis and lead time bias using DT adjustments.  Importantly, the HCC BRIDGE study in Taiwan 
included a large number of HCC patients who underwent surveillance to facilitate propensity-based 
matching without sacrificing a large number of HCC cases. The analyses additionally leveraged 
previously established methods for lead time bias adjustment using the well-established formula for 
tumor growth in HCC,
 10-13
 and further extended this work by incorporating the full range in median DT 
estimated across prior tumor growth studies.
 14-27
   As a result, the study provides an accurate portrayal 
of the survival benefit of surveillance using current strategies in Taiwan, controlling for a plausible range 
in estimated lead time.    
Additionally, the detailed clinical information from the HCC BRIDGE study in China, combined 
with well-established data on the epidemiology of chronic HBV infection and tumor growth in HCC, 
presented the unique opportunity to develop an in-depth representation of the natural disease course 
of HCC through the use of an individual-based model.  One of the main strengths of this model was the 
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ability to flexibly incorporate individual-level heterogeneity in HCC disease progression and survival 
outcomes.  Recognizing that previous estimates of tumor growth in HCC are highly variable across 
studies, analyses incorporated a meta-analysis to synthesize estimates of DT in HCC.  Additional 
unknown parameters of HCC disease progression and incidental diagnosis, which cannot be directly 
measured in clinical practice, were calibrated based on clinical data from the HCC BRIDGE study in China. 
The HCC BRIDGE study data was further used to model individual-level heterogeneity in survival with 
treatment using a series of parametric survival curves, which controlled for the main determinants of 
survival with HCC: patient demographics, disease characteristics and liver function.
 2,3
 Lastly, by defining 
survival with HCC from the time of HCC development, as opposed to diagnosis, the model effectively 
removed lead time bias and also accounted for cases of HCC-related mortality prior to HCC diagnosis to 
provide a more accurate portrayal of the true benefit of surveillance among the full population of HCC 
tumors.  This simulation model not only helps to identify the optimal approach for HCC surveillance, but 
also provides a basis for exploring other issues surrounding surveillance, such as poor compliance and 
specific high-risk groups that should be targeted, as policy efforts to improve early detection evolve in 
China. 
There are several limitations to the analyses described in this dissertation.  First, as with any 
retrospective chart review study, data included in the HCC BRIDGE study were based solely on 
documented evidence in the patient medical record.  As a result, potential miscoding of clinical 
characteristics across different hospital sites may have been present.  Approximately 15% of the study 
sample in China was excluded due to missing disease stage or follow-up information; in contrast, only 
3% of the study sample for the hospital site in Taiwan was excluded due to missing relevant information.   
In addition, only treatments provided to patients at each of the participating hospital sites were 
generally documented; thus, the results may not reflect additional treatments if received from other 
sites.  
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For the Aim 3 analyses using the HCC BRIDGE study data in Taiwan, another limitation was the 
incomplete definition of HCC surveillance, which indicated whether patients underwent surveillance 
prior to diagnosis, but did not account for the duration and frequency of surveillance. For patients 
treated at the University hospital, surveillance was provided using a standard protocol (i.e., US and AFP 
every 6 months); however, surveillance provided to patients diagnosed at another hospital/clinic prior 
to referral may have differed and was not consistently recorded.  As a result, there was some possibility 
that certain patients in the no surveillance group had some monitoring of liver disease.  Thus, the true 
benefit of HCC surveillance may be slightly greater than the observed benefit found in this study.  
Whereas the observational study design of the HCC BRIDGE study allowed an accurate portrayal 
of HCC management in regular clinical practice, survival comparisons were complicated due to non-
random allocation of treatment and surveillance.   In order to effectively control for underlying 
differences in patient characteristics across treatments for Aim 1 and between surveillance groups for 
Aim 3, multivariate models were constructed, and PS analysis was further conducted to control for 
selection bias. 32 Nevertheless, residual confounding may still have been present, leading to biased 
survival comparisons.  For Aim 1, the HCC BRIDGE database did not capture information on tumor 
location, which may have lead to biased estimates of the impact of resection on survival among patients 
with multinodular tumors.  More evidence is needed to better understand the comparative 
effectiveness of therapies for this patient population.  In addition, information on socioeconomic status 
would provide relevant context surrounding the decision to undergo surveillance in Aim 1 and treatment 
decisions affecting survival in Aim 3. 
 A major concern when assessing the impact of surveillance on survival is inherent lead time bias 
related to the earlier diagnosis of HCC. 
 8
  To address this bias, lead time adjustments for the Aim 3 
analyses were approximated using the full range of median DT (60-200 days) estimated across tumor 
growth studies, synthesized in Aim 2.
 14-27
  The results suggested that survival gains with surveillance are 
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consistent across these assumptions; however, such methods are based solely on current knowledge 
surrounding HCC tumor growth. Tumor growth in HCC is highly heterogeneous across individuals, and 
other aspects of HCC progression, including the development of multinodular HCC, vascular invasion and 
tumor metastases, are not fully understood.
 14-27
   
An advantage of the simulation model, described in Aim 3, was that survival with HCC could be 
defined from the time of HCC development, as opposed to diagnosis, to effectively remove lead time 
bias and also account for cases of HCC-related mortality prior to HCC diagnosis.  The model provided a 
detailed representation of tumor growth in HCC, based on evidence synthesized across published tumor 
growth studies,
 14-27
 and further sought to expand the representation of disease progression in HCC by 
incorporating individual-level heterogeneity in tumor growth and disease-related complications through 
model calibration.  The model-based projections were generally concordant with trends in the 
distribution of tumor characteristics seen in clinical practice in China (as seen in Aim 1); nevertheless, 
several assumptions were incorporated to simplify the calibration process.  Thus, further research on 
the biological mechanisms surrounding HCC progression, if feasible, would help test and inform the 
model-based assumptions. Likewise, additional large-scale datasets of patients diagnosed with HCC are 
needed to cross-validate the model-based outcomes.   
In interpreting the results of this dissertation, it is important to note that survival outcomes 
from the HCC BRIDGE study were based on data from HCC patients diagnosed and treated at large 
tertiary hospitals in China and Taiwan.  Thus, the results may represent a more ideal scenario in which 
patients were routinely provided appropriate care. Physician’s level of experience in staging and treating 
HCC patients can have a profound impact on survival outcomes. 46,137 A trial conducted in China noted 
that screening with AFP led to earlier diagnosis, but did not result in an overall reduction in mortality 
largely due to ineffective treatment. 46  
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In addition, the analyses in Aim 2 and Aim 3 identified the impact of HCC surveillance on 
survival, based on current practice, but did not distinguish differences in the impact of surveillance 
among different risk groups and factors that affect their implementation.  In Aim 2, for patients treated 
at the University hospital in Taiwan, surveillance was provided using a standard protocol (i.e., US and 
AFP every 6 months).  Data from community-based screening projects in Taiwan have suggested that 
two-stage screening consisting of AFP followed by US among suspected cases of HCC is economically 
feasible with a large proportion of HCC cases detected in the early disease stage. 7,138-140 On the other 
hand, the lack of a suitable comparator group has limited survival comparisons to establish the survival 
impact of surveillance in this setting.  7 Whereas individuals incorporated in the simulation model of HCC 
surveillance were assumed to be fully adherent to the surveillance protocol, results from the seminal 
trial of surveillance in China, which arguably represents a more ideal scenario for patient follow-up, 
suggests that patient compliance with surveillance is often poor (only ~60%). 9  Therefore, additional 
research is needed to understand the current impact of non-compliance and geographical variations in 
access to effective HCC treatments on the survival benefits associated with surveillance in East Asia. 
Lastly, the simulation model in Aim 3 was designed to assess survival among individuals who 
develop HCC as a result of chronic HBV infection, the most common etiology of HCC disease in China, 
representing over 80% of all HCC cases.
 45
   With the implementation of vaccination programs against the 
spread of HBV infection in most parts of East Asia, the underlying risk factors surrounding HCC disease 
will likely change in future generations.
 45,53 
  Further research is needed to understand the impact of 
surveillance among the population of HCC patients with other underlying risk factors, including chronic 
HCV infection and alcohol liver disease, which generally present with more advanced liver disease (CP 
B/C: 30-49%).
 10,28,30,77
   Advanced liver disease has been found to reduce the survival benefit associated 
with surveillance, as these patients are generally not optimal candidates for surgical resection and 
experience higher mortality from liver-disease related complications.
 11
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Despite these limitations, this study is a policy-relevant and timely contribution to the literature 
surrounding the comparative effectiveness of surveillance and current treatment approaches for the 
detection and management of HCC in East Asia.  From this study, it is clear that surveillance among 
individuals at high-risk for HCC significantly improves the survival of patients who develop HCC.  In 
addition, current treatment approaches for HCC in China, which are distinct from other settings in the 
use of surgical resection among more advanced stage patients, are both clinically valid and consistent 
with current guideline recommendations.   
Future Research Agenda 
Considering current issues of poor compliance with surveillance programs in China and other 
settings, a natural extension of this work would be to incorporate assumptions surrounding non-
adherence with surveillance to the simulation model.
 9
  Doing so would provide a more accurate 
portrayal of survival outcomes with surveillance in actual clinical practice, and could help quantify the 
potential impact of increasing compliance with surveillance protocols.  As a starting point, the 
randomized controlled trial of surveillance in China provides information on the proportion of 
individuals who participated in surveillance over the 5-year trial period.
 9
  Using this information as a 
guide, unknown parameters surrounding surveillance program drop-out and general non-attendance 
can be calibrated to reflect the trends seen in the randomized trial.  Following calibration, the survival 
results from the simulation model could be further compared with the results of the randomized trial to 
assess model validity.    
Another natural extension of this work would be to assess the cost-effectiveness of HCC 
surveillance.  Currently, the results of the simulation model suggest that resource use is a concern when 
comparing surveillance conducted in 12-month as opposed to 6-month intervals, given that a large 
number of screening tests are needed to detect one case of HCC with little additional survival benefit.   
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Indeed, clinical guidelines have explicitly considered evidence from prior cost-effectiveness studies 
when forming recommendations surrounding the use of different surveillance strategies.
 2,8
  Likewise, 
assessing the cost-effectiveness in the setting of poor compliance would provide additional context 
surrounding the potential cost and outcomes of increasing participation in surveillance programs.  
As the landscape surrounding HCC disease evolves over time in China, the simulation model can 
also serve as the foundation for evaluating public health policies and clinical decision making.  HBV is 
endemic in China and is a direct risk factor for HCC disease, resulting in a high clinical and economic 
burden to society.
 1
  In response to this challenge, health authorities in East Asia have instituted national 
vaccination campaigns to prevent HBV transmission and effectively lower the incidence of HCC disease 
in the next 20-30 years. 
 45,53 
  In addition, government-funded community-based programs in HBV 
endemic areas are actively screening patients at high-risk for developing HCC and working to increase 
the use of antiviral treatment for HCC prevention. 6,87-89 With the availability of additional data, the 
simulation model can be adapted to facilitate future analyses of HCC surveillance, in addition to the 
effects of antiviral treatment, as HCC disease characteristics and available treatments options evolve 
over time.  
The analyses incorporated in this dissertation identify the impact of surveillance and treatment 
approaches for HCC, based on current practice, but do not distinguish differences in the application of 
surveillance and treatment among different risk groups as well as factors that affect their 
implementation.  Future research should assess the impact of regional differences in access to 
surveillance and HCC treatment, as well as disparities among individuals with various etiologies of 
disease and comorbidities to provide a broader representation of survival outcomes with HCC in East 
Asia.  Qualitative research could further elucidate the contextual factors, such as socioeconomic status 
and cultural beliefs, that affect the decision to undergo regular surveillance and treatment decisions 
following diagnosis in East Asia.    
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Conclusions 
This dissertation revealed that current treatment approaches for patients with HCC in China, 
which largely differ from approaches in other settings, are both clinically appropriate and consistent 
with consensus guideline recommendations. Patients with intermediate to advanced disease tolerate 
surgical resection and have better outcomes than those who undergo alternative modalities of HCC 
therapy.  The results additionally showed that surveillance to detect HCC leads to earlier diagnosis, 
increased use of curative treatment and, consequently, improved survival among individuals who 
developed HCC.  In the setting of limited resources, surveillance performed at 12-month as opposed to 
6-month intervals as currently recommended in China, can be more easily implemented with little 
impact on the survival of patients who develop HCC. This dissertation provides a unique contribution to 
the clinical literature surrounding HCC in that it helps identify optimal approaches for the early detection 
and treatment of HCC.  The findings can help policymakers and clinicians better target efforts to ensure 
that individuals who are at high-risk for developing HCC are properly monitored, and patients with HCC 
receive appropriate treatment to improve survival outcomes. 
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APPENDIX A: TREATMENT APPROACHES CAPTURED IN THE HCC BRIDGE STUDY DATABASE. 
Treatments 
Surgical Resection 
Liver Transplant 
Tumor Ablation 
radiofrequency ablation (RFA), microwave ablation, cryoablation, or percutaneous ethanol injection 
(PEI) 
Trans-arterial (TA) Therapy  
transcatheter arterial chemoembolization (TAE), transcatheter arterial embolization (TAE), trans-
artieral radioembolization (TARE), or intrarterial chemotherapy 
Systemic Therapy 
sorafenib, oxorubucin, gemcitabine, cisplatin, oxaliplatin, capecitabine, interferon, sunitinib, 
bevacizumab, cetuximab, erlotinib, fluorouracil, daunorubicin, epirubicin, mitomycin C, carboplatin, 
lobaplatin, floxuridine, thalidomide, lenalidomide, and other 
Supportive Care 
narcotic and non-narcotic analgesics, laxatives, anti-diarrhea medications, antihistamines, 
antidepressants, anxiolytics, sedative/hypnotics, oxygen, and other 
Radiation Therapy/Other 
radiation therapy, conformal radiation therapy or other loco-regional therapy 
 
HCC BRIDGE = The Bridge to Better Outcomes in Hepatocellular Carcinoma Study 
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APPENDIX B: SUMMARY OF RESULTS FOR THE LITERATURE SEARCH ON PUBLISHED ARTICLES THAT 
ASSESSED THE NATURAL HISTORY OF HEPATOCELLULAR CARCINOMA AMONG INDIVIDUALS WITH 
CHRONIC HEPATITIS B VIRUS INFECTION. 
 
PubMed Search– conducted on May 22, 2012 and updated on February 13, 2014 
 
# Facet Search Terms 
Results 
5/22/12 
Results* 
2/13/14 
1 Hepatitis B “Hepatitis B”[MESH] 41,660 2,340 
2 Hepatocellular carcinoma “Carcinoma, Hepatocellular” [MESH] 51,046 4,490 
3 Liver Cirrhosis “liver cirrhosis” [MESH] 65,710 3,016 
4 HBV/Cirrhosis/HCC  #1 OR #2 OR #3 145,937 8,805 
5 
Epidemiology, Incidence, 
natural history 
“epidemiology”[MESH] OR “natural 
history"[MESH] OR “incidence"[MESH] OR 
“disease progression"[MESH] 
264,858 26,932 
6 
HBV/Cirrhosis/HCC 
epidemiology 
#4 AND #5 5,095 677 
7 
HBV/Cirrhosis/HCC 
epidemiology 
Limited to English Language 4,538 648 
 
Embase Search– conducted on May 22, 2012 and updated on February 13, 2014 
 
# Facet Search Terms 
Results 
5/22/12 
Results* 
2/13/14 
1 
Hepatocellular 
Carcinoma 
'hepatocellular carcinoma'/exp 75,010 14,881 
2 Hepatitis B 'hepatitis b'/exp 60,352 10,058 
3 Liver Cirrhosis 'liver cirrhosis'/exp 108,121 15,016 
4 HBV/Cirrhosis/HCC #1 AND #2 AND #3 3,986 852 
5 Epidemiology, Incidence 'incidence'/exp 224,560 36,733 
6 
HBV/Cirrhosis/HCC 
incidence 
#4 AND #5 395 74 
 
Total on May 22, 2012 (after removal of duplicates): 4,687 Articles 
 
Total on February 13, 2014 (after removal of duplicates): 5,246 Articles 
 
* Searches conducted on February 13, 2014 were restricted to studies published as of May 1, 2012 (PubMed) and 
January 1, 2012 (Embase), respectively.  
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APPENDIX C: SUMMARY OF RESULTS FOR THE LITERATURE SEARCH ON PUBLISHED ARTICLES THAT 
ASSESSED TUMOR GROWTH IN HEPATOCELLULAR CARCINOMA. 
 
PubMed Search – conducted on November 8, 2012 and updated on February 13, 2014 
 
# Facet Search Terms 
Results 
11/8/12 
Results* 
2/13/14 
1 
Hepatocellular 
carcinoma 
“Liver Neoplasms”[Mesh] OR “hepatocellular 
carcinoma”[Title/Abstract] OR “hepatic 
carcinoma”[Title/Abstract] OR “liver 
carcinoma”[Title/Abstract] OR “liver 
cancer”[Title/Abstract] OR “hepatic 
cancer”[Title/Abstract] OR hepatoma[Title/Abstract] 
134,454 13,297 
2 Tumor Growth 
“growth rate”[Title/Abstract] OR “doubling time” 
[Title/Abstract]  OR “tumor volume” [Title/Abstract] 
47,704 5,619 
3 
HCC & Tumor 
Growth 
#1 AND #2 1,321 139 
4 Filter to Human 
Studies/Exclude 
Animal Studies 
Filters: Humans 788 81 
5 #4 NOT (rat[Title/Abstract] OR mice[Title/Abstract]) 569 58 
6 
Exclude HCC 
Treatments 
#5 NOT (“Hepatectomy”[Mesh] OR “resection” 
[Title/Abstract] OR “Liver Transplantation”[Mesh] OR 
“transplant” [Title/Abstract] OR “Ablation 
Techniques”[Mesh] OR ablat* [Title/Abstract] OR 
“cryoablation” [Title/Abstract] OR “percutaneous 
ethanol injection”[Title/Abstract] OR 
“PEI”[Title/Abstract] OR “chemoembolization, 
therapeutic”[Mesh] OR “TACE” [Title/Abstract] OR 
chemoemboliz*[Title/Abstract]  OR “transarterial” 
[Title/Abstract] OR “trans-arterial” [Title/Abstract] 
OR radioemboliz*[Title/Abstract]  OR “TARE” 
[Title/Abstract] OR “chemotherapy” [Title/Abstract] 
OR “erlotinib”[Title/Abstract] OR 
“tarceva”[Title/Abstract] OR 
“sorafenib”[Title/Abstract] OR 
“nexavar”[Title/Abstract] OR 
“brivanib”[Title/Abstract] OR linifanib[Title/Abstract] 
OR "everolimus"[Title/Abstract] OR 
"afinitor"[Title/Abstract] OR 
"ramucirumab"[Title/Abstract]) 
342 26 
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Embase Search – conducted on November 8, 2012 and updated on February 13, 2014 
 
# Facet Search Terms 
Results 
11/8/12 
Results* 
2/13/14 
1 
Hepatocellular 
Carcinoma 
'hepatocellular carcinoma'/exp OR 'hepatocellular 
carcinoma' 
90,442 19,662 
2 'liver cancer'/exp OR 'liver cancer' 138,073 28,302 
3 'liver carcinoma'/exp OR 'liver carcinoma' 84,109 18,440 
4 'liver cell carcinoma'/exp OR 'liver cell carcinoma' 83,711 18,367 
5 #1 OR #2 OR #3 OR #4 143,800 29,435 
6 
Tumor Growth 
'growth rate'/exp OR 'growth rate' 98,578 13,473 
7 'tumor growth'/exp OR 'tumor growth' 87,595 20,726 
8 'tumor volume'/exp OR 'tumor volume' 77,617 23,969 
9 #6 OR #7 OR #8 180,797 53,804 
10 
HCC & Tumor 
Growth 
#5 AND #9 13,206 4,209 
11 
Exclude Animal 
Studies & Non-
Peer-reviewed 
Articles 
#10 NOT ('animal cell'/de OR 'animal experiment'/de 
OR 'animal model'/de OR 'animal tissue'/de OR 'case 
report'/de OR 'in vitro study'/de OR 'nonhuman'/de 
OR 'book'/it OR 'conference abstract'/it OR 
'conference paper'/it OR 'conference review'/it OR 
'editorial'/it OR 'erratum'/it OR 'letter'/it OR 'note'/it 
OR 'short survey'/it) 
5,785 1,458 
12 #11 NOT ('mice'/exp OR 'mice' OR 'rat'/exp OR 'rat') 2,333 1,404 
13 
HCC Treatments 
(for exclusion) 
'liver'/exp OR liver AND ('resection'/exp OR 
resection) 
247,451 44,560 
14 'liver transplantation'/exp OR 'liver transplantation' 70,416 14,080 
15 
'radiofrequency ablation'/exp OR 'radiofrequency 
ablation' 
17,186 5,293 
16 'cryoablation'/exp OR cryoablation 3,450 1,097 
17 'microwave therapy'/exp OR 'microwave therapy' 1,243 463 
18 'percutaneous ethanol injection' 1,407 117 
19 'chemoembolization'/exp OR chemoembolization 7,563 2,505 
20 radioembolization 693 505 
21 'embolization'/exp OR embolization 59,138 11,464 
22 'chemotherapy'/exp OR chemotherapy 557,379 94,157 
23 'sorafenib'/exp OR sorafenib 11,148 5,077 
24 'brivanib'/exp OR brivanib 338 248 
25 'radiotherapy'/exp OR radiotherapy 496,002 72,327 
26 'systemic therapy'/exp OR 'systemic therapy' 13,313 4,823 
27 #12 thru #26 connected with OR 1,216,062 191,114 
28 
Exclude HCC 
Treatments 
#12 NOT #27 1,701 370 
 
Total (after removal of duplicates): 1,912 Articles 
 
Total on February 13, 2014 (after removal of duplicates): 2,186 Articles 
 
* Searches conducted on February 13, 2014 were restricted to studies published as of November 1, 2012 
(PubMed) and January 1, 2012 (Embase), respectively.  
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APPENDIX D: SUMMARY OF PUBLISHED STUDIES THAT ASSESSED TUMOR GROWTH IN HEPATOCELLULAR CARCINOMA AND REPORTED 
ESTIMATES FOR TUMOR VOLUME DOUBLING TIME (N=19), GROUPED ACCORDING TO INCLUSION STATUS IN THE POOLED META-ANALYSIS.† 
Study, Year Country 
Imaging 
Modality 
N = tumors 
(n=patients) Follow-up (months) 
Initial Tumor Size, 
diameter (cm) 
Tumor Volume Doubling Time 
(DT, days) * 
Included Studies (n=14) †      
Yoshino et al., 
1983
 14
 
Japan US or CT 
N = 16  
(n = 13) 
Mean ± SD: 5.2 ± 3.1 
Range: 0.3-9.6 
Mean ± SD: 3.0 ± 1.5 
Range: 0.9-6.5 
Mean, 95% CI: 104, 71-153 
Median: 112.5 
Range: 41-315 
       
Sheu et al.,  
1985
 15
 
Taiwan US 
N = 30  
(n = 28) 
Mean: 7.8 
Range: 1.2-28.3 
Mean ± SD: 2.3 ± 0.8 
Range: 1.1-4.1 
Mean, 95% CI: 111, 87-142 
Median: 117 
Range: 29-398 
Ebara et al.,  
1986
 16
 
Japan US N = 22 
Mean: 21.6 
Range: 6-37 
Mean ± SD: 1.9 ± 0.6 
Range: 1.0-3.0 
Mean ± SD: 196 ± 173 
Range: 30-593 
Okazaki et al., 
1989
 17
 
Japan US & CT N = 15 Range: 1.0-13.0 
Mean ± SD: 2.8 ± 1.0 
Range: 1.3-4.5 
Mean, 95% CI: 83, 59-118 
Median: 71 
Range: 41-305 
Barbara et al., 
1992
 18
 
Italy US 
N = 59  
(n = 39) 
Mean ± SD: 12.0 ± 7.5 
Range: 3.0-31.6 
Range: 0.7-5.0 
Mean ± SD: 204 ± 135 
Median: 172 
Range: 27-606 
Imaeda et al.,  
1993
 19
 
Japan CT N = 18 
Mean ± SD: 12.1 ± 8.3 
Range: 3.8-35.0 
Mean ± SD: 1.9 ± 0.7 
Range: 0.4-3.0 
Mean, 95% CI: 71, 54-94 
Median: 67 
Range: 28-230 
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Study, Year Country 
Imaging 
Modality 
N = tumors 
(n=patients) Follow-up (months) 
Initial Tumor Size, 
diameter (cm) 
Tumor Volume Doubling Time 
(DT, days) * 
Saitoh et al.,  
1995
 20
 
Japan 
CEUS or 
CT 
N = 17  
(n = 12) 
Mean ± SD: 10.2 ± 4.3 
Range: 4.2-22.3 
Mean ± SD: 1.6 ± 0.6 
Range: 1.0-3.1 
Mean, 95% CI: 272, 204-363 
Median: 299 
Range: 89-607 
Ebara et al.,  
1998
 21
 
Japan US N = 30 
Mean ± SD: 20.9 ± 
11.5 
Range: 6-48 
Mean ± SD: 1.8 ± 0.6 
Range: 0.8-2.9 
Mean, 95% CI: 167, 121-230 
Range: 30-1,086 
Saito et al.,  
1998
 22
 
Japan US N = 21 
Mean ± SD: 7.6 ± 6.0 
Range: 2.0-25.1 
Mean ± SD: 1.8 ± 0.8 
Range: 0.6-3.0 
Mean, 95% CI: 169, 128-223 
Median: 143 
Range: 76-720 
Nakajima et al., 
2002
 23
 
Japan 
US, CT or 
MRI 
N = 34 
Mean ± SD: 3.9 ± 2.3 
Range: 0.4-8.3 
Mean ± SD: 2.4 ± 1.2 
Range: 0.4-5.9 
Mean, 95% CI: 70, 54-91 
Median: 74 
Range: 17-274 
Kubota et al.,  
2003
 24
 
Japan CT N = 22 
Mean ± SD: 9.4 ± 9.1 
Range: 0.9-35.7 
Mean ± SD: 1.0 ± 0.7 
Range: 0.3-3.0 
Mean, 95% CI: 88, 64-121 
Median: 83 
Range: 33-496 
Saftoiu et al.,  
2004
 25
 
Romania US N = 27 ≥ 6 
Mean ± SD: 6.8 ± 2.3 
Range: 1.5-12.7 
Mean ± SD: 140 ± 122 
Median: 160 
Range: 28-580 
Taouli et al.,  
2005
 26
 
United 
States 
CT or 
MRI 
N = 16  
(n = 11) 
Mean, 95% CI: 5.8, 
1.6-20.5 
Range: 2.5-15.5 
Mean, 95% CI: 3.0, 2.4-3.7 
Range: 1.4-8.0 
Mean, 95% CI: 127, 80-203 
Range: 17-541 
Shingaki et al., 
2013
 27
 
Japan CT N = 22 
Mean ± SD: 1.5 ± 0.8 
Range: 0.5-3.7 
Mean ± SD: 2.6 ± 1.4 
Mean ± SD: 91 ± 94 
Range: 9-406 
  
1
3
3
 
Study, Year Country 
Imaging 
Modality 
N = tumors 
(n=patients) Follow-up (months) 
Initial Tumor Size, 
diameter (cm) 
Tumor Volume Doubling Time 
(DT, days) * 
Excluded Studies (n=3)      
Cucchetti et al., 
2005
 122
 
Italy 
CT or 
MRI 
N = 62 
Median: 2.6 
Range: 0.7-4.1 
Median: 3.2 
Range: 1.2-6.8 
Median: 80 
Range: 13-356 
Choi et al.,  
2007
 123
 
United 
States 
MRI 
N = 33  
(n = 21) 
Mean: 12.4 
Mean: 1.1 
Range: 0.6-1.9 
Mean: 285, 
Median: 188 
Range: 69-2,042 
Furlan et al.,  
2012
 124
 
United 
States 
MRI 
N = 69  
(n = 48) 
Mean: 8.8 
Range: 1.3-33.3 
Mean ± SD: 1.2 ± 0.3 
Range: 0.5-2.0 
Median: 210, 
Range: 30-2,671 
 
Cat. = category, CI = confidence interval, CT = computed tomography, HCC = hepatocellular carcinoma, MRI = magnetic resonance imaging, SD = standard 
deviation, US = ultrasound 
† To satisfy the normality assumption for the random effects model, the meta-analysis was conducted using the geometric mean
 
± SD for DT to achieve 
normality at the log-scale.
 39,125
 Studies were included in the meta-analysis if they directly estimated the geometric mean,
 24,26
 or provided raw data to allow 
estimation of the geometric mean.
 14,15,17,19-23
 For studies that only estimated the arithmetic mean ± SD,
 16,18,25,27
 the geometric mean
 
and 95% CI were 
approximated using previously validated methods.
 125
 Studies that provided only the median and range for DT were ultimately excluded.
 122-124
 
* Mean, 95% CI represents the geometric mean and 95% confidence interval, unless where noted,
 16,18,25,27
 mean ± SD represents the arithmetic mean and 
standard deviation.   
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APPENDIX E:  SUMMARY OF RESULTS FOR THE LITERATURE SEARCH ON PUBLISHED ARTICLES THAT 
ASSESSED THE ACCURACY OF DIAGNOSTIC IMAGING MODALITIES FOR THE DETECTION OF 
HEPATOCELLULAR CARCINOMA. 
 
PubMed Search – conducted on November 18, 2012 and updated on February 13, 2014 
# Facet Search Terms 
Results 
11/18/12 
Results* 
2/13/14 
1 
Hepatocellular 
carcinoma 
“Liver Neoplasms”[Mesh] OR “hepatocellular 
carcinoma”[Title/Abstract] OR “hepatic 
carcinoma”[Title/Abstract] OR “liver 
carcinoma”[Title/Abstract] OR “liver 
cancer”[Title/Abstract] OR “hepatic 
cancer”[Title/Abstract] OR 
hepatoma[Title/Abstract] 
134,622 13,297 
2 AFP 
"alpha-Fetoproteins"[Substance Name] OR alpha-
fetoprotein[Title/Abstract] OR α-
fetoprotein[Title/Abstract] OR α-
foetoprotein[Title/Abstract] OR alpha-
foetoprotein[Title/Abstract] OR “alpha 
fetoprotein”[Title/Abstract] OR “α 
fetoprotein”[Title/Abstract] OR “α 
foetoprotein”[Title/Abstract] OR “alpha 
foetoprotein”[Title/Abstract] OR 
alphafetoprotein[Title/Abstract] OR 
alphafoetoprotein[Title/Abstract] OR 
AFP[Title/Abstract] 
20,645 1,539 
3 Ultrasound 
Ultrasonography[Mesh] OR 
ultrasound[Title/Abstract] OR 
“ultrasonography”[Title/Abstract] OR 
“ultrasonographic”[Title/Abstract] OR 
“ultrasonic”[Title/Abstract] 
365,903 37,431 
4 CT 
"Tomography, X-Ray Computed "[MESH] OR 
“computed tomography”[Title/Abstract] OR 
“computerized tomography”[Title/Abstract] OR 
“computer tomography”[Title/Abstract] OR 
“Computed axial tomography” [Title/Abstract] OR 
“CT”[Title/Abstract] 
399,941 53,745 
5 MRI 
"Magnetic Resonance Imaging"[Mesh] OR 
"magnetic resonance imaging"[Title/Abstract] OR 
“MRI”[Title/Abstract] 
330,612 49,056 
6 Biopsy Biopsy[Mesh] OR biopsy[Title/Abstract] 331,470 26,173 
7 Combine Imaging #2 OR #3 OR #4 OR #5 1,242,312 143,083 
8 HCC Imaging #1 AND #7 29,872 3,006 
9 
Diagnostic 
Imaging Accuracy  
"Sensitivity and Specificity"[Mesh] OR “Predictive 
Value of Tests”[Mesh] OR “False Negative 
Reactions”[Mesh] OR “False Positive 
Reactions”[Mesh] OR sensitivity[Title/Abstract] 
OR specificity[Title/Abstract] OR “predictive 
value”[Title/Abstract] OR “false 
962,505 110,324 
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positive”[Title/Abstract] OR “false 
negative”[Title/Abstract] 
10 
HCC Imaging 
Accuracy 
#8 AND #9 4,472 658 
12 
Exclude Colorectal 
Cancer 
Metastases 
#10 NOT ("colon"[Title/Abstract] OR 
"colorectal"[Title/Abstract] OR "Colorectal 
Neoplasms"[Mesh] OR "Colonic 
Neoplasms"[Mesh]) 
3,888 593 
11 
Published as of 
01/01/2000 * 
#10   Filters: Publication date from 2000/01/01 
 
2,538 ---- 
 
Embase Search – conducted on November 18, 2012 and updated on February 13, 2014 
# Facet Search Terms  
Results* 
11/8/12 
Results** 
2/13/14 
1 
Hepatocellular 
Carcinoma 
'hepatocellular carcinoma'/exp OR 'hepatocellular 
carcinoma' 
90,442 19,662 
2 'liver cancer'/exp OR 'liver cancer' 138,073 28,302 
3 'liver carcinoma'/exp OR 'liver carcinoma' 84,109 18,440 
4 'liver cell carcinoma'/exp OR 'liver cell carcinoma' 83,711 18,367 
5 #1 OR #2 OR #3 OR #4 143,800 29,435 
6 
AFP 
'alpha fetoprotein'/exp OR 'alpha fetoprotein'  10,997 3,074 
7 afp  9,758 3,264 
8 #6 OR #7 16,917 5,219 
9 
Ultrasound 
'ultrasonography'/exp OR ultrasonography  305,439 83,383 
10 'ultrasound'/exp OR ultrasound 175,438 51,656 
11 ultrasonographic  11,474 2,469 
12 'ultrasonic'/exp OR ultrasonic  71,449 23,834 
13 #9 OR #10 OR #11 OR #12 398,626 112,001 
14 
CT 
'computer assisted tomography'/exp OR 
'computer assisted tomography'  
365,298 102,980 
15 
'computed tomography'/exp OR 'computed 
tomography'  
378,174 106,695 
16 ct  275,181 86,504 
17 #14 OR #15 OR #16 523,678 152,047 
18 
MRI 
'magnetic resonance imaging'/exp OR 'magnetic 
resonance imaging'  
375,963 113,592 
19 'mri'/exp OR mri  375,451 113,551 
20 #18 OR #19 387,984 116,711 
21 Biopsy 'biopsy'/exp OR biopsy  305,771 84,091 
22 Combine Imaging #8 OR #13 OR #17 OR #20 OR #21 1,305,103 371,561 
23 HCC Imaging #5 AND #22 27,670 9,144 
24 
Diagnostic 
Imaging Accuracy 
'sensitivity and specificity'/exp OR 'sensitivity and 
specificity'  
164,355 43,533 
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Total on November 18, 2012 (after removal of duplicates): 3,564 Articles 
Total on February 13, 2014 (after removal of duplicates): 4,341 Articles 
 
* Both the PubMed and Embase searches were restricted to articles published as of January 1, 2000 to ensure both 
accurate and current assessments of the diagnostic accuracy of the HCC imaging modalities listed above. The year 
2000 was deemed an appropriate cut-point based on a review of HCC diagnostic imaging studies referenced in a 
prior health technology assessment of HCC surveillance conducted in the United Kingdom.
 83
    
** Searches conducted on February 13, 2014 were restricted to studies published as of November 1, 2012 
(PubMed) and January 1, 2012 (Embase), respectively.  
25 'predictive value'/exp OR 'predictive value'  61,232 34,066 
26 'false negative'  16,113 4,796 
27 'false positive'  27,129 7,981 
28 #24 OR #25 OR #26 OR #27 231,926 73,593 
29 
HCC Imaging 
Accuracy 
#23 AND #28 2,352 948 
30 
Exclude 
Colorectal Cancer 
Metastases 
'colon'/exp OR colon 435,653 71,245 
31 colorectal AND ('cancer'/exp OR cancer) 123,772 30,574 
32 colorectal AND ('carcinoma'/exp OR carcinoma) 42,865 8,691 
33 #30 OR #31 OR #32 448,573 75,133 
34 #29 NOT #33 1,955 789 
  
APPENDIX F: HCC BRIDGE STUDY SAMPLE SELE
 
 
 
Dx = diagnosis, HBV = hepatitis B virus, HCC BRIDGE = BRIDGE to Better Outcomes in Hepatocellular Carcinoma
Study 
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APPENDIX G: DEMOGRAPHICS AND CLINICAL CHARACTERISTICS FOR PATIENTS DIAGNOSED WITH HCC 
IN TAIWAN, ACCORDING TO SURVEILLANCE STATUS, AFTER PROPENSITY SCORE ANALYSIS. 
 
 Propensity-Based Weighting  Propensity-Based Matching ** 
Characteristic *  
Surveillance  
(n=829)  
No 
Surveillance  
(n=704)  p-value 
Surveillance  
(n=829)  
No 
Surveillance  
(n=829)  p-value 
Age years  61.1 ± 11.6  61.0 ± 12.9  0.9 62.1 ± 11.7  61.9 ± 13.0  0.7 
Male Gender 594 (71.7)   509 (72.3) 0.8 554 (66.8)   594 (71.7) 0.03 
Co-morbidities     
Diabetes mellitus 162 (19.5) 143 (20.3) 0.7 165 (19.9) 154 (18.6) 0.5 
CVD   92 (11.1) 77 (10.9) 0.9   80 (9.7) 81 (9.8) 0.9 
Hypertension 289 (34.9)   246 (35.0) 0.9 282 (34.0)   251 (30.3) 0.1 
HCC Etiologies     
HBV 524 (63.2) 451 (64.1) 0.9 532 (64.2) 538 (64.9) 0.8 
HCV 261 (31.5) 223 (31.7) 0.9 320 (38.6) 324 (39.1) 0.8 
ALD    43 (5.2) 31 (4.4) 0.5   27 (3.3) 23 (2.8) 0.6 
NAFLD 69 (8.3) 60 (8.5) 0.9 62 (7.5) 67 (8.1) 0.6 
Other/Idiopathic 59 (7.1) 52 (7.4) 0.8 20 (2.4) 23 (2.8) 0.6 
Liver Function     
CP A/No Cirrhosis  765 (92.3) 650 (92.3)  792 (95.5) 622 (97.0) 
CP B 64 (7.7) 52 (7.4) 0.3 37 (4.5) 25 (3.0) 0.1 
CP C 0 (0.0)   2 (0.3)  0 (0.0)   0 (0.0) 
 
ALD = alcohol liver disease, CP = Child-Pugh score, CVD = cardiovascular disease, HBV = hepatitis B virus, HCC = 
hepatocellular carcinoma, HCV = hepatitis C virus, NAFLD = non-alcoholic fatty liver disease 
 
* Values are expressed as mean ± standard deviation and n (%) for continuous and categorical variables, 
respectively.    
 
** Patients in the no surveillance group were matched with patients in the surveillance group within a ± 0.05 range 
of the PS;
 42,141
  a total of 526 patients from the no surveillance group (74.7%) were identified as matches.  To retain 
the full sample of patients in the surveillance group, patients in the no surveillance group were sampled with 
replacement to achieve a 1:1 ratio of patients in the two groups. 
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